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Abstract 
Endometrial cancer is the 4th most common gynaecological malignancy in developed 
countries with a continual rise in incidence of >40% reported between the years of 1993-
2007. Though endometrial cancer presents early with abnormal uterine bleeding the 
therapeutic options are limited with surgery being the hallmark treatment for these 
women. Recent evidence published has implicated the new gaseous transmitter hydrogen 
sulphide (H2S) in the pathogenesis of colorectal carcinoma. The results of this study 
strongly suggested a role for H2S synthase inhibitors as a possible therapeutic option. No 
prior studies have been conducted exploring the role of H2S in relation to endometrial 
carcinogenesis. This study aims to produce novel research exploring the role of H2S in 
endometrial carcinogenesis.  
Immunohistochemical techniques were used to stain a total of 81 human endometrial 
samples (post-menopausal n=16, complex atypical hyperplasias n=4 and endometrial 
cancers n=61) with H2S synthases i.e. Cystathionine-β-synthase (CBS), Cystathionine 
gamma-lyase (CSE) and 3-mercaptopyruvate sulphurtransferase (3-MPST) to elucidate their 
differential expression between these groups. In vitro experiments were carried out 
investigating the effects of H2S donors i.e. GYY4137 and H2S substrates such as L-cysteine 
on the proliferative potential of the endometrial cancer cell known as MFE280. 
The results of this study concluded that the endometrium positively expresses all 3 
enzymes. 3-MPST displayed higher levels of expression in the atrophic post-menopausal 
endometrium with a significant loss in its expression seen in low grade endometrial cancer 
cells (p<0.0001), suggesting a possible role for 3-MPST as an early disease marker. CSE like 
3-MPST displayed a significant reduction in expression in cancerous cells when compared 
with post-menopausal and hyperplastic endometrium (p<0.001) whilst CBS showed no 
overall difference in expression between all study groups (p=0.136). Results of the in vitro 
investigations revealed an overall inhibition of cell viability of endometrial cancer cells 
when treated with a range of concentrations of H2S donors and substrates.  
Analysis of the above results presents a possible protective role of 3-MPST and CSE within 
the endometrium and their subsequent loss contributing to the development of 
endometrial carcinogenesis. Furthermore, the possibility of employing H2S donors as 
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therapeutic agents in endometrial carcinomas may be a promising intervention and further 
functional studies will need to be conducted before conclusions regarding the latter can be 
determined.  
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 Literature review Chapter 1
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The endometrium is the internal mucous lining of the uterine cavity. It is a highly sensitive 
target organ for the action of ovarian hormones such as oestrogen and progesterone. In 
response to these hormones it is subject to cyclical changes throughout a woman’s 
reproductive life. The endometrium is divided into two functionally different layers, i.e. the 
stratum functionalis and stratum basalis3. The basal cells possess a large capacity for 
renewal and allow the monthly regeneration of the stratum functionalis to occur. This 
highly proliferative ability of the endometrium increases the risk of somatic mutations that 
may cause abnormal replication of endometrial cells. Recent evidence has emerged 
implicating the role of hydrogen sulphide (H2S) as a tumour growth factor secondary to its 
ability to stimulate cellular bioenergetics4. The abnormal replication of cells may lead to 
endometrial hyperplasia or progress to neoplasia. Endometrial carcinoma is the 6th most 
common malignancy in females worldwide with a continual increase in incidence in the UK 
by over 40%5. A 100% increase in incidence of endometrial cancer is hypothesised by the 
year 2025 based on trends in incidence seen in Norway6.  
H2S is an endogenous gaseous transmitter that has both physiological and pathological 
functions4, 7. It is generated from the metabolism of the sulphurous substrate L-cysteine by 
cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), two pyridoxal-5′-phospate–
dependent enzymes and the combined action of cysteine aminotransferase with 3- 
mercaptopyruvate sulphurtransferase (3-MPST)4, 7. In vivo H2S was proposed to cause 
vasorelaxation, promote angiogenesis and stimulate cell proliferation. Angiogenesis and 
ATP synthesis are both vital for the growth and proliferation of cells. Evidence has shown 
the selective up- regulation of CBS in both colorectal and ovarian carcinomas.4 The 
subsequent increase in H2S allows the gaseous molecule to exert its effects by causing an 
increase in cellular mitochondrial function (oxygen consumption, ATP turnover), 
angiogenesis and stimulation of kinase pathways amongst other mechanisms4.  
The suspected ability of H2S to initiate and maintain tumour growth is yet to be 
investigated in endometrial cancer. The most up to date evidence regarding the structure 
and function of the endometrium, endometrial cancer and hydrogen sulphide’s 
physiological role and its implication in cancer will be reviewed and analysed. 
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1.1 Anatomy: 
 Uterus 1.1.1
 
A pear shaped, thick walled muscular organ, the uterus is 7.5 centimetres long and is 
mainly contained within the pelvic cavity and perineum8. In vivo it is mostly anteverted and 
positioned in the midline amidst the bladder and the rectum, figure 1. A rectovaginal 
septum isolates the posterior wall of the vagina from the rectum3. For illustrative purposes 
the uterus is divided into 3 major parts; the fundus, body and cervix, as seen in figure 1. 
Anatomically the uterus is divided into 2 distinct parts: the uterine body and the uterine 
cervix3. Made up of the body and cervix, the uterus communicates with the vagina 
inferiorly. Superiorly, the fallopian tubes project laterally from the fundus forming a 
continuum between the endometrial cavity and the peritoneal cavity as they come to rest 
adjacent to the ovaries3. Functionally the uterus exists to receive the fertilised embryo, 
provide a site for implantation and expand to shelter the foetus during pregnancy before 
contracting during delivery3. 
 
 
 
 
 
 
The uterus has a triple-layered wall namely: the perimetrium (tunica serosa), myometrium 
(thick tunica muscularis) and endometrium (tunica mucosa). The myometrium is a smooth 
muscle layer that is made up of poorly defined muscle fibres arranged in a circular, 
longitudinal and diagonal direction.  It is the thickest layer and accounts for the growth of 
the uterus during pregnancy and responds to hormones to produce powerful contractions 
during labour3.  
Uterine ateries are the major source of blood suply for the uterus; they originate bilaterally 
from the anterior section of the hypogastric artery and runs medially towards the cervix 
Figure 1 Anatomy of the female reproductive tract. (Adapted from Drake et al.)
1 
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uteri9. Lending a branch to the urethra its reaches the lateral aspect of the uterus and 
ascends towards the junction between the fallopian tube and uterus9. Branches of the 
uterine atery anastamose with the ovarian artery branches creating an arterial arcade. The 
uterine veins mirror the path of the uterine arteries and form venous plexuses that drain 
into the internal iliac vein. They also form 2 plexuses with the vaginal blood vessels 
inferiorly (utero vaginal venous plexus) and ovarian blood vessels superiorly (utero-ovarian 
plexus)9.  
The uterine vessels undergo changes in growth through different phases of the menstrual 
cycle. The endometrium is the sole site of neovascularisation within the body in health9. As 
the endometrium proliferates in the proliferative phase of the menstrual cycle the 
vasculature undergoes similar growth. The vessels become increasingly coiled as they 
extend from the basal layer to the functional layer and are known as spiral ateries9.  
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 Endometrium  1.1.2
 
 
 
 
 
 
 
 
 
 
 
The endometrium is made up of two functionally different layers: the upper two-thirds 
known as the stratum functionalis and the lower third, the stratum basalis3, 10. The 
functional layer of the endometrium can be further divided into 2 distinct layers, the most 
superficial layer known as the stratum compactum and a deeper stratum spongiosum3. 
During the proliferative phase of the menstrual cycle these 2 strata develop into the 
stratum functionalis. The stratum functionalis contains fewer glands in relation to stroma 
in the superficial zona compacta, particularly in pre-menopausal endometrium. The deeper 
zona spongiosa retains abundant number of glands. The stratum functionalis is the location 
for the implantation of a blastocyst or development of the placenta3. The stratum basalis is 
highly glandular with reduced stroma and consists of endometrial progenitor cells, owing 
to its role in the monthly regeneration of the stratum functionalis10. A single layer of 
columnar epithelium lines the luminal surface of the endometrium and invaginates into the 
stroma to form the endometrial glandular epithelium10. These glands span the depth of the 
endometrium through to the myometrial layer.  Endometrial proliferative conditions 
include both stromal and glandular proliferations e.g. hyperplasia or adenocarcinomas 
arise from the glandular epithelium10. 
Figure 2: Layers of the endometrium.  
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Figure 2 Layers of the endometrium 
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Prior to puberty this tissue lies dormant with a constant morphology and thickness. It 
reverts back to this stage post menopause due to the lack of periodic hormonal change. 
The features of pre-pubescent endometrium include tubular glands, dense fibroblasts and 
thin blood vessels. At the onset of puberty the glands, stroma and blood vessels undergo 
change and under the influence of oestrogens and progesterone the endometrium begins 
to prepare itself in each menstrual cycle to support a fertilised oocyte10. If fertilisation does 
not occur this leads to degeneration and shedding of the functional layer of the 
endometrium, resulting in a withdrawal bleed3.  
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1.2 Physiology  
 Ovarian cycle 1.2.1
 
At birth approximately 500,000 primordial follicles are present in each of the 
ovaries. An increasing number of ovulatory cycles results in a reduction in the total 
number of available follicles3, 11. Only 480 of the recruited follicles reach the 
Graafian follicle stage to release an oocyte during ovulation11, 12. The initiation of 
follicular recruitment spans a long duration of time and is autonomous. The 
hypothalamo- hypophyseal tract controls the monthly recruitment of follicles13. 
The pulsatile release of gonadotropin releasing hormone (GnRH) by the 
hypothalamus is vital for the release of the two anterior hypophyseal 
gonadotropins: Follicle Stimulating Hormone (FSH) and Luteinising Hormone (LH)11, 
14.  
The ovarian cycle is composed of two phases and lasts approximately 28 days11. 
The first phase (14 days) known as the follicular/ proliferative phase is highly 
variable and involves the recruitment of a cohort of follicles, eventually leading to 
the maturation of one follicle14, 15. This phase ends in ovulation refer to figure 3.  
The luteal/ secretory phase is fixed and its beginning is marked by ovulation and 
consists of progesterone production by the corpus luteum11. The follicular and 
luteal phases of the ovarian cycle correspond to the proliferative/ secretory phases 
of the menstrual cycle respectively. A rise in serum FSH level occurs as oestrogen 
levels drop secondary to the degeneration of the corpus luteum. FSH sensitive pre-
antral follicles are recruited in response to the rising levels of FSH11, 14. As the level 
of FSH peaks a period of time termed the ‘FSH window’ opens allowing one follicle 
to mature to the graafian stage and secrete oestradiol secondary to aromatase 
activity11, 13. An increase in LH levels is also required for the sensitisation of theca 
cells to initiate production of androgens16. These androgens are the precursors for 
the production of oestradiol under FSH stimulation11, 13.  FSH production is 
inhibited secondary to the raised serum oestradiol levels, highlighting the long- 
loop negative feedback mechanisms at the levels of the hypothalamus and 
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pituitary11. This fall in FSH levels limits follicular maturation leading to atresia of 
remaining follicles, thus preventing multiple follicular ovulations11, 13, 14.  
 Menstrual cycle 1.2.2
 
The hypothalamic-pituitary-ovarian axis marks the three levels at which the hormonal 
regulation of menstruation takes place via feedback mechanisms17. The expression of 
steroid receptors varies across the phases of the menstrual cycle, thereby regulating the 
extent of the hormonal regulation17. The menstrual cycle is divided into 3 phases: the 
menstruation phase (1st-4th day), the proliferative/ follicular phase (4th -14th day) and the 
secretory/ luteal phase (14th-28th days)17.  
 Menstruation phase  1.2.2.1
 
The menstruation phase represents the start of a new menstrual cycle. In the absence of 
successful implantation, the degradation of the corpus luteum leads to a drop in levels of 
circulating oestradiol and progesterone17.  The radial and basal arterioles are not 
responsive to the drop in serum levels of the sex hormones18. The reduction in serum 
progesterone results in constriction of the spiral arteries that supply the stratum 
functionalis, thereby causing ischaemia and necrosis18. The rupture of the spiral arterioles 
and rapid blood flow results in shedding of the functional layer of the endometrium. The 
basal layer obtains its blood supply from the straight arteries and therefore remains 
undisturbed. Regeneration of the endometrium begins imminently within this phase from 
the basal glands, with completion of surface epithelial growth within 48 hours post 
sloughing of the stratum functionalis8, 9. 
 Proliferative phase 1.2.2.2
 
The duration of the proliferative phase is variable lasting between 10-20 days, with any 
variation in cycle length attributed to this phase. Endometrial cell proliferation, 
vascularisation and regeneration are stimulated by oestrogen. The tubular glands in the 
stratum functionalis open into the luminal surface8. The thickness of the endometrium 
increases by >10-fold secondary to the growth of the glands, stroma and spiral arteries in 
the stratum functionalis9. This phase can be divided into an early and late proliferative 
phase8. The early proliferative phase is characterised by a reasonably uniform and thin 
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endometrium, whereas the late proliferative phase is confirmed by a thickened 
endometrium that includes a larger number of glands and mitoses, clearly seen in the 
stroma and epithelium. The stromal cells tend to possess an elongated, spindle like 
architecture8. The maturing follicle causes a peak in oestradiol that causes a surge in 
luteinising hormone leading to ovulation 35-44 hours after the LH peak19, thus making the 
endometrium sensitive to progesterone as it progresses into the secretory phase17, 18.  
 Secretory phase 1.2.2.3
 
The secretory phase occurs once ovulation has ensued; the corpus luteum secretes 
oestrogen and progesterone that influence the endometrium to mature and become 
receptive for a possible blastocyst1, 11. The time period between 20th – and 23rd days is 
known as the ‘implantation window’ and represents the most favourable environment of 
the endometrium to receive a blastocyst for successful implantation. Characteristic 
features seen in secretory phase include the corkscrew shape of the glands with increased 
glycogen rich secretions1, 11.  
 
Figure 3 Phases of Ovarian and endometrial cycle
20
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 Menopause  1.2.3
 
Once a woman reaches the climacteric phase of her reproductive life she is known to be 
peri-menopausal. Clinically, menopause is defined as the “the permanent cessation of 
menstruation and fertility occurring 12 months after your last menstrual period”21. In the 
UK the average age of menopause is 51 years, but some women may undergo menopause 
through their 30s or 40s. If menopause occurs earlier than 40 years it is deemed as 
premature menopause.  
Menstrual cessation occurs secondary to the failure of the ovaries to respond to hormonal 
signalling. During the peri-menopausal period the hormone production gradually wanes 
away leading to irregularity in the menstrual cycles. The non-existence of oogonal stem 
cells secondary to their exhaustion prior to birth means there is a finite number of follicles 
available form birth12.  In addition, with increasing age the loss of a group of follicles 
monthly results in decreasing numbers of follicles available for recruitment. Monthly 
recruitment of an ovum no longer takes place and will eventually cease to occur due to the 
diminishing response of follicles to the pituitary hormones e.g. FSH and LH.  
The lack of circulating oestrogen results in the absence of the LH surge that prolongs the 
proliferative recruitment phase and results in anovulatory cycles22. The low serum 
oestrogen levels within the body can also have physical and emotional effects leading to 
the common symptoms; hot flushes, night sweats, mood swings and vaginal dryness. The 
morphology of the uterus was shown to change as the woman goes through menopause23. 
The findings clearly show a reduction in uterine size and endometrial thickness 24 months 
before compared with after menopause.  
Histologically the endometrium undergoes changes during the menopause24. Both pre-
menopausal and post-menopausal endometrium consists of the luminal epithelium, 
stroma and glands. Decreasing hormonal stimulation of the endometrium causes structural 
changes such as: closing of the small tubular glands and reduced stroma, resembling the 
stratum basalis of menstruating women. ‘Cystic atrophy’ also termed ‘Swiss cheese 
endometrium’ in the past is a characteristic of post- menopausal endometrium where the 
glands are dilated and matter rich in protein collects in the glands25. In the postmenopausal 
endometrium, atrophy of the stratum functionalis results in difficulty in differentiation 
between the functional and basal layers, resulting in a thin endometrium. The endometrial 
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thickness in healthy post-menopausal women ranges from 1 to 5 millimetres (mm) thick, 
when compared with the normal 15mm thickness seen in the secretory phase of the 
cycling endometrium23, 26.  
Post-menopausal endometrium is atrophic but retains the ability to respond oestrogen and 
progesterone if present systemically27, 28. Therefore, endogenous (obesity) or exogenous 
oestrogens (unopposed by progesterone) may cause the endometrium to become 
proliferative. The post-menopausal endometrium can be further divided into 3 states, 
depending on its level of proliferation: mixed endometrium, atrophic/ weakly proliferative 
endometrium, and atrophied inactive endometrium.  
1. Mixed:  
The endometrium is mostly atrophic and inactive, but there are islands of weakly 
proliferative glands.  
2. Atrophic/ weakly proliferative  
The endometrium is thin measuring 2.2mm with no distinction between the stratum 
functionalis and stratum basalis. Tortuous endometrial glands are visible and the epithelia 
appear to be columnar psuedostratified. Minimal mitoses are apparent with oval nuclei 
surrounded by dense, fibrotic stroma28.   
3. Inactive endometrium 
The stratum basalis exists alone without a functional layer making the endometrium very 
thin. A few tubular glands exist within the basal layer with cuboidal epithelium that is 
inactive. Characteristics of an atrophic endometrium include dilated glands coated by 
flattened, undifferentiated epithelium28. 
Over 80% of endometrial carcinomas develop in post-menopausal women28. The post-
menopausal endometrium retains the ability to proliferate in response to oestrogen. 
Oestrogen receptor regulation is proposed to be lost in post-menopausal endometrium. 
Type 1 endometrial cancers are known to arise on a background of obesity from post-
menopausal endometrium28. 
 
12 
 
  Steroid hormone receptors 1.2.4
 
As the endometrium is the target organ for oestrogens and progestins, it expresses the 
respective receptors. These steroid receptors have many functions, ranging from their role 
as transcription factors or steroid ligand binding, dimer genesis to communication with 
other proteins. Genomic and non- genomic signalling controls the expression of these 
steroid hormones receptors.  
 Oestrogen receptor (-alpha and –beta) 1.2.4.1
 
Oestrogen receptors (ERs) control the expression of a variety of genes by either activating 
or inhibiting them, like transcription factors29. The monthly oestrogen induced changes in 
the endometrium are a result of the presence of the ER in the nuclei of endometrial cells. 
This allows the prompt conversion of hormonal stimulation into structural re-
configuration. Two functionally distinct types of oestrogen receptors exist encoded for by 
different genes, namely; ER-alpha and ER-beta30. Oestrogen can bind to either of these 
receptors with the resulting cellular response being different and often opposing30. Both 
these receptors are distributed in different tissues, but they both interact with the same 
oestrogen ligand; oestradiol-17. These oestrogen receptors can be broken down into 3 
different sections dependent on their functional capacity; the N terminal is a flexible hinge 
region where DNA binding occurs, Ligand/ hormone- binding domain and finally a second 
transactivation domain located within the ligand binding domain termed as the C-
terminal30. The n-terminal (A/B DOMAIN) consists of only 18% identical amino acids, in 
contrast to, the hormone binding domain which possesses 56% identical amino acids30. 
This difference seen between these domains justifies the ideology that ER-alpha and ER-
beta may exert their carcinogenic function via different methods in endometrial cancer.  
ERα and ERβ are expressed in the stratum basalis in both the glands and stroma and 
remain unchanged throughout the menstrual cycle31. The expression of these receptors is 
variable in the stratum functionalis, post-menopausal and cancerous endometrium. A 
reduction in glandular expression of both subtypes of ER can be seen in the secretory 
phase with no change in stromal expression31. Furthermore, the expression of these ERs in 
the stratum basalis stays constant throughout the phases of the menstrual cycle. 
Oestrogens’ proliferative function is recognized in the endometrium, with both ERα and 
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ERβ functions implicated in endometrial carcinogenesis32, 33.    Increasing levels of ER-alpha 
expression have been evidenced to increase expression of progesterone receptor and 
proliferation of endometrial cells secondary to the effects of oestrogen. ERβ expression 
was shown in endometrial endothelial cells suggesting that any direct effects of oestrogen 
in relation to angiogenesis could be regulated by ERβ expression31.  
 Progesterone receptor 1.2.4.2
 
The progesterone receptor (PR) exists in the 2 isoforms PR-A and PR-B. PR expression is 
regulated by the steroid hormone oestrogen. Low levels of PR expression are noticed in the 
secretory phase as the progesterone receptor is down –regulated by the hormone 
progesterone (ligand) via a negative feedback loop32.  Progesterone is also suggested to 
down regulate the expression of ERα, thus, limiting further action of oestrogen in the 
luminal and glandular epithelium and stromal cells, thereby allowing cellular 
differentiation to ensue32. A high PR expression was confirmed in stromal cells adjacent to 
uterine vasculature34. PR-positive stromal cells are thereby implicated in mediating the 
effects of progesterone on vasculature. Studies regarding the endometrial cancer 
progesterone receptor status have shown improved overall survival rates in those who 
have PR-positive tumours when compared with PR-negative patients. A reduction in 
recurrence of cancer has also been highlighted in PR-positive tumours34. 
The expression of PR-A was localised to the nucleus regardless of the presence of 
progesterone, whereas PR-B is largely expressed in the cytoplasm in the absence of 
progesterone, but translocates rapidly to the nucleus in the presence of progesterone35. 
Conflicting evidence exists implicating the role of PR status in endometrial cancers. 
Literature exists proposing an increase in expression of PR-B in advanced endometrial 
cancer, whilst another study concludes that an increase in PR-A can be seen in poorly 
differentiated cancers. A study conducted by Arnette-Mansfield et al36 suggests the loss of 
both isoforms of PR in endometrial cancer. In contrast, a study conducted by Kumar et al37 
suggests that PR-A and PR-B are associated with low grade tumours and it is the ratio of 
PR-A: PR-B that is implicated. If the ratio is <1 it is associated with a poor prognosis.  
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 Androgen receptor (AR) 1.2.4.3
 
Androgen receptor is widely expressed in the stromal compartment of the endometrium38. 
The expression of AR is variable and changes in cycling endometrium38, 39.  Both androgens 
and AR play a crucial role in the conversion of stromal cells into decidual cells39. The 
importance of androgen signalling for normal reproductive function was evidenced with a 
deviation from standard expression resulting in reproductive failure39. In the proliferating 
endometrium a fall in progesterone levels secondary to a rise in AR was shown in recent 
publications38. Studies have hypothesised that the up regulation of AR in glandular 
epithelium secondary to long-standing progesterone administration is a mechanism 
through which progesterone exerts its anti-proliferative effects.  
In the postmenopausal endometrium the circulating androgens are converted to oestrones 
causing a small reduction in androgen levels40. Inconsistent evidence exists attributing 
either ovarian or adrenal function as the source of androgens in the post-menopausal 
state. Either way the dominant hormones in the post- menopausal endometrium are 
androgens and their role in endometrial carcinogenesis was proposed39, 41. The 
mechanisms through which androgens exert their effect are both direct (AR) and indirect 
(ER- due to increased conversion of androgens to oestrones). The androgens investigated 
in endometrial carcinogenesis are testosterone, androstenedione (A4) and 
dehydroepiandrosterone (DHEA)42. A positive correlation was suggested between serum 
levels of free testosterone and endometrial cancer risk, but no increased risk was noted 
with A4 and DHEA. Obesity is known to be a hyperandrogenic state and an increasing level 
of obesity within the female population was implicated in an increased risk of endometrial 
carcinogenesis38.   
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1.3 Precancerous states and principles of metastasis 
 
Hyperplasia is known as an abnormal increase in cellular number in a tissue or organ, 
resulting in an increase in the size of the tissue or organ.  
Metastasis can be defined as the transfer of cancerous cells from the primary site of origin 
to one or more distant sited of the body. All malignant tumours have the capability of 
metastasising. The pathways through which this can occur are discussed later.  
 Precancerous states  1.3.1
 
Increased proliferation of the endometrial glands under the influence of oestrogens results 
in a greater gland: stromal ratio, when compared with normal endometrium. The 
proliferating glandular epithelium will show irregularities in shape and size and may display 
cytological atypia. Endometrial hyperplasia can be divided by its ability to progress into 
neoplasia or remain non-neoplastic43, 44. 
Neoplastic Non-neoplastic 
 Some complex hyperplasias  Simple hyperplasias 
 All complex atypical hyperplasias.  Some complex hyperplasias 
(without atypia) 
 
Neoplastic hyperplasia need not exist as a precursor state for the development of 
endometrial cancer. However, if present a high risk of progression to endometrial 
carcinomas exists. This form of hyperplasia tends to progress into the most common form 
of endometrial carcinoma i.e. endometrioid carcinoma. 
World Health Organisation (WHO) classification of endometrial hyperplasia takes 2 specific 
features into account: 
 The architectural pattern of the endometrium: simple/ complex 
 Presence of nuclear atypia.  
This permits four categories of classification for endometrial hyperplasia45, 46, as shown 
below: 
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 Simple hyperplasia no atypia  
 Simple atypical hyperplasia   
 Complex hyperplasia no atypia 
 Complex atypical hyperplasia  
In 2014 WHO devised a new classification method for hyperplasias. The 2 categories 
include: 
 Hyperplasias with atypia 
 Hyperplasias without atypia 
The occurrence of simple atypical hyperplasia is rare and women with simple hyperplasia 
without atypia are least at risk of developing endometrial cancer43. The most likely cohort 
that is at an increased risk of developing endometrial cancer is women who are diagnosed 
with complex atypical hyperplasia43. The most insidious finding is nuclear atypia which 
carries a great risk of incidence of cancer47.  
Women suffering from endometrial hyperplasia tend to present with abnormal uterine 
bleeding, vaginal discharge or cervical smear abnormalities46. Statistically the risk of 
progression to cancer in complex atypical hyperplasia is around 30% in contrast to no 
cytological atypia where the risk drops to less than 5%47 . In addition recent evidence has 
proposed that the risk of developing well –differentiated endometrial carcinoma from 
complex atypical hyperplasia has increased to 40-50%48. The variance in risk stated above 
exists due to the difficulty if attributing percentage risk of progression into EC in patients 
with hyperplasia. Many patients who have a biopsy diagnosis of atypical hyperplasia will 
also have endometrial cancer in the hysterectomy specimen.  In addition an increasing 
number of patients are developing concurrent carcinomas. The risk of progression will be 
difficult to assess as most patients will have a hysterectomy. In 2000 the endometrial 
intraepithelial neoplasia classification was proposed by an international group of 
pathologists. It suggests two classes of endometrial changes that are clinically relevant 
such as; endometrial hyperplasia (EH) and endometrial intraepithelial neoplasia (EIN). EH is 
diagnosed with endometrial morphology that is proliferative and includes a few cysts in 
and EIN should displace stroma resulting in a stromal volume that is approximately half the 
tissue volume. The intraobserver reproducibility would not be high to the trained 
professional and not to a less experienced eye. Furthermore, there is a lack of ability to 
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differentiate between severity and therefore groups findings that would require 
individually tailored treatment together49.  
With the increasing rates of obesity, women are exposed to higher levels of endogenous 
oestrogens which increases the risk of endometrial hyperplasia46. Obesity is a 
hyperandrogenic state, an increased level of aromatase mediated conversion of androgen 
to oestrones occurs, thereby exposing the endometrium to unopposed oestrogens, thus, 
increasing risk. In contrast, the use of combined oral contraceptives was shown to 
decrease the risk of developing endometrial hyperplasia46.  
 
 Principles of metastasis 1.3.2
 
In health, normal cells retain their architecture with basal to apical differentiation and an 
intact basement membrane. The primary beginnings of abnormality and loss of normal 
differentiation can be seen when cells become dysplastic. Dysplastic cells are characterised 
by their abnormal proliferation and loss of cell shape, size and orientation50. Malignant 
change within cells is apparent when there is a high nuclear/cytoplasmic ratio and clumped 
chromatin. The lack of invasion into the basement membrane results in the carcinoma 
being termed as ‘in situ’. When invasion of the basement membrane occurs with the 
involvement of collagenases and hydrolases, it is termed an invasive carcinoma.  
Two theories of metastatic spread have been proposed. Stephen Paget51 suggested that 
metastases arose from the replication of a few tumour cells in select organs that provided 
conditions required for growth. 40 years later James Ewing proposed the ‘mechanical 
entrapment theory’ that focused on the anatomical progression of metastases52. The 
notion of this theory explains that the first organ that encounters these cancerous cells will 
house the largest number of metastatic clusters52. Both the theories have some accuracy 
as some metastases are colonised in the first organ, whereas some are more selective in 
their spread.  
Locally invasive carcinoma has the possibility of metastasising via haematogenous/ 
lymphatic spread50. Many cells can break away from the tumour on a daily basis, but not all 
of these will metastasise to distant organs within the body. In order to successfully 
metastasise the neoplastic cells need to survive many steps, primarily the initial separation 
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from the primary tumour and entry into the blood/ lymph system50. Furthermore, in an 
immune-competent individual the cells need to be able to survive the body’s immune 
response during their travel to their new location.  Once in the vascular or lymph system 
their ability to adhere and invade the vessel walls to arrive at their new site and their 
ability to thrive there determines their metastatic potential.  Due to the vast number of 
hurdles that the cancerous cells need to overcome, by the time they establish themselves 
at another location they may no longer resemble the cells of the primary tumour leading to 
difficulties with treatment50.  
As endometrial cancer generally tends to present early with abnormal uterine bleeding the 
cancers can be treated with a local surgical procedure and adjuvant pharmacological 
therapies if required. Cancers that originate in the endometrium can spread locally into the 
vagina, peritoneum and omentum.53-55 Metastatic spread to the liver and lungs are 
common. In some other highly invasive cancers that present late, the cells may have 
already metastasised and established themselves at other sites at the time of initial 
diagnosis. The detection of metastasis prior to the primary cancer- is termed ‘cancer of 
unknown origin’50.   
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1.4  Endometrial cancer 
 Epidemiology  1.4.1
 
Endometrial cancer is the 6th most common malignancy amongst females worldwide and 
the 4th most common amongst women in developed countries55. On average 7400 cases 
are registered in the UK annually54. Over 250+ endometrial cancer patients are diagnosed 
and treated each year at the Liverpool Women’s hospital where this study is being 
conducted.  More than 90% of cases are diagnosed in females over 50 years of age with a 
median age of diagnosis stated at 63 years54, 55. In the UK and EU there was an increase in 
incidence of endometrial cancer of more than 40% between the years of 1993-2007 with a 
predicted 100% increase in incidence by the year 2025 as stated in a Norwegian study6. In 
addition the incidence is reported to double by 2015 from the year 20056. Research has 
shown that the spread of this disease is highest in developed countries such as those of 
North America and Central and Eastern Europe with lowest incidences occurring in Central 
and Western Africa. The increase in incidence of this condition is attributed to the 
continual increase in body mass index and life expectancy56.  
 Classification of endometrial cancer  1.4.2
 
Endometrial cancer generally tends to arise from malignant transformation of epithelial 
cells, but rarely cancer may be of stromal origin57. Endometrial carcinoma can be classified 
into two major groups dependent on its appearance at light microscopy, clinical behaviour 
and epidemiology57. The majority of endometrial cancers are endometrioid carcinomas. 
Nevertheless, rare cancers such as carcinosarcomas also arise from the endometrium. 
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Table 1: Classification of endometrial cancer
57
 
Endometrial Cancer 
Type 1 Endometrioid (75-80%)57 Type 2 (15-20%)57 
 
• Ciliated adenocarcinoma 
• Secretory adenocarcinoma 
• Papillary/villioglandular 
• Adenocarcinoma with squamous 
differentiation 
 
 
• Uterine papillary serous (<10%) 
• Mucinous (1%) 
• Clear cell (4%) 
• Squamous cell (<1%) 
• Carcinosarcoma/ MMMT (10%) 
• Undifferentiated 
 
Type 1 endometrial cancers tend to arise from complex atypical hyperplasias and are 
linked with prolonged periods of unopposed oestrogen exposure47. These cancers are well 
differentiated and composed of glands that resemble those found in normal endometrium. 
They tend to be of a lower grade (1/2) and have a favorable prognosis.  In contrast, type 2 
endometrial cancers develop from atrophic endometrium and are not oestrogen 
dependent58. Grade 3 endometrioid carcinomas are classed as type 2 with the inclusion of 
tumors of non-endometrioid histology. They tend to be less differentiated, possess an 
increased risk of metastases and are associated with a poor prognosis53-55.    
The current classification of EC into type 1 and type 2 EC is very simple and difficulties arise 
in assigning grade 3 endometrioid carcinomas into either of those categories. New 
molecular/genomic approach of classification of endometrial cancer has arisen combining 
both genomic and histopathological features to create and integrated classification of 
clinical and biologically relevant subcategories of EC. The genomic classification divides 
endometrial cancers into 4 groups as seen in table 259. 
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Table 2 Four genomic classifications of endometrial cancer59 
 POLE 
(ultramutated) 
MSI 
(hypermutated) 
Copy-number 
low 
(endometrioid) 
Copy-number 
high (serous-like) 
Copy-number 
aberrations 
Low Low Low High 
MSI/MLH1 
methylation 
Mixed MSI high, 
low, stable 
MSI high MSI stable MSI stable 
Mutation 
rate 
Very high (232 × 
10−6 
mutations/Mb) 
High (18 × 10−6 
mutations/Mb) 
Low (2·9 × 10−6 
mutations/Mb) 
Low (2·3 × 10−6 
mutations/Mb) 
Genes 
commonly 
mutated 
(prevalence) 
POLE (100%) 
PTEN (94%) 
PIK3CA (71%) 
PIK3R1 (65%) 
FBXW7 (82%) 
ARID1A (76%) 
KRAS (53%) 
ARID5B (47%) 
PTEN (88%) 
RPL22 (37%) 
KRAS (35%) 
PIK3CA (54%) 
PIK3R1 (40%) 
ARID1A (37%) 
PTEN (77%) 
CTNNB1 (52%) 
PIK3CA (53%) 
PIK3R1 (33%) 
ARID1A (42%) 
TP53 (92%) 
PPP2R1A (22%) 
PIK3CA (47%) 
Histological 
type 
Endometrioid Endometrioid Endometrioid Serous, 
endometrioid, 
and mixed serous 
and 
endometrioid 
Tumour 
grade 
Mixed (grades 
1–3) 
Mixed (grades 
1–3) 
Grades 1 and 2 Grade 3 
Progression-
free survival 
Good Intermediate Intermediate Poor 
 
As we can see in table 2, a simple classification of endometrial cancer into type1 and type 2 
is insufficient due to the diversity of endometrial cancers. Type I EC according to the 
genomic classification encompass tumour with microsatellite instability, copy- number low 
and POLE characteristics. In contrast, type 2 EC may include grade 3 and serous 
carcinomas59. Genomic classification of EC will have application beyond therapeutic aid and 
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could possibly allow for the development of accurate screening tests and methods for 
disease monitoring59.  
 
 Histopathology and grading 1.4.3
 
The most common site of origin of endometrial cancer is within the corpus proper; it may 
also develop in the lower uterine segment60. On a macroscopic level no distinction can be 
made in regards to the cell type of the cancer. The appearance may be grossly described as 
a lush, polypoid expansile mass with yellow necrotic regions, located within the 
endometrial cavity60. The cancer can be visible as a single, large dominant mass or 
widespread involvement of the endometrium can show a sunken appearance with no 
visible exophytic mass. In the presence of myometrial involvement, islands of well-defined 
grey-white areas are seen when compared to the surrounding unaffected myometrium.  
Microscopic assessment of the cancer tissue allows the cell type to be differentiated, 
guiding the appropriate management. Characteristic microscopic changes that occur within 
endometrial cancer cells include: 1) stromal invasion – cribriform pattern of well 
differentiated endometrial cancer, 2) presence of cytological atypia (prominent = high 
grade, minimal= low grade), 3) myometrial invasion61.  
The current most validated classification of staging and grading for endometrial carcinoma 
was developed by The International Federation of Gynaecology and Obstetrics (FIGO), 
refer to table 3. This ever evolving classification provides a common language between 
professionals when diagnosing and managing patients. In 1998 FIGO classification of 
endometrial carcinoma was based mostly upon the architecture of the cancer as seen in 
table 2.  
Table 3: 1998 FIGO classification of grading endometrial cancer
62, 63
. 
Grade 1  < 5% of solid areas 
Grade 2 6-50% solid areas 
Grade 3 > 50 % solid areas 
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Table 4: Revised FIGO 2009 staging for endometrial cancer (excluding uterine sarcomas
55, 62
) 
ENDOMETRIAL CANCER STAGING63 
IA Tumour confined to the corpus uteri, 
+no involvement of myometrium OR 
+< ½ myometrial invasion  
IB Tumour confined to the corpus uteri,  
+> ½ myometrial invasion 
II  Tumour invades cervical stroma but does not extend beyond the uterus 
III 
 
Local and / or regional spread of tumour 
IIIA Tumor invades the serosa of the corpus uteri and/or adnexae 
IIIB Vaginal and/or parametrial involvement. 
IIIC Metastases to pelvic and/or para-aortic lymph nodes 
IIIC1 Positive pelvic nodes. 
IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph 
nodes 
IV Tumor invades bladder and/or bowel mucosa, and/or distant metastases 
IVA Tumor invasion of bladder and/or bowel mucosa 
IVB Distant metastases, including intra-abdominal metastases and/or inguinal 
lymph nodes. 
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 Associated risk factors 1.4.4
 
A risk factor is defined as any reason that alters a person’s risk of developing morbidities.  
The risk factors that lead to the development of endometrial cancer are mainly secondary 
to excessive unopposed oestrogens, either endogenous or exogenous53-55. High levels of 
oestrogen have a proliferative effect on endometrial cells, thereby increasing mitoses and 
the likelihood of mutations. 
Obesity (BMI 30-39.9 kg/m2) and morbid obesity (BMI>40kg/m2), increasing age, nulliparity 
and longer reproductive years of a woman are vital risks that increase the possibility of 
females developing endometrial cancer64 as highlighted in table 4.  In pre-menopausal 
women an imbalance between the 2 main regulatory hormones; oestrogen and 
progesterone can cause a disruption in the monthly menstrual cycles. In females who have 
polycystic ovarian syndrome (PCOS) higher levels of oestrogen and androgens exist 
systemically when compared to progesterone, contributing to an increased risk of 
neoplastic change65. 
Extensive research into the correlation between obesity and endometrial cancer has 
shown that with increasing BMI there is a 3.5 fold rise in risk of developing endometrial 
cancer. Within the UK 50% of women diagnosed with endometrial cancer have a BMI 
>30kg/m2.  A high BMI (>30kg/m2) is associated with an overall increased risk in developing 
endometrial cancer. Furthermore, a positive correlation was revealed between obesity and 
the development of endometrioid cancers when compared to their non-endometrioid 
counterparts66.  In the post-menopausal state there are low levels of circulating 
oestrogens. In obese women the peripheral adipose tissue allows the enzyme aromatase 
to convert adrenal androgens and existing androgens into oestrogen67, 68 refer to figure 3. 
This creates an unopposed (by progesterone) hyper-oestrogenic state in these post-
menopausal females.  This continual stimulation of oestrogen receptors allows the 
endometrium to retain its proliferative functions, rather than becoming atrophic as 
expected post menopause. This persistent endometrial cell proliferation creates an 
increased risk of neoplastic change secondary to an increase in probability of mutations 
occurring in these cells46, 66.  
Obesity not only poses a threat via alteration of physiological function56 but also affects 
management of women suspected of or diagnosed with endometrial cancer. Obese 
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women are at an increased risk of developing co-morbidities, such as: hypertension and 
secondary cardiac events or insulin resistance69. A more intensive peri-operative 
assessment is required to minimise the problems due to co-morbidities. This intensive care 
in turn places pressure on medical resources. Therefore reassessment of treatment for 
endometrial cancer in the rising BMI population is necessary.    
The use of combined oral contraceptives was proven to be a protective factor against the 
development of endometrial cancer70. The protection lasts for up to ten years after 
cessation of the pill. In contrast, other drugs such as: Tamoxifen (selective oestrogen 
receptor modulator) is thought to have pro- oestrogenic effects in the endometrium, 
thereby- contributes to increasing the risk of developing endometrial cancer.  
Table 5: Endometrial cancer risk factors 
Endometrial cancer risk factors53-55 
Factors implicated in 
increased risk 
Factors associated 
with decreased 
risk 
Interventions 
associated with 
decreased risk 
No effect on risk 
 Endogenous or 
exogenous 
oestrogens 
 SERMs: 
Tamoxifen and 
Raloxifen 
 Anovulatory 
cycles 
 Obesity 
 Increasing age 
Genetic predisposition:  
 PCOS
65, 71
 
 Lynch 
syndrome
72
 
 Increasing 
parity 
 Increasing 
lactation 
 COCPs 
 Physical 
activity 
 Weight loss 
 Increased 
intake of 
fruits, 
vegetables 
and vitamins 
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Reduced cell death 
(apoptosis) 
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proliferation 
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oestradiol and 
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Aromatase 
Figure 4 Conversion of excess androgens resulting in elevated plasma oestradiol and testosterone 
in obesity contributing to increased risk of endometrial carcinogenesis. 
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 Clinical presentation and management of patients  1.4.5
 
Endometrial cancer presents early with abnormal uterine bleeding (post-menopausal 
bleeding or intermenstrual bleeding).  Blood soaked discharge and pelvic pain are other 
ominous ways in which the cancer may present, as they are also privy to menopausal 
women and are not specific to cancer. Peak incidence occurs in women aged mid to late 
50s or above, with 1:100 females being affected. Once a female presents with symptoms 
suggestive of cancer they are assessed rapidly and managed accordingly53-55.  
The National Institute of Clinical Excellence (NICE) has set gold standard guidelines for the 
management of patients with suspected endometrial cancer. The primary assessment 
involves a thorough clerking of the presenting complaint followed by a bimanual 
examination55. Once an appropriate referral to the gynaecology outpatient department is 
done, a transvaginal ultrasound scan is the first investigation of choice.  Samples of 
endometrium obtained from a pipelle biopsy or dilatation and curettage73 at hysteroscopy 
are analysed. If pathology suggestive of neoplasia is detected further management of the 
patient is reviewed by the gynaecologic oncology MDT55.  
Management is highly dependent upon the stage of cancer at diagnosis62. Diagnostic 
procedures can be invasive or non-invasive. Invasive methods involve the use of dilatation 
and curettage (D&C), endometrial biopsies or hysteroscopy and directed biopsy. Non- 
invasive methods include ultrasonography or endometrial cytology74.   
With endometrial cancer the hallmark of treatment is surgery. Procedures such as total 
abdominal hysterectomy with bilateral salpingo-oophorectomy and peritoneal washings 
are most common treatment measures. In the presence of advanced stage disease local 
lymphadenectomy and omentectomy can be carried out to analyse metastatic potential of 
the cancer62, 74, 75.  
Previous inconsistencies exist with the diagnosis of non- atypical endometrial hyperplasias 
generally being phenotypically poly-/ mono- clonal61, 76. In contrast, clear evidence has 
emerged defining the architectural diagnostic criteria required, thereby standardising the 
diagnosis of endometrial hyperplasias. Management of hyperplastic endometrium is varied 
depending on the presence of cytological atypia. Simple and complex hyperplasias with no 
cytological atypia are managed conservatively with use of progesterone therapy77. The 
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most commonly used progesterones are medroxyprogesterone acetate or megestrol 
acetate78. They may be administered in a cyclical or continuous fashion. In addition to oral 
progestins many patients are now treated with Mirena (levonorgestrel) which provides 
local progesterone and proposed to be more effective. In the presence of cytological atypia 
no role exists for conservative pharmacological management due to the strong association 
(19% to 62%) between invasive carcinoma and cytological atypia. In the presence of simple 
or complex atypical hyperplasias, hysterectomy is adopted as the choice of treatment.  
In contrast, literature validating the role of progesterone therapy leading to regression of 
atypical hyperplasias in 60% to 95% of patients was published. Nevertheless the strong 
relationship between invasive EC and atypical hyperplasia showing a high risk of 
progression results in hysterectomies being the standard treatment, reserving 
progesterone therapy for women who require preservation of fertility.   
Generally low grade well differentiated adenocarcinomas without myometrial invasion are 
managed with a TAH+BSO alone without the necessity for node sampling or adjuvant 
therapies, refer to table 5. Poorly differentiated high grade cancers (stage 2 and above) are 
given post-operative radiation62.  
Radiotherapy and chemotherapy are adjuvant therapies that can be employed in the 
management of endometrial cancer. Radiotherapy was useful to shrink cancers that are 
inoperable to allow surgical management. Current research is being carried out analysing 
the efficacy of combined chemotherapy and radiotherapy or the effect of radiotherapy 
alone in palliation55.  
 
 
 
 
 
 
 
29 
 
 
Table 6: Management options for endometrial cancer
55
 
Treatment options for endometrial cancer 
Surgery Radiation 
therapy 
 
Chemotherapy Palliation 
Total hysterectomy 
TAH+BSO, peritoneal 
washings. 
+/- Lymphadenectomy 
+/- Omentectomy 
 
External 
beam/ vaginal 
brachytherapy  
 
Systemic / regional 
chemotherapy 
Carboplatin+/- 
Doxorubicin+/- Taxol 
Radiotherapy 
Hormone therapy  
Supportive interventions 
 
For prognosis the FIGO staging criteria holds much importance and weight. 5 year survival 
rates are generally promising when the disease is picked up at an early stage. More than 
50% of recurrences are secondary to type 2 endometrial carcinomas i.e. clear cell or serous 
carcinomas. A delay in diagnosis leads to a rapid drop in the survival rates of these women, 
as highlighted in table 6: 
Table 7 5 year survival rates for endometrial cancer
55
 
STAGE 5 – YEAR SURVIVAL RATE 
1 92% 
2 75% 
3 50% 
4 20% 
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Although endometrial carcinoma is a rising problem with the western population, 
screening for early endometrial cancer is only likely to marginally reduce mortality. 
Furthermore, current minimally investigative methods i.e. histology from endometrial 
biopsies or transvaginal ultrasonography (TVU) are highly accurate for diagnosis and the 
early presentation of endometrial cancer with postmenopausal bleeding means that 
disease can be caught in its early stages. Emphasis should be placed on health education of 
the current population to the importance of investigating abnormal uterine especially in 
post-menopausal women or those undergoing Tamoxifen therapy.   
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 Pathogenesis of endometrial cancer 1.4.6
 
Several molecular pathways have been implicated in the initiation and maintenance of 
endometrial carcinoma28. The exact biological interactions that occur are not clearly 
defined. The architectural changes seen in endometrial cancer cause a disruption in the 
normal hormonal interaction between the glands and extra cellular matrix/ stroma28. Some 
of the pathways that are postulated to contribute to the development of endometrial 
cancer have been highlighted.  
 Embryology 1.4.6.1
 
Stem cells can be defined as unspecialised cells that possess the capability to replicate via 
mitosis to produce more undifferentiated cells or become tissue specific cells that carry 
out specific functions. They have the ability to regenerate on a long-term basis retaining 
their undifferentiated status with a high proliferative potential79. The role of endometrial 
somatic stem cells present in the stratum basalis is to regenerate the endometrial stratum 
functionalis on a cyclical basis. Therefore the malfunctioning of these stem/ progenitor 
cells and/or their surrounding cells can contribute to the incidence of gynaecological 
disease, such as; endometrial hyperplasia, endometrial cancer or even the formation of 
endometriosis80.   
 
 Hormonal imbalance 1.4.6.2
 
Prolonged, unopposed oestrogen exposure was strongly linked as a risk factor in 
endometrial cancer. In the normal cycling endometrium the presence of progesterone 
counter-acts the increased level of oestrogen secretion by the corpus luteum. The 
endometrium proliferates under the effects of oestrogen, whereas progesterone has an 
anti-proliferative effect on the endometrial cells, thereby inhibiting the epithelial to 
mesenchymal cell transition77. In advanced disease a loss of progesterone signalling or an 
increase in systemic levels of oestrogen encourages endometrial proliferation. Although 
elevated oestrogen levels pose a risk, development of cancer is multifactorial and ensues 
in response to genomic mutations77.  
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 Genetic Mutations  1.4.6.3
 
Multiple genetic mutations are responsible for the development of endometrial cancer. 
Different pathways are implicated in endometrial carcinomas, dependent on their 
oestrogen sensitivity81. In addition to the microsatellite instability seen in endometrioid 
carcinomas, the most frequently altered gene is phosphatase and tensin homologue 
(PTEN) and a mutation in the β-catenin gene is also seen in 20% of these cancers. Kirsten 
rat sarcoma viral oncogene homologue (K-ras) mutations are detected in 15-30% of these 
cancers, and show no association with the existence of endometrial hyperplasia81. Dualistic 
model of carcinogenesis can be seen with specific genetic mutations being attributed to 
the 2 types of endometrial carcinomas. Type 1 endometrial carcinomas are associated with 
mutations in: PTEN82 as aforementioned, KRAS2 oncogene82, faults in DNA mismatch repair 
and near- diploid karyotype. In contrast, most type 2 endometrial carcinomas (non- 
endometrioid) are most are non-diploid and associated with TP5383 and Her2/neu 
pathways82, 84.   
79% of endometrioid endometrial cancers have reported mutations in the PTEN tumour 
suppressor genes. The loss of this gene is mainly localised to the tumour epithelia. The 
somatically mutated cells that failed to express the PTEN protein secondary to mutation 
and /or deletion of the gene were found to form high-density clusters85. Conflicting 
evidence exists describing the effect of progesterone therapy on these tumours. However, 
recent evidence has shown the high sensitivity of these tumours to progesterone therapy 
and described PTEN as a possible biomarker of response to progesterone therapy in 
endometrial cancer patients.  
Inheritable mutations e.g. Lynch syndrome characterised by a MSH2/MSH6 protein 
complex deficiency is associated with 72 endometrial cancer. The development of 
endometrial cancer is localised to the lower uterine segment and endometrioid carcinomas 
of a woman of any age whose tumour displays peritumoural lymphocytes and tumour 
heterogeneity is associated with Lynch syndrome. Particularly in dedifferentiated EC86.  
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 Trans-sulphuration pathway 1.4.6.4
 
Hydrogen sulphide is one of the by-products of sulphur metabolism within the body. A 
gaseous transmitter within the body, H2S was implicated in the pathogenesis of colon and 
ovarian carcinomas. The angiogenic and cellular proliferative functions of H2S have based 
the mechanisms through which it initiates and maintains neoplasia. Comprehensive 
investigations carried out on cancer cell lines have affirmed the possibility of using enzyme 
inhibitors to limit the production of H2S and thereby halt tumour progression. This role of 
H2S has not yet been investigated in the endometrium and its prospective pathway that 
may contribute to endometrial carcinogenesis.  
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1.5 Hydrogen sulphide 
Hydrogen sulphide (H2S) is a colourless, flammable gas, famously known by its rotten egg 
odour. It is a highly water soluble and lipophilic gas4, 7, 32, 87. H2S is an upcoming novel 
gaseous transmitter implicated in tumourigenesis behind nitric oxide (NO) and carbon 
monoxide (CO)4. H2S is detected at levels of 0.0047 ppm and at a higher concentration of 
approximately 500 ppm it is known to be fatal. Like the other noxious gases, in the body it 
is converted to a less toxic form. In vivo H2S is synthesised by 2 possible methods e.g. the 
local sulphate- reducing bacteria present in the colon or metabolism of L-cysteine.   
Initial studies conducted by Kimura in 199688 defined the role of H2S as a neuromodulator 
in the brain, thus propelling research associated with biological effects of H2S. The 
functions of hydrogen sulphide have been suggested in an increasing number of tissues 
including: anti-nociception89, blood pressure90 control mediated by vascular dilatation and 
neuromodulation91 by shielding the neuron from oxidative stress and stimulating 
glutathione (GSH) production92. Increasing the concentrations of H2S in cancer may be 
reversed by the use of H2S synthase inhibitors (CBS/CSE inhibitors)
93, thus, implicating the 
successful role of H2S synthase inhibitors in modulating H2S production.  
Studies investigating the role of H2S as a pro-/ anti-apoptotic agent have emerged
94. H2S 
was implicated in modulating the proliferation of various cells within the body, displaying a 
tissue specific action94. Its highly soluble and lipophilic nature allows the rapid diffusion of 
H2S through cell membranes without the need for transport proteins, allowing it to have 
rapid effects on cells95. Once H2S has entered the cytoplasm, intracellular signaling is 
activated resulting in communication between signaling and target proteins. Under the 
influence of H2S the target proteins alter cellular programming to bring about apoptosis or 
DNA repair.  Mitotic division of cells is a highly regulated process and regulated by DNA 
expression. H2S was proposed to alter cellular replication by interrupting the cell cycle 
phases96.  However, its definite role is still under debate.  
The pharmacological functions of H2S on cell growth and its uses as an alternate therapy 
for inflammation and pain have been described97. Peculiarly a rise in endogenous H2S 
synthesis is seen at sites of inflammation, associated with exponential proliferation of 
cells97. Its anti-inflammatory function has not been clearly defined. Further to this a study 
conducted in septic mice has shown that H2S exerts its effects by restoring neutrophil 
migration (via an ATP-dependent K+ channel- dependent pathway) to sites of infection98.   
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The cytoprotective and therapeutic nature of H2S was described in studies investigating its 
roles in vascular diseases e.g. atherosclerosis99, hypertension99 and ischaemic- reperfusion 
injury100 or in inflammation as previously described. In addition the scavenging role of H2S 
was described, thus regulating the production of reactive oxygen species (ROS) and 
conserving tissue function101. In contrast, it has also been described to potentiate diseases 
such as asthma102 and diabetes103. 
 
 Endogenous H2S synthesis  1.5.1
 
The source of sulphide within our bodies comes from the essential amino acid; methionine. 
Methionine is not synthesised in the body and therefore needs to be ingested. The 
production of endogenous H2S occurs by desulphuration of cysteine (derived from 
methionine) via the trans-sulphuration pathway, the only pathway capable of removing 
sulphur-containing amino acids when in excess4, 104-106. The three enzymes involved in the 
conversion of cysteine to H2S include CBS a homotetramer, CSE a tetramer and 3-MPST a 
disulphide-linked dimeric protein or a monomer. Although the expression of all three 
enzymes is tissue specific, they all possess the same role; conversion of cysteine and its 
derivatives to H2S
4, 7, 87. 
 
In adults CBS is expressed predominantly in the brain, nervous system and liver. CBS is a 
sulphur metabolising enzyme coded for by the CBS gene and is mapped onto the gene 
locus on the long (q) arm of chromosome 21 at position 22.3107. The presence of this gene 
enables the production of CBS in vivo. CBS has a molecular weight of approximately 530 
kDa and consists of 3 functional domains; the C-terminal, N-terminal and middle domain. 
Composed of haem, the N terminal domain regulates the enzyme in response to redox 
reactions. The C- terminal domain controls the allosteric activation of the enzyme by S-
adenosylmethionine. Finally, the middle domain account for the catalytic activity that is 
responsible for the production of hydrogen sulphide via the pyridoxal 5 phosphate 
prosthetic group107, 108.  This enzyme occupies a pivotal position in mammalian sulphur 
homeostasis at the homocysteine junction109. At this point in the chemical pathway CBS 
catalyses the conversion of homocysteine to cystathionine via the use of vitamin B6 to 
enable the β-replacement of the sulphhydryl group of homocysteine and the hydroxyl 
group derived from serine to form cystathionine7. In the presence of a mutation of this 
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gene, homocystinuria develops. 150 mutations of this gene have been implicated in the 
development of this disease. These mutations lead to a disruption in the standard 
functioning of this enzyme causing a build-up of homocysteine and other toxic compounds 
systemically, resulting in its excretion via the urinary system. Hyperhomocysteinaemia has 
also been implicated as a risk factor for co-morbidities such as preeclampsia, congenital 
birth defects e.g. spina bifida and miscarriages in humans110. However, no literature was 
published looking at CBS expression in cycling, atrophic or cancerous endometrium.  To 
date its expression and role in the human endometrium has not been defined.  
 
Human CSE is a protein made up of four subunits, 2 dimers and each monomer binds to 
pyridoxal 5- phosphate (P5P), the prosthetic group of this enzyme. CSE is mapped onto the 
gene locus on the short arm of chromosome 1, made up of 13 exons and 12 introns. 
Secondary to a variation merging of the protein, 3 different isoforms of CSE exist. CSE is a 
key enzyme in glutathione synthesis and enters the chemical pathway at the cystathionine 
junction where cystathionine is converted to cysteine and alpha-ketobutyrate. The enzyme 
CSE converts cystathionine by catalysing the elimination of α, γ-carbon to produce 
cysteine, ammonia and α-oxobutyrate. In addition CSE was described to potentiate the β-
elimination of cysteine to form the intermediate thiocysteine, which in turn degrades to 
form H2S
111. The α, β-elimination of cysteine was described as the predominant reaction 
for H2S synthesis. A reduction in expression of CSE leads to a reduction in levels of cysteine 
and a systemic increase in cystathionine causing cystathioninuria112. This is an autosomal 
recessive condition that results in an excess of cystathionine excretion in the urine, 
secondary to the high levels in the blood due to dysfunctional conversion to cysteine.  In 
vascular endothelium H2S produced by CSE was implicated in neovascularisation. Therefore 
CSE expression is expected to be strong in the endothelial cells113. The mechanism through 
which CSE regulates angiogenesis will be discussed later114.   
3-mercaptopyruvate sulphurtransferase, also known as 3-MPST, is part of the chemical 
family of transferases. This class of enzymes regulates the transfer of functional groups 
from a donor molecule to the acceptor molecules. This family of enzymes throughout the 
body oversees many biochemical reactions and therefore they play an integral role in 
physiological functioning115. 3-MPST occupies a key role in 2 major reactions such as 
cysteine degradation and cyanide detoxification116. The role of 3-MPST under investigation 
is its ability to convert cysteine into H2S as part of the trans-sulphuration pathway. A 
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deficiency of this enzyme has reported to play a part in a rare inheritable disorder known 
as mercaptolactate-cysteine disulphiduria (MCDU)117. A defective MPST gene has not been 
identified and associated with this disorder. 
3-MPST is now well recognised as a H2S generator. It is expressed in most cells and is 
distributed between the mitochondrial and cytosolic compartments of most tissues118. H2S 
produced via the 3-MPST pathways was evidenced to play a role in vasodilation or as a 
neurological signalling molecule. Experiments conducted in hepatocytes have shown the 
down regulation of intramitochondrial 3-MPST mediated production of H2S secondary to 
exposure to increased levels of H2O2
119
.  Therefore under conditions of increased oxidative 
stress H2S production via the 3-MPST pathways is proposed to be reduced.  
Oxidative stress occupies a vital role in mammalian bioenergetics. The reactive oxygen 
species (ROS) e.g. superoxide (O2
-) are produced under physiological and pathological 
conditions120. Mitochondrial respiration produces oxidants that are successfully 
counteracted by endogenous antioxidants. However, in conditions of increased oxidative 
stress this clearance of radicals does not happen optimally. In endometrial 
adenocarcinoma and hyperplastic endometrium the activity of the antioxidant superoxide 
dismustase is significantly down regulated by 50%, when compared to benign endometrial 
disease120.  This reduction in anti-oxidative activity leads to an accumulation of free 
radicals, thereby increasing oxidative stress on cells120. No evidence exists looking at the 
regulation of 3-MPST in endometrial cancer and with above the evidence a reduction in 3-
MPST mediated production of H2S should be seen.  
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 Commercial compounds used in the investigation of H2S in tissues  1.5.2
 
H2S is a sulphur analogue of water with a lower polarity allowing it to dissociate freely in a 
medium of any polarity121. As aforementioned the highly lipophilic nature of H2S allows it 
to dissolve and cross cell membranes without the need for transporter proteins. It is 
weakly acidic in solution with a pH 7.4 at 37°C as found in vivo.  At 37°C 80% of H2S 
dissociates to form HS- ions. It is not clearly defined which form of H2S contributes to its 
physiological effects. In vivo the predominant HS- species binds to haemoglobin voluntarily 
or reacts with other metallic compounds121.  
The role of H2S in redox reactions was explored and its strong ‘reducing’ nature was 
confirmed122. It readily oxidizes to different forms of sulphur i.e. sulphur or sulphur dioxide 
and these reactions are catalysed by the presence of metals including Fe2+ and blocked by 
the addition of metal ion chelators such as diethylene triamine pentacetic acid (DTPA)123.  
Figure 5 Conversion of L-cysteine into hydrogen sulphide via the trans-sulphuration pathway. (Adapted from: 
H2S releasing agents: chemistry and biological applications)
2
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Besides directly measuring H2S levels drugs can also be used to indirectly observe the 
effects in biological samples. Drugs related to hydrogen sulphide can be classified as H2S 
administrators or inhibitors of H2S synthesising enzymes. The H2S administrators augment 
the systemic and local production of H2S and the inhibitors have the opposite effect. H2S 
donors can be organised into 3 groups; inorganic, organic and agonists of H2S synthesising 
enzymes124. 
 Inorganic sulphide salts2 1.5.2.1
 
The inorganic compounds such as sodium hydrogen sulphide (NaHS) and sodium sulphide 
(Na2S) have a rapid reactivity upon contact with aqueous solutions, with a half-life of 5 
minutes2. The use of inorganic compounds in research is limited as a rapid peak in H2S, as 
seen in a pulse cure, can be toxic to local tissues and errors in long term investigations 
leading to divergent results. In contrast, inorganic sulphide salts have been employed to 
treat various diseased cellular states, with resultant protective effects being exposed. 
Protective effects of sulphide salts were noticed against myocardial injury and 
inflammatory states such as osteoarthritis. Nevertheless these effects were highly sensitive 
to concentrations and duration of treatment, and showed pro-inflammatory effects when 
exceeding therapeutic parameters.  
This highly unstable release of H2S by these inorganic donors impedes tight control over 
H2S release in vitro and can be damaging in vivo. Notably commercial inorganic sulphides 
consist of impurities leading to the formation of polysulphides in NaHS solutions2. 
 Lawesson’s reagent 2 1.5.2.2
 
2,4-Bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulphide or also known as 
Lawesson’s reagent is produced by combining an anisole with phosphorus pentasulphide 
over heat. This reagent expressed H2S donor properties as an anti-inflammatory. Its role as 
a H2S donor is limited secondary to its poor solubility and rapid release of H2S aqueous 
solutions.  
Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphino-dithioate (GYY4137) is a water 
soluble derivative of Lawesson’s reagent, produced by the chemical reaction between 
morpholine and Lawesson’s reagent at room temperature. For the current study 
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experiments have been conducted over a period between 24-72 hours. Therefore a 
synthetic slow release organic compound GYY4137 was employed. This organic compound 
has a sustained and controlled release of H2S in aqueous media. GYY4137 was identified to 
cause a concentration dependent apoptosis of cancer cells (MCF-7) with no obvious 
detriment to normal cells, such as IMR90. As H2S is toxic to tissues at high doses it was 
imperative that pilot experiments were conducted to determine the concentrations at 
which the endometrial cancer cell lines could tolerate being treated with GYY4137. H2S 
release from GYY4137 is dependent on experimental parameters such as pH and 
temperature of solutions. An increased release of H2S is seen in acidic solutions and 
reduced at low temperature2.  
A comparative study looking at the function of H2S and GYY4137 in culture media has 
shown the differences in H2S release from these two donors
125. The release of H2S from 
GYY4137 was 10% of that released from NaHS but the release of H2S was controlled and 
sustained over a period of 7 days. NaHS released H2S rapidly with peak values reached 
between 30-50 minutes with a resultant decline in H2S levels
125.  
To observe the effect of suppressing the activity of H2S enzyme inhibitors have been used 
successfully. In vivo aminooxyacetic acid (AOAA) acts an inhibitor of aminobutyrate 
aminotransferase activity (GABA-T), thereby raising the levels of gamma- aminobutyric acid 
in tissues126. Further to this it is a known general inhibitor of pyridoxal phosphate 
dependent enzymes. It acts at the level of Schiff base links by attacking the interaction 
between pyridoxal phosphate (prosthetic group) and the enzyme. This prevents the 
substrate-enzyme complex from forming, thus impeding the catalytic activity of the 
enzyme126.  
DL-Propargylglycine (PAG) is a selective irreversible inhibitor of cystathionine gamma-lyase. 
Due to its high lipophilic properties it is able to easily permeate the cell membrane with 
little to no damage and exert its effects. 
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 Chemical reactions involving H2S 1.5.3
 
H2S was described to exert its effects by 3 mechanisms including methylation, oxidation 
and scavenging.  The methylation process is divided into primary and secondary stages. 
Primary methylation occurs in the cytoplasm. H2S is methylated into methanethiol and this 
reaction is catalysed using S methyltransferase. Methanethiol has a distinct odour and is 
subsequently converted to dimethylsulphide , secondary methylation. H2S methylation is a 
much slower process than oxidation127.  
Oxidation is the main process of H2S catabolism and occurs 10,000 times faster than 
methylation of H2S. Oxidation is the process through which the atoms in an element lose 
electrons with a resultant increase in the valence of the element. Mitochondrial oxidation 
of H2S produces thiosulphate, which is converted to sulphite and sulphate
128. This 
conversion is catalysed sulphide-detoxifying enzymes such as Rhodanese.  The oxidation 
process of H2S is catalysed by the presence of metal compounds i.e. Fe
2+129. H2S is a strong 
reducing compound and is used by the endogenous oxidation species present in 
vasculature such as superoxide and hydrogen peroxide.  
The scavenging role of H2S has described under conditions of acute oxidative stress. H2S 
was shown to elicit vasoprotection by both scavenging free radicals and by reducing 
radicals derived by the oxidation of NADPH. Furthermore,  methaemoglobin can scavenge 
H2S to form sulphhaemoglobin. In the presence of methaemoglobin the production of H2S 
is suggested to be reduced128.  
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 Measuring tissue and blood levels of H2S 1.5.4
 
Much deliberation and controversy exist around the most suitable method for monitoring 
the levels of H2S production and blood levels
130. This is owed partially to the difficulties that 
arise during attempts to measure free sulphide in biological tissues. H2S as a gas is highly 
volatile oxidative and reactive130. In addition inconsistencies arise in measurement of H2S 
due to the presence of bound labile sulphur in tissues. Hydrogen sulphide has a pKa of 6.84 
at a temperature of 37°C and hence, at body temperature approximately 30% of H2S is 
present in that form and the rest dissociates to form HS- anions. Uncertainty exists 
regarding whether one or both species of hydrogen sulphide contribute to its physiological 
function. In order to accurately measure free sulphide levels in samples the technique 
needs to be able to differentiate between free and bound labile sulphur, address the 
volatility and reactivity of H2S and distinguish between H2S and HS
2-.   
 
Several methods of measuring H2S are suggested and they can be direct or indirect 
methods. The direct methods measure H2S itself by trapping the gas; these include: gas 
chromatography and HPLC, methylene blue assay. Methods using fluorescence have been 
described where liberated H2S is trapped and the resulting product (sulphide dibimane) 
measured by reverse phase HPLC131, 132.  A modification of the methylene blue assay 
consists of a zinc precipitate phase. As the methylene blue assay takes place in acidic 
conditions the modified zinc precipitation method eliminates the acidic conditions and an 
extra protein solubilisation and wash step to remove artefacts that may produce 
inaccurate results131, 132. H2S serum levels in healthy adults have been measured using the 
methylene blue assay and sulphide sensitive electrodes.  
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 Role of H2S in vasculature 1.5.5
 
Endogenous H2S was shown to play a role in both physiological and pathological 
functions133-136. The physiological roles of H2S include vasorelaxation, cytoprotection 
against oxidative stress and promotion of angiogenesis4. These functions of H2S and its 
increased production in cancers have directly implicated it in the progression of many 
tumours. Angiogenesis is a prerequisite for the development and maintenance of tumour 
growth. It is defined as neovascularisation from existing blood vessels137. In adults 
angiogenesis is tightly regulated, with the endometrium being the site of cyclical 
neovascularisation.  The endometrium expresses both pro- and anti-angiogenic factors. 2 
of the main angiogenesis regulatory factors in the endometrium include the growth factors 
families {vascular endothelial growth factor (VEGF) and fibroblast growth factor family 
(FGFs)} and molecules involved in mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3-kinase (PI3K) signalling138.  The VEGF family is made up of six members 
(VEGF –A, -B, -C, -D and –E) with 3 receptors to bind to: VEGFR-1, -2 and -3. The ligands are 
dimeric cysteine – linked glycoproteins.  In the endometrium VEGF-A is mainly up regulated 
in hypoxic conditions but is also found to be oestrogen responsive. Oncogenes are also 
known to stimulate the production of VEGFs137.  VEGF-C/ uNK cells have been implicated in 
angiogenesis in the endometrium and its expression is noted to vary with menstrual cycle 
phase.  Moreover the receptors VEGFR-2 and VEGFR-1 are expressed in the endometrium, 
with up regulation of VEGFR-2 in the proliferative phase of the endometrium and its 
subsequent down regulation after ovulation with accompanied increased expression of 
VEGFR-1. VEGFR-3 is not expressed in the endometrium. The fibroblast growth factors 
(FGF) 1, 2 and 4 are expressed in the endometrium and play a synergistic role with the 
VEGF family. The FGF family up regulates the expression of VEGF-2 which in turn increases 
the release of FGF from the extra cellular matrix (ECM)87, 136, 137, 139.  
In many tumours VEGF-A is proposed to be the most effective angiogenic factor and its 
secretion is crucial in tumour maintenance. Epithelial membrane protein – 2 belongs to the 
GAS-3/PMP22 family and was shown to exert angiogenic effects via the up regulation of 
VEGF-A expression in endometrial vascular endothelial cells136. It is therefore apparent that 
the VEGF family play an important role in the tumourigenesis. In this study the role of 
hydrogen sulphide is being investigated. H2S is a known promoter of angiogenesis via 
stimulatory and inhibitory mechanisms136. In vascular tissue H2S production is mainly 
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regulated by CSE. Pathways implicated in H2S mediated angiogenesis include: the mitogen 
activated protein kinase pathway, PI-3K/Akt pathway and ATP- sensitive potassium 
channels. H2S is also proposed to inhibit phosphodiesterase, thereby promoting 
angiogenesis87.  
The role of H2S in the regulation of smooth muscle activity was proposed as one of its 
major functions. The endogenous levels of H2S in aortic smooth muscle have shown to be 
up to 100-fold more when compared with other organs such as liver, brain or heart, 
thereby suggesting an importance of H2S in smooth muscle regulation
140. H2S was shown to 
cause relaxation of smooth muscle in the GI tract, bronchial passages and bladder141. In 
vitro studies investigating the effect of H2S on rat thoracic aorta by H2S and NaHS and L-
cysteine resulted in relaxation of the arteries. This relaxation was counteracted with the 
addition of the CSE inhibitor PAG; thereby showing that L-cysteine exerted its effects via 
H2S production. In vivo studies showed the intravenous injection of H2S reduced mean 
arterial pressure142.  
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 Pathways involved in exerting effect of H2S 1.5.6
 
H2S exerts its effects through a variety of mechanisms. The most implicated pathway in H2S 
signaling is the KATP channels. Hyperpolarisation of the vascular smooth muscle cells results 
in the opening of these channels. Research studies where smooth muscle cells have been 
isolated from the rat mesenteric artery and incubated with H2S has shown the increased 
recruitment of open KATP channels with no alteration in their conductance.  Furthermore,  
the use of KATP channels antagonist, glibenclamide opposed the vascular relaxation effect 
of H2S both in vivo and in vitro. The incubation of smooth muscle cells in high K
+ conditions 
also counteracted the effects of H2S. In contrast, studies have also found that vascular 
endothelial relaxation is not dependent on KATP channels
143.  
Further mechanisms involved include   L-Type calcium channels, activation of myosin light 
chain phosphatase and stimulation of Cl-/HCO-3 in smooth muscle cells143. Sulphhydration 
of the reactive cys residue in target proteins was linked to H2S signaling. It was proposed 
that H2S exert its effect on ion channels via this mechanism. Sulphhydration is the addition 
of sulphur to cysteine from H2S to result in the conversion of the –SH group to –S-SH
144.  
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 H2S signalling in neoplasia 1.5.7
 
H2S may have an indirect approach in initiating neoplasia via interactions with other 
biological agents. H2S is known to act as a strong reducing agent and can be utilised 
endogenously in oxidative reactions. H2S is a highly reactive substance and can interact 
with S-nitrosothiol, producing metabolites such as NO, NO-, NO+. Nitric oxide (NO) was 
implicated in the endometrial cancer tumorigenesis via a variety of mechanisms. The 
expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) are up 
regulated in endometrial cancer145. The role of COX-2 as an angiogenic agent exerting its 
effect via the release of growth factors was implicated in endometrial tumorigenesis. NO 
was associated with carcinogenesis through its ability to assist genetic changes occurring in 
early phase disease, thus initiating tumorigenesis and the maintenance of tumour cells 
through angiogenesis145. A synergistic relationship between COX-2 and iNOS was described 
secondary to evidence suggesting that NO produced by iNOS activity enhances the activity 
of COX-2145.  
 
Recent evidence published by Csaba Szabo confirming the role of tumor derived H2S 
produced by CBS in colon cancer has lent a skeleton upon which experiments can be 
modified to apply in endometrial cancer. Human colon cancer biopsies and patient 
matched normal marginal mucosa were analysed to reveal a selective up regulation of CBS 
with a simultaneous increase in H2S, which was also true of colon cancer cell derived 
epithelial cell lines (HCT116, HT29, LoVo) when compared to benign colonic mucosal cells 
(NCM356.). As a secondary method ShRNA- mediated silencing or pharmacological 
inhibition using the CBS inhibitor aminooxyacetic acid (AOAA) resulted in a reduction of 
proliferation, migration and invasion of the HCT116 cell line4. Animal studies were 
conducted prior to which ethical approval was sought and approved by the Institutional 
Animal Care and Use Committee of the University of Texas Medical Branch. Nude mice 
were treated with AOAA resulting in attenuation of the growth of patient derived colon 
cancer xenograft and reduced tumour blood flow. Expression of CSE levels remained 
unchanged in colon cancer, thereby silencing of CSE using its inhibitor DL-Propargylglycine 
(PAG) did not affect tumour growth or bioenergetics. The overall concluding point 
highlighted by this study was the identification of CBS derived H2S as a tumour growth 
factor and anticancer drug target4.  
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The up regulation of CBS has also been described and its role attributed towards the 
progression of advanced ovarian cancer and drug resistance. Using patient tissue 
microarray (TMA), in vitro and in vivo studies were conducted during which it was shown 
that the expression of CBS was common in primary serous ovarian carcinoma. TMA 
consists of many small tissue samples derived from a variety of numerous cases on a single 
slide, thereby allowing analysis of many samples at one time. Results of this study 
concluded that in vitro the effects of pharmacological CBS silencing can be reversed by 
exogenous supplementation with the H2S donor sodium hydrogen sulphide
146. 
 
Conflicting evidence was published investigating the use of slow release H2S donors as anti-
cancer drug targets. The alternating role of H2S in exerting pro-apoptotic or anti-apoptotic 
effects was reportedly previously in cultured cells, though the exact mechanisms still 
remain undefined. In vitro and in vivo treatments of neoplastic and normal cell lines with 
the slow release GYY4137 revealed an anti-proliferative effect on neoplastic cells with no 
effect on normal cell line proliferation125. The use of a rapid releasing H2S donor i.e. sodium 
hydrogen sulphide (NaH2S) showed no effect on either neoplastic or normal cell lines. A 
study was conducted investigating the role of various slow release H2S donors (GYY4137 
analogues) to elicit their anticancer potential. A dose- dependent cellular apoptosis of 
neoplastic cells of seven differing human cancer cell lines was seen, with no effect on 
normal human cells. This conflicting evidence could be a result of the complex and 
ambiguous role of H2S and its synthases in tumorigenesis
125. The above articles are proof to 
the tissue specific roles of H2S and its effect in the endometrium is yet to be described.  
 
This study presents novel evidence looking at the expression of the three H2S synthesising 
enzymes CBS, CSE and 3-MPST in endometrial cancer and their correlation with expression 
of steroid receptors such as ER- alpha and –beta, PR and AR. Further cell culture 
investigations using the H2S donor GYY4137 and the H2S substrate L-cysteine have been 
used to treat an endometrial cancer cell line (MFE280s) to elicit any effects on proliferation 
if present. These are preliminary experiments and aim to show an association between H2S 
and endometrial cancer if present.  
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  Summary of project aims Chapter 2
and hypotheses 
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Growing evidence exists defining the role of endogenous hydrogen sulphide as tumour 
growth factor. Its effects include maintenance of cellular bioenergetics, angiogenesis and 
vasorelaxation, thereby supporting tumour growth and maintenance. This effect of 
hydrogen sulphide was confirmed in recent publications. Szabo et al4 compared patient 
matched normal colonic mucosa with colon cancer epithelial cells and cell lines to conclude 
the positive selective up regulation CBS. A similar selective up regulation of CBS and a 
subsequent rise in H2S was shown in primary ovarian carcinoma by Bhattacharya et al
146 
Owing to the established evidence this project explores the possibility of an existing 
relationship between H2S and endometrial cancer within a large cohort of women.  
Proof of principle for this study came from a small scale investigation conducted at The 
Women’s Hospital in Liverpool. Samples from a small sample size of n= 31 women were 
used for this study. 25 of these females had been diagnosed with endometrial carcinoma 
and n=6 were a postmenopausal, control group. Results of this study confirmed the 
presence of both CBS and CSE in human endometrium. The positive staining was confined 
to the endothelial and epithelial cells. There was weak diffuse cytoplasmic staining and 
strongly stained cells for CSE. CBS staining appeared solely cytoplasmic. A grade dependent 
increase in expression was also found with CBS (P<0.007). This pilot study concluded that 
CBS was a possible novel therapeutic drug target in endometrial cancer.  
 
2.1 Project objectives and hypotheses 
 Main objectives 2.1.1
 
1. Do hydrogen sulphide and its synthases (CBS, CSE and 3-MPST) play a role in 
endometrial cancer tumourigenesis? 
 
Hypothesis: There will be an up regulation of all the hydrogen sulphide synthesising 
enzymes, evidenced as increased cytoplasmic staining within the endometrial 
cancer cells when compared to their post-menopausal controls. 
 
 
2. Does a grade dependant expression of enzymes exist? 
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Hypothesis: The intensity of enzymatic cytoplasmic staining of cells will increase 
with an increase in grade of endometrial cancer..  
 
 Secondary objectives 2.1.2
 
1. Does the addition of a H2S donor have a direct effect on the proliferative 
potential of the MFE280 endometrial cancer cell line? 
 
Hypothesis: The addition of the organic H2S donor, GYY4137, will show an increase 
in proliferation of the MFE280s, thereby displaying the tumorigenic effects of H2S.  
 
2. Does addition of the substrate L-cysteine have an effect on the proliferation of 
MFE280s cell line? 
 
Hypothesis: The addition of L-cysteine will indirectly have a positive effect on 
proliferation of the endometrial cancer cell line. The H2S synthesising enzymes will 
metabolise the L-cysteine to produce H2S, with subsequent increase in proliferation.  
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  General materials and Chapter 3
methods 
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3.1 Ethical approval 
 
Human endometrial samples were collected from women undergoing surgery at the 
Liverpool Women’s hospital. The approval to do so was granted by the Liverpool Adult 
Local Ethics Committee (Appendix 1). The endometrial cancer and post-menopausal 
samples were collected under the terms stated in LREC references 11/H1005/4. Prior to 
sampling the endometrium, written informed consent was gained from every patient on 
the day of surgery.  
3.2 Patient recruitment  
 Patient identification and enlistment 3.2.1
 
Planned theatre lists at the Liverpool Women’s Hospital were studied to identify women 
who were undergoing suitable gynaecological surgeries. Once recognised, these women 
were approached by selected GCP trained recruits within the research team to be 
consented. At the time of gaining informed voluntary consent, further details were 
attained with regards to patient demographics. This included information concerning their: 
BMI, age, menstrual history, parity, previous gynaecological conditions, current or previous 
hormonal treatments and smoking history. During the consultation, a detailed information 
sheet (refer to appendix 2) covering the content of the research project was specified. 
Furthermore, the rights of the patient to refuse participation were stressed with 
reassurance that their decision would not affect their management.   
3.3 Study groups involved   
 
In this study non- pregnant endometrial cancer samples were compared against normal 
post-menopausal tissue. Patients were only recruited into the study if they met all the 
inclusion criteria and excluded if they met any of the absolute exclusion criterions. The 
absolute exclusion criteria included: pregnancy, breastfeeding or women undergoing 
hormonal therapy within 3 months of surgery.  
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 Endometrial cancer patients 3.3.1
61 endometrial cancer biopsies were obtained from women diagnosed with either type 1 
(n=43) {FIGO grade 1 (n=24), grade 2 (n=11) or grade 3 (n=8)} or type 2 (n=18) endometrial 
cancer.  
 Post- Menopausal patients 3.3.2
 
The post-menopausal group was included as a comparative/ control group for the 
endometrial cancer group. All of the patients diagnosed with endometrial cancer were 
post-menopausal in this study (age range 51-87). The women included in the post-
menopausal group (n=16) were undergoing surgery for pathologies distinct from neoplastic 
endometrium.   
PM endometrium is atrophic and the use of pre-menopausal proliferating endometrium 
may also be valid as endometrial cancers develop with oestrogen stimulation. However 
some endometrial cancers develop without oestrogen stimulation. PM endometrium 
retains the ability to respond to oestrogen and progesterone if present systemically and 
therefore PM endometrium has been used for this study.  
 Inclusion and Exclusion criteria 3.3.3
 
Highlighted below are the inclusion and exclusion criteria for the recruitment of patients 
for this study.  
Table 8 Inclusion criteria for both endometrial cancer and post-menopausal groups within the study 
Group Inclusion criterion 
 
Endometrial cancer 1- Patients must have the capacity to give 
written informed consent 
2- Undergoing surgical hysterectomy and pipelle 
biopsies at the Liverpool Women’s hospital 
for endometrial cancer 
Post-menopausal 1- 12 months since LMP 
2- Operated upon at the Liverpool Women’s 
Hospital for a benign, non-endometrial 
pathology. 
3- Patients must be competent and thereby 
have the capacity to give written informed 
consent 
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Table 9: Exclusion criteria for both endometrial cancer and post-menopausal groups within the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Exclusion criterion 
 
Endometrial cancer 1- Pregnancy, breast-feeding or hormone 
therapy up to 3 months before surgery. 
Post-menopausal 1. History of post-menopausal bleeding / 
endometrial pathology 
2. Hormone replacement therapy (HRT) 
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3.4 Tissue collection techniques 
 
Either full thickness or pipelle sampling can obtain endometrial biopsies. The process of 
endometrial sampling is dependent on the type of surgical technique employed. Trained 
individuals of the research team held the responsibility of collecting tissue samples in 
theatre once the surgical procedure had been completed. Tissue samples used for this 
study were collected over the past 3 years.  
 Endometrial biopsy  3.4.1
 
 Full thickness samples: 
Women undergoing hysterectomies were the group from whom full thickness endometrial 
biopsy samples were taken. Full thickness samples comprise of the endometrial lining 
extending through to the myometrium. In order to collect a full thickness sample, once the 
uterus was excavated from its anatomical position it was transferred onto a surgery trolley 
and placed face down. An incision was made with the use of a size 22 carbon steel surgical 
blade (Swann- Morton, UK) on the posterior aspect of the uterus spanning the length, from 
the fundus down to, but not including the cervical canal. The exposed endometrium was 
sampled by making a 25 mm lateral incision and dissecting 10 mm into the uterine wall. To 
ensure that the endometrium, endo-myometrial junction and myometrial layers were 
acquired the uterine tissue was held by Bonney tissue forceps (Phoenix Surgical 
instrument, Ltd, UK) whilst a medial cut was made to free the tissue.  
 
 Pipelle Samples: 
In cases where a hysterectomy was not performed a pipelle sample was taken at 
commencement of surgery. The patients’ external genitalia and surrounding area were 
thoroughly washed using a sterile aqueous solution (Sterets Unisept, Medlock Medical Ltd, 
UK). Once the area had been cleaned a Sims speculum was inserted into the vagina, 
allowing the cervix to be visualised. Vulsellum uterine forceps (Phoenix Surgical 
instrument, Ltd, UK) were used to draw the anterior lip of the cervix into the vagina. A 
pipelle was then passed through the cervix up to the fundus of the uterus. Once the total 
length from the external cervical os to the uterine fundus was noted, the plunger was 
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pulled back to create suction, drawing the endometrial tissue into the pipelle as it was 
slowly rotated and withdrawn from the uterus. This slow rotatory movement ensured 
maximal sampling of the endometrium.  
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3.5 Tissue processing 
 
Once the endometrial tissue samples for immunostaining were obtained they were placed 
directly into 15 ml of neutral buffered formalin (NBF; Sigma-Aldrich, UK) contained within a 
universal tube. NBF consists of approximately 3.7-4% formaldehyde. This is an organic 
compound that allows the formation of cross links between primary amino groups in 
proteins to adjacent nitrogen atoms in proteins or DNA. By placing the samples into NBF, 
the tissue sample is preserved as close to its original biological state as possible. Prior to 
processing the samples were incubated for at least 24 hours in NBF. The Shandon Citadel 
1000 machine was then used to dehydrate and impregnate these tissue samples with 
paraffin. For a detailed explanation of tissue processing please refer to appendix 3a.  
 Tissue processing protocol 3.5.1
 
The incubation times and solution in which the tissue was processed is highlighted below 
in table 9. 
Table 10 Tissue processing protocol 
Solutions Time 
(Minutes) 
10% NBF 45 
Ethanol 60% 60 
Ethanol 70% 60 
Ethanol 90% 60 
Ethanol 100% 60 
Ethanol 100% 90 
Ethanol 100% 120 
Xylene 1 60 
Xylene 2 90 
Xylene 3 120 
Parrafin wax 1 150 
Paraffin Wax 2 210 
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 Sectioning 3.5.2
 
Once processed the samples were embedded in paraffin wax, after which sectioning took 
place. Care was taken whilst embedding to ensure the accurate orientation of the tissue to 
depict its morphology accurately. The paraffin embedded tissue samples were sectioned 
into 4μm thick slices using the Microm HM355 rotary microtome (Microm Ltds, UK). Once 
the samples were cut they were floated onto a waterbath kept at a temperature of ~40°C 
(refer to appendix 3b ‘Cutting paraffin sections’).  Slides coated with aminopropyl triethoxy 
silane (APES) were dipped into the water bath collecting the tissue onto them (refer to 
appendix 3c for ‘APES coating procedure’). The slides were labelled and allowed to air-dry  
prior to use. Once dry, the slides were filed away into labelled plastic slide cases.  
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3.6 Preparation of slides prior to IHC 
 
Once the appropriate tissue samples had been selected, they were labelled with the 
experiment criterion: date, incubation time, antigen retrieval specifics and concentration 
of antibody used. The slides were transferred to a metal staining rack and later placed into 
a heated chamber at 60°C for one hour or at 37°C overnight for ‘baking’. Heating the slides 
ensures the removal of residual moisture between the tissue section and slide that may 
impede adhesion. At this point care was taken not to ‘over bake’ the slides leading to 
degradation of proteins within the tissue leading to divergent staining results.  
3.7 Immunohistochemistry (IHC) 
 
IHC is a procedure that shows specific antigens in tissues by the use of enzyme markers. 
The application of primary antibodies allows specific antibody –antigen complexes to form 
and horse radish peroxidase labelled secondary antibody reacts with the enzyme substrate 
to produce a brown coloured product, thereby allowing the visualisation of antibody 
localisation. Therefore it can be concluded that a crucial component of immunostaining is 
the antibody.  
Antibodies are proteins that are also known as immunoglobulins or IgG molecules. These 
immunoglobulins are synthesised by the plasma cells and there are 5 major groups within 
the body, namely: Immunoglobulin A (IgA), IgD, IgE, IgG, IgM. They are present in the blood 
and are used by the immune system to attack foreign molecules (antigens) that enter the 
body. Antigens are also protein compounds, often polysaccharides that are present on the 
surface of cells. IgG antibodies are found in most body fluids and are present in antiserum 
once the cells and fibrin are removed. This property can be used to generate antibodies for 
clinical use. An antigen from a human can be injected into a host animal, such as a mouse. 
This host species creates antibodies against the antigen. These antibodies are extracted 
and purified, to be applied to human tissue to identify the location of antigen within a cell. 
Monoclonal antibodies are a homogenous group of immunoglobulins that can bind only to 
a single epitope and are most commonly developed in mice. Monoclonal antibodies were 
used in this study and are made by combining myeloma cells with splenic cells from a 
mouse that was injected with the antigen of choice. Though monoclonal antibodies are 
expensive to produced when compared with polyclonal antibodies, the advantages of 
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using monoclonal antibodies include; homogeneity, highly specific, unlimited quantitates 
of a single, well- defined reagent can be produced. Although relatively inexpensive to 
produce polyclonal antibodies tend to recognise many epitopes on a single antigen and 
display batch-to-batch variability. 
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3.8 Immunohistochemistry Methodology  
 Deparaffinisation regime  3.8.1
 
In order to successfully stain the tissue, the sections were submerged in xylene and 
progressively rehydrated by stepping the slides down an alcohol gradient. This ensures the 
successful adherence and tissue penetration. After de waxing samples the metal racks 
were transferred to a staining dish filled with tap water (See appendix 3d ‘prepping 
paraffin section for immunostaining’).  
Table 11 Deparaffinisation regime 
 
 Epitope (antigen) recovery  3.8.2
 
Formalin fixation prevented tissue autolysis and immobilised antigens. During fixation 
antigens undergo chemical alterations of their primary, secondary and tertiary structures. 
This can result in masking of antigenic sites due to changes to the epitopes or adjacent 
proteins, thus preventing the formation of antigen-antibody complexes. Resultant 
divergent results would be seen as false negative staining / weakly stained tissue samples. 
The epitopes were unmasked by the use of a heated solution such as citric acid or Tris -
EDTA known as heat induced epitope retrieval (HIER).  The table below represent the HIER 
parameter for all 3 antibodies used.  
Table 12 Antigen retrieval conditions 
 CBS CSE 3-MPST ER-alpha 
Antigen retrieval Tris- EDTA 
3 minutes 
Citrate  
4 minutes 
Citrate  
4 minutes 
Citrate  
2minutes 
 
Solution Minimum time in solutions (minutes) 
Xylene 1  10 
Xylene 2 10 
Ethanol 100%- 1 5 
Ethanol 100%- 2 5 
Ethanol 90% 1 
Ethanol 70% 1 
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The samples were heated at full pressure in a pressure cooker. The buffer solutions used 
include a 0.1M concentration citrate based buffer (pH 6) for CSE, 3-MPST and ER-alpha 
10mM Tris in 1mM –EDTA concentration Tris-EDTA buffer (pH 9) for CBS. Both buffer 
solutions were diluted with distilled water immediately prior to use. Citrate (150mls 
buffer+1350mls distilled water), Tris-EDTA (300mls buffer+ 1200mls distilled water). The 
heated environment causes protein links to unfold whilst the buffer solution maintained 
the unravelled structure of the proteins. The duration of treatment varied for all 4 
antibodies that were stained for and are stated in the table above. Once the slides 
underwent antigen retrieval they were returned to the staining dishes filled with water, 
following which they were transferred into Tris buffered saline (TBS) for 5 minutes.  
 
 
 
 
 
 
 
 
 
 Blocking endogenous peroxidase activity 3.8.3
 
Red blood cells and eosinophils may contain reactive sites that are similar to the binding 
sites on target antigens, resulting in false positives staining, illustrated in figure 6. 
Reduction of background staining can be achieved by incubating the tissue samples with a 
buffer solution known as hydrogen peroxide (Sigma, lot# S2BC3560V, H1009-500 mls, USA) 
30% (w/w) in water for 10 minutes. This buffer blocks the reactive sites at which the 
antibodies may bind, thus limiting background staining.  
 
A 
B 
C
V 
D 
Prior to epitope retrieval After HIER epitope 
retrieval 
Tissue 
Figure 6 HIER: A) protein bonds masking antigen binding sites, B) Primary antibody, C) buffer 
solution + heat and D) formation of primary antigen- antibody complex. 
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Endogenous 
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staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incubating tissue samples with normal horse serum prevents non-specific antibody binding 
refer to figure 7. Preliminary experiments conducted using the mouse monoclonal 
antibodies CBS, CSE and 3-MPST revealed no significant change in staining with or without 
a horse serum block. Hence this step was omitted from the IHC protocol for these 
antibodies in this study. However whilst staining for ER-alpha a rabbit polyclonal antibody 
the tissue sections were incubated with normal horse serum for 30 minutes.  
 
 
 
 
 
 
 
Figure 7 Illustration showing the false positive staining prior to blocking endogenous 
peroxidase activity 
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Normal horse 
serum blocks 
non- specific 
antibody binding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Illustration displaying results of blocking non- specific antibody staining. 
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Antigen 
Primary antibody 
 Primary and Secondary antibody staining 3.8.4
 
Prior to the application of primary antibody to the tissue sections a DAKO hydrophobic 
marker pen (DAKO, Cambridge, UK) was utilised to encircle the sections, after which the 
slides were returned to the humidifying chamber.  
The IHC protocol can be split into 2 stages. The first stage focused on incubation of the 
tissue sections with a primary antibody, to allow the formation of an antibody-antigen 
complex, as shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Illustration of a primary antibody-antigen complex 
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Two different CSE antibodies have been used to stain the tissue sections in this project, 
owing to the first batch running out partway through the experiments. The first run (7 
sections out of 81) was stained with CSE 1:500 dilution, Novus biologicals, 0.1mg/ml. 
Thereafter all sections have been stained using the CSE antibody sourced from Abnova 
following its optimisation as will be discussed in chapter 4.  
A table containing the details of the primary antibodies used in the study is listed below.  
Table 13 Immunohistochemistry (IHC) – Antibody details and conditions 
Conditions Enzymes stained for 
 CBS CSE 3-MPST 
Company Abcam Abnova Santa Cruz 
Concentration 1:300 1:3000 1:400 
External control Liver Liver Human colon 
Antigen retrieval 
 
 
 
Tris-EDTA  
3 minutes 
  
Citrate 
4 minutes 
Citrate 
4 minutes 
Negative control Mouse IgG 
1:500 
Mouse IgG 
1:500 
Mouse IgG 
1:500 
Incubation period 4C overnight 4C overnight 4C overnight 
Mono/poly clonal Monoclonal Monoclonal Monoclonal 
Clone 3E1 (ab 124276) 4E1-1B7 H-11 
Suggested dilutions 5µg/ml.  0.5 mg/ml 200 µg/ml 
 
For correlation of CBS, CSE and 3-MPST expression with steroid receptor expression, a 
similar sample dataset were stained and score by Dr. Areege Kamal and Miss Eve Bunni. 
The antibody details and experimental parameters are detailed in table 13.   
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Table 14 IHC: Antibody details for steroid receptors stained and scored by Dr. Areege Kamal and Miss Eve 
Bunni. 
 Androgen receptor 
 
Progesterone 
receptor  
Oestrogen Receptor- 
beta 
Company Dako, Glostrup, 
Denmark 
Dako, Glostrup, 
Denmark 
Serotec 
Concentration 1:75 1:1000 1:50 
Antigen retrieval 
 
 
 
Citrate 
3 minutes 
Citrate 
2minutes 
 
Citrate  
2 minutes 
Internal control Endocancer 74-2 SPCN 118 tube Endocancer 72 
Negative control Mouse IgG Mouse IgG Mouse IgG 
Incubation period 4⁰C overnight 30 minutes, room 
temperature 
4⁰C overnight 
Clone M3562 M3569 MCA1974S 
 
Table 15 IHC antibody details for oestrogen receptor-alpha 
 Oestrogen receptor- alpha  
Company Abcam, Cambridge, UK 
Concentration 1:50 
Antigen retrieval 
 
 
 
Citrate  
2 minutes 
Internal control Endocancer 72 
Negative control Rabbit IgG 
Incubation period 2 hours, room temperature 
Clone Ab137738, Rabbit polyclonal 
 
For CBS, CSE and 3-MPST the tissue sections were incubated with 70 μl of primary 
antibody, overnight at a temperature of 4˚C. The primary antibody was diluted in 
phosphate-buffered saline (PBS) containing 2% (w/v) bovine serum albumen (BSA). For ER-
alpha the section were incubated with 70 μl of primary antibody for 2 hours at room 
temperature. Once the primary antibody incubation was completed it was removed by 
tapping the slide on its side before the slides were washed twice for 5 minutes in TBS to 
remove any excess antibody. The tissue sections were incubated for 30 minutes at room 
temperature with 1-2 drops of Horseradish peroxidase (HRP) labelled secondary antibodies 
derived from mouse hosts (Vector ImmPRESS, Cat #: MP-7402,  Vector, Peterborough, UK).  
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ANTIGEN 
Primary 
antibody 
Secondary 
antibody 
HRP 
 
 
 
 
 
 
 
 
 
HRP is a common enzyme found in tissues and is often used to label secondary antibodies 
to allow the detection of target antigens. The use of DAB to detect these complexes is 
based upon enzymatic action. The addition of DAB chromogen to the HRP labelled 
secondary antibody initiates an instantaneous formation of coloured insoluble precipitate, 
seen as a dark brown colour.  
DAB chromogen solution (30 μl of DAB concentrate in 1ml OF ImmPACT diluent) (ImmPACT 
DAB, Vector, Peterborough, UK) was applied to the tissue section for 10 minutes at room 
temperature. Upon removal of DAB the slides were transferred immediately into water, to 
halt the reaction. Gills-2 hematoxylin (Thermoscientific, Loughborough, UK) was used to 
counterstain the slides for 2 minutes and the slides were placed under running tap water 
for 1 minute. The slides were momentarily immersed in 1% acid alcohol removing excess 
hematoxylin staining. This is a regressive method of staining where tissue samples are 
deliberately over stained then differentiated until acceptable staining is reached.  
Following acid alcohol treatment the slides were placed under running tap water. The 
tissue sections were dehydrated up a concentration gradient of alcohols, ending in xylene 
and mounted with cover slips using Consul Mount (Thermoscientific, Loughborough, UK). 
The slides were allowed to dry within the fume hood overnight before they were imaged. 
For a detailed description of the IHC procedure please refer to Appendix 3E.  
 
Figure 10 Formation of the secondary antibody-antigen complex after the 
administration of HRP labelled secondary 
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 Controls  3.8.5
 
Ordered sections of one positively staining sample was cut and included in every run. 
These positive internal controls were paralleled against one another to compare the 
intensity of staining in each run. Provided the intensity of staining was consistent 
throughout all runs, the samples were scored. In addition to the positive controls, each run 
also included a negative IgG control for each specimen in one slide at the very least to 
ensure specificity of staining in each run. External tissue positive control sections were also 
included in a run at commencement of staining for each antibody and were consistent 
throughout. This allows an accurate assessment of staining to be made compared to a 
tissue in which the staining pattern was established. A negative control was included for 
each antibody in every run as highlighted in table 15. 
Table 16 IHC controls for all antibodies 
Antibody Internal intensity of 
staining control 
External positive 
control 
Negative control  
CBS Endocancer 14-2 Liver Endocancer 14-2 
Mouse IgG 
CSE Endocancer 15-1 Liver Endocancer 15-1 
Mouse IgG 
3-MPST Endocancer 3 Human colon Endocancer 3 
Mouse IgG 
ER- alpha Endocancer 72-4 Endometrium  Endocancer 72-4 
Rabbit IgG 
ER-beta Endocancer 72-4 Endometrium Endocancer 72-4 
Mouse IgG 
PR SPCN 118- tube Endometrium SPCN 118- tube 
Mouse IgG 
AR Endocancer 72-4 Endometrium Endocancer 72-4 
Rabbit IgG 
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3.9 Image capture  
In order to assess the differential staining patterns seen with all 3 antibodies it was 
necessary to assess the location and intensity of staining.  
 Image capture  3.9.1
 
High-resolution images of the stained tissue sections were captured using the Nikon 
Eclipse microscope and camera head (Nikon, Tokyo, Japan). 10 consecutive detailed 
micrographs containing the malignant cells of the endometrial cancer tissue sections were 
taken. With regards to the post-menopausal and other full thickness samples, only the 
glandular epithelium was imaged and scored as it is the epithelial cells that undergo 
malignant transformation. By ensuring that only the functional layer of the endometrium is 
imaged and scored, a more accurate direct comparison of these samples can be made with 
those obtained by a pipelle. The images were taken at x400 magnification (x40 objective 
and x10 eyepiece).  
 Modified QuickScore 3.9.2
 
The fundamental principles of this technique focus on combining the intensity and 
proportion of staining. Prior to the commencement of scoring these samples, images were 
taken to define the weak, moderate and strong staining for each enzyme. The samples 
were thoroughly examined on a lower power at x4 or x10 and once an overall picture of 
staining was attained the samples were visualised at a higher magnification x20 and 
imaged at x40. A standardised set of values was used to keep scoring consistent between 
users, as listed in the table below. 
Table 17 Standardised criteria for Quickscore 
Percentage of stained tissue (%) Intensity of staining 
1 Less than 25%stained 0  No staining 
2 25-50 % stained 1 Weak staining 
3 50-75% stained 2 Moderate staining 
4 More than 75% 3 Strong staining 
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Before the final scores were used to create graphs all the micrographs were scored 3 times 
to ensure accuracy of scoring. Further to this 16 slides from the 81 cohort were blinded 
and scored by one other person. The scores were then compared and only 2 scores were 
found to be no more than 2 points off one another with the rest being identical.  
Once the score was determined the values were inserted into a Microsoft Excel 
spreadsheet and a total value for each section was calculated as seen in table. 
A formula to calculate the total score for each tissue section is as follows: 
Total quick score = (0xa) + (1xb) + (2xc) + (3xd) 
The maximum score achievable by the use of this method is 12 (sum of % x intensity of 
score). Furthermore, a maximum value of 4 can be attributed for percentage of tissue 
stained. If 100% of the tissue section is strongly stained then the scores would be as 
follows.  
Grade Cancer 
Sample 
Intensity    Total Total 
  0 1 2 3   
Example: 1 Endocancer  0 0 0 4 0+0+0+12 12/12 
 
Table: Example score sheet.  
Grade Cancer 
Sample 
Intensity    Total Total 
  0 1 2 3   
1 Endocancer 2 0 2 1 1 2+2+3 7 
Serous Endocancer 6 0 1 3 0 1+6 7 
MMMT Endocancer 7  0 2 2 0 0+2+4 6 
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 Statistical analysis 3.9.3
 
Prism 6, GraphPad (GraphPad Software, Fay Avenue, USA) was used for the analysis of data 
obtained in this study. SPSS database 20 (IBM, PORTSMOUTH UK) was used for the 
correlational studies conducted with the steroid receptors. Non-parametric tests were 
used for the analysis as the data were not normally distributed. Mann-Whitney test was 
used to compare pairs of data and the Kruskal-Wallis test was used for comparison of 
groups of data. P values <0.05 were considered to be significant and post hoc tests were 
used at the second stage of analysis of variance (ANOVA). Once expression of CBS, CSE and 
3-MPST between the cancer and control cohort had been determined, correlational studies 
using the Spearman’s rank correlations test were conducted.  
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3.10 Cell culture 
 
The essence of cell culture is the removal of cells from their hosts and their consequent 
growth in an artificial environment under favourable conditions. Cells can be cultured in an 
adherent/ monolayer culture or a suspension culture. In this study the former method was 
used.  
Endometrial cancer cell lines were cultured in vitro in order to treat them with hydrogen 
sulphide donors and enzyme substrates to evaluate the subsequent effect on their 
proliferative potential. 2 endometrial cancer cell lines were chosen to undergo the above 
investigations.  
Initial experiments were carried out using the Ishikawa cell-line which was derived from a 
grade 1 well-differentiated human endometrial adenocarcinoma (Public Health England, 
Salisbury, UK). 10 millilitres of Dulbecco's Modified Eagle Medium (DMEM/F12) (Sigma, 
UK), FBS 10% (BioSera, UK) to which the antibiotic, PrimocinTM (1:500 in media, InvivoGen) 
and L-glutamine (2mM, Sigma) were added was used as the culture medium to support the 
growth of the cells. The same medium was used to culture another endometrial cancer cell 
line known as MFE280.  
Later experiments were conducted using the MFE280s alone. These cells were cultured 
and maintained in 10mls of DMEM/F12 (phenol free, Life Technologies, UK) with 5% 
charcoal stripped FBS (Sigma, UK). In contrast to the Ishikawa cell line, the MFE280s are 
slow growing and require a long incubation period ranging between 4 and 6 days to 
achieve an appropriate confluence (80-90%) before cells can be seeded.  In light of using 
reduced serum media to maintain cells the cells required a change in media 3 days post 
commencement of culturing. This is to ensure that cells did not enter a state of starvation 
and consequently their survival compromised.  
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 Cell culture methodology 3.10.1
 
The human endometrial MFE280 cell line (#98050131) was from Public Health England, 
Salisbury, UK. The cells were derived from a recurrent, poorly differentiated endometrial 
carcinoma from an elderly patient. The cell lines were stored at -70C in a freezer in 
solution (90% FBS+ 10%DMSO). Dimethyl sulphoxide (DMSO) stops intracellular 
crystallisation of cells.  Prior to placing them onto cell culture plates they were defrosted 
rapidly in a waterbath at 37°C. Once defrosted, they were handled in the class II 
microbiological safety cabinet (MSC). 25 centilitre tissue culture flasks were filled with 10 
ml of pre warmed DMEM (Sigma, UK) containing 10% FBS (BioSera, UK), PrimocinTM  (50 
mg/ml, 1:500 in media, InvivoGen) and L-glutamine (2mM, Sigma) to which 1ml of 
MFE280s were added using a 1000 μl pipette and left to adhere to the surface of the flask 
over-night in an incubator maintained at a temperature of 37C. Ensuring the cells had 
adhered to the culture plate, the media was changed 24 hours after plating to ensure all 
DMSO was cleared. The cells were monitored daily to assess the confluence.   
Once the cultured cells reached an appropriate confluence (80-90%) they were ‘split’. The 
cell culture plate (100mmx 20mm treated and non-pyogenic) was transferred to the MSC 
where the resting media was removed using a Pasteur pipette. The cells were washed 
thrice using phosphate buffered saline (PBS). 1 ml of trypsin was added to the cells for 5 
minutes and returned to the incubator to allow protein bond degradation between the 
cells and the tissue culture plates. Once a ‘mucus’ consistency was seen in the plate 2 ml of 
media was added to the plate to inactivate the trypsin. Cells were collected into a 15 ml 
tube and centrifuged to allow the formation of a cell pellet. The centrifuge was set to run 
for 5 minutes at 500 RCF. The supernatant was tipped into Virkon, and 3 ml of fresh media 
was added to the cells and thoroughly mixed to create the stock solution. 3 consecutive 15 
ml tubes were arranged into which the serial cell dilutions were placed. 1 ml of stock 
solution was mixed into 10 ml of media. Once the 2 solutions had been combined, 10μl of 
this dilution was placed onto a cell grid to enable analysis of number of cells/100 μl. 
Further dilutions were calculated dependent on number of cells present.  
100 μl of cellular media was pipetted into each well and seeded in triplicates at various 
densities ranging from 18.5x104 cells/ml to 4.5x104 cells/ml in 96-well tissue culture 
microtiter plates (Nunc, Fisher Scientific, UK). More than one plate was set up at once with 
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respect to different treatment times. The 96 well microtiter plates were returned to the 
incubator overnight to allow adhesion of cells to the surface of wells prior to treatment of 
cells with various reagents.  
 Substances used to alter the proliferation rate of endometrial cancer cells 3.10.2
lines 
 
GYY4137 is a small molecule releaser of H2S and is used in investigations where slow and 
controlled release of H2S is required over a long period of time. An 80 mM stock was 
produced by dissolving 30 mg of GYY4137 in 1 ml of water. Further dilutions of 50, 100, 
200 and 400 μM solutions were used for the treatment of Ishikawa cells in initial 
experiments. However, concentrations over 100 μM were observed to be toxic and so 
weaker concentrations of 25, 50, 75 and 100 μM were used for further investigations.   
L-cysteine (25mg/ml in water, Sigma, UK) is a known sulphur containing compound that is 
used as a substrate by CBS, CSE and 3-MPST in H2S synthesis. MFE280s were treated with 
100 μl of 1 mM and 3 mM concentrations of L-cysteine and any effect on proliferative 
potential of the cell line was measured reading the absorbance of the solubilised solution.   
After the overnight incubation of the 96 well microtiter plates, they were removed from 
the incubator and transferred to the MSC. The existing media was removed using a pipette 
and disposed into Virkon, after which the cells were treated with 100 μl of various 
concentrations of GYY4137and L-cysteine. In addition to treated cells a row of control cells 
were left untreated to which 100 μl fresh media was added. These cells were returned to 
the incubator for the times stated below. 
Table 18 Experimental solvents and criteria for investigating cell viability of the MFE280 endometrial cancer 
cell line 
 
 
 GYY4137 L-cysteine 
Final Concentrations 25, 50, 75 and 100 μM 1, 3 mM 
Final Times 24 hours 48 hours 
76 
 
3.11 Monitoring cell proliferation using 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
 
Determination of cellular proliferation is an essential technique in cell based research. 
Proliferation is a useful marker to evaluate cytokine or hormonal activity. Techniques to 
stain cells are varied and can include tryphan blue staining that uses cell membrane 
integrity to approximate cell proliferation or death. However, this method is not very 
sensitive and cannot be moulded for high throughput screening. Radioactive material such 
as tritium-labelled thymidine is accurate but there are hazards associated with working 
with radioactivity.  
The technique used to evaluate the number of viable cells in this study was a colorimetric 
assay known as the MTT assay. This method of cell determination is useful in the 
measurement of cell growth in response to mitogens and growth factors, cytotoxic studies 
and production of cell growth curves. Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) is a tetrazole. This yellow, soluble substance is reduced to 
the insoluble purple formazan only in the presence of reductase enzymes found within the 
mitochondria of living cells. 
When the mitochondrial reductase enzymes come into contact with the MTT they cleave 
the tetrazolium ring which results in the production of formazan crystals which are 
insoluble in aqueous solutions and can only be solubilised in acidified isopropanol. Once 
the insoluble formazan crystals were solubilised the absorbance of this solution can be 
measured using a spectrophotometer at a wavelength of 570nm. The absorption max 
tends to rely on the solvent used. The cells were harvested in triplicates and were treated 
with varying concentrations of the substance under investigation, in this case the organic 
H2S donor GYY4137. The treated cells were then directly compared with cells that were left 
untreated, the controls. This allows the deduction of any relationship between the cells 
and H2S and provides results to evaluate whether a dose response relationship exists.  
If an increase in absorbance is detected, this assumes an increase in the amount of 
formazan produced representing a rise in the number of viable cells. Although accurate, 
the MTT assay does have certain drawbacks, such as the physiological conditions and 
variability of the activity of the reductase enzymes in different cells. Furthermore,  there 
are potential sources of error whilst conducting this assay. Appropriate storage of MTT at -
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20 °C away from light should be ensured to avoid degradation. Possible contamination with 
microbes leading to an increase in cleavage of tetrazolium rings causing divergent results. 
Finally irregular evaporation of media from wells in multi-well plates could produce 
erroneous results. 
 
 Cell proliferation assay 3.11.1
 
Once the treatment time with solutions was completed the plates were returned to MSC 
where the existing media was removed and replaced with 100μl of fresh media and 20μl of 
3(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reagent (5 mg/ml) (MTT; 
Sigma, USA) dissolved in PBS. Once the MTT was applied to the cells they were returned to 
the incubator for 3.5 hours in 5% CO2/air at 37
ºC. The 120 μl of solution was removed from 
the cells and disposed into Virkon. The cells were solubilised using 100 μl of a MTT 
solubilising solution made up of 4mM HCl 0.1% Triton X-100 in isopropanol. The microtiter 
plate was covered with foil and placed on the varishaker (DYNATECH) for 15 minutes. The 
absorbance of the solution was recorded using MultiSkan Ascent (Thermo Electron 
Corporation) with the Ascent software version 2.6 (Thermo Lab systems).   
Absorbance readings were averaged and corrected for blank (media alone with MTT 
reagent). The ratio relative to control (value of 1) was calculated.  GraphPad Prism 6 was 
used to analyse the standard error margins and create graphs of the numerical data. All 
graphs were plotted relative to the control value.  
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  Optimisation Chapter Chapter 4
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4.1 Immunohistochemistry (IHC) optimisation 
 
IHC is a highly sensitive staining technique that requires all components, such as: antibody 
concentrations, antigen retrieval, antibody incubation times and DAB to be optimal for 
effective staining. Prior to the commencement of immunostaining, various concentrations 
of antibodies were used to stain specific tissue sections. Different times of antigen retrieval 
were also employed. The optimal concentrations and times were chosen for staining.  
CBS antibody was optimised prior to the commencement of this project and therefore will 
not be discussed further in this chapter. 
 
 Optimisation of cystathionine gamma-lyase (CSE) antibody  4.1.1
 
A new batch of CSE antibody was received partway through the project and gave much 
stronger staining than the previous batch due to different stock concentrations (CSE 1:500 
dilution, Novus biologicals, 0.1mg/ml). Therefore titration of this antibody was required to 
match the staining intensity for the 2 batches on the same tissue before continuing with 
staining the remaining samples. The new batch of CSE antibody was sourced form Abnova 
(0.5 mg/ml) and was used to stain the endometrial tissue with various concentrations. This 
is an unpurified mouse monoclonal antibody raised against a full length recombinant CSE. 
Initially the new CSE antibody from Abnova was trialed at 1:100, 1:200, 1:400 and 1:500 
dilutions. Published evidence on the use of CSE antibodies for immunostaining revealed 
the appropriate conditions for antigen retrieval. The CSE (0.5 mg/ml) antibody was sourced 
form Abnova (clone number: 4E1-1B7). IHC staining was carried out using a horse-radish 
peroxidase (HRP) labelled polymer technique with (3,3-diaminobenzidine, DAB) (DAKO 
Ltd). A hydrogen peroxide (0.3% hydrogen peroxide in TBS) block was applied to sections 
for 10 minutes to inactivate all endogenous peroxidase activity. The sections were 
incubated in a humidifying chamber, overnight at 4°C. 70 microliters (µl) of the CSE 
antibody diluted in Tris-buffered saline (TBS) containing 0.5% (w/v) bovine serum albumen 
(BSA) with concentrations ranging from 1:100 to 1:500 were applied to the sections. These 
concentrations produced very dark and intense staining of the antibody throughout the 
tissue section, as can be seen in figure 12. 
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Figure 11 Comparison between the 2 clones of CSE antibodies 
Figure 12 Serial dilutions of new clone of CSE antibody at 1:2000, 1:2500, 1:3000 dilutions 
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The increased staining seen at concentrations of 1:500 resulted in further dilutions being 
applied. The CSE antibody was further diluted to produce concentrations of 1:1000, 
1:2000, 1:2500 and 1:3000. Dilutions of 1:2000 and 1:2500 still appeared very strong, as 
seen in figure 11. 
 
High magnification x400 {x40 objective and x10 eyepiece} micrographs displaying similar 
staining intensities at 1: 500 and 1:3000 CSE antibody dilutions as seen in figure 12. 
As the antibodies have been supplied at 2 different concentrations the dilutions were 
bound to differ. The difference in stock concentrations would suggest a 1:500 dilution of 
the previous antibody to contain a similar protein concentration in a 1:5000 dilution of the 
new CSE antibody sourced from Abnova. At 1:3000 dilutions the staining between the two 
antibodies was similar resulting in a 0.3 µg/ml staining with the new antibody and 
0.2µg/ml staining with the previous CSE antibody. A 1:3000 concentration was therefore 
decided upon for staining with the new CSE antibody.  
 
 
Figure 13 similar staining seen between 1:500 dilution of the previous CSE antibody and 1:3000 dilution of 
the new batch of CSE antibody 
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 Optimisation of 3-mercaptopyruvate sulphurtransferase (3-MPST) 4.1.2
antibody 
 
Little evidence exists regarding the expression of 3-MPST in the endometrium and any 
associated pattern of change in its expression in endometrial disease.  The suggested 
dilution for optimal 3-MPST antibody staining is 200 µg/ml (Santa Cruz Biotechnology, 
USA).  
 
An initial 1:400 dilution was used to stain specimens with ‘human colon’ being included as 
the external positive tissue control. Myometrial and endometrial samples were prepared 
with HIER in a citric acid buffer solution for 4 minutes and incubated overnight at 4°C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Faint staining of 3-MPST seen at 1:400 dilutions in citrate for 2 
minutes on an endometrial sample  
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The human colon was used as the external positive control for 3-MPST. When comparing 
the intensity of staining between human colon and the type 1 EC samples stained in figure 
13 it is apparent that the staining is weaker. The antigen retrieval time was increased from 
2 minutes to 4 minutes. This produced similar intensity of staining between the external 
human colon control and endometrial sample.  
 
 
 
 
 
 
 
 
 
Figure 15 Similar staining seen between human colon and PM controls 
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4.2 Optimisation of GYY4137 concentrations  
 
In vitro functional studies have been conducted with the use of GYY4137, an organic H2S 
donor derived from Lawesson’s reagent. The Ishikawa cell line (ISK) derived from a grade 1, 
well differentiated, endometrial adenocarcinoma was used. Once cells were cultured and 
seeded at appropriate densities, subsequent treatment of cells seeded in triplicates with 
GYY4137 over long periods of time, ranging from 12-72 hours was commenced. 
Concentrations ranging from 0 to 400 micromolar (μM) were investigated. Analysis of MTT 
assay results showed a lack of a dose dependent relationship, illustrated in figure 15. 
 
 
 
 
 
 
 
 
The lack of proliferation of the ISK cells in response to GYY4137 was thought to be due to 
its lower expression of CBS when compared to the MFE280s relative to GAPDH. In order to 
find the cell line that expressed CBS the most, all available cell lines were normalised to the 
enzyme glyceraldehyde 3- phosphate dehydrogenase (GAPDH). The results of 
normalisation can be seen below. 
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Figure 16 No change in cell viability of the Ishikawa cells could be seen after the administration of GYY4137 
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The MFE280 cell line expressed CBS the most and therefore was used to conduct all further 
in vitro experiments. The MFE280s have been derived from recurrent, poorly differentiated 
endometrial carcinomas. The cells required a longer incubation time in DMEM (Sigma, UK) 
containing 10% FBS (BioSera, UK), PrimocinTM (50 mg/ml, 1:500 in media, InvivoGen) and L-
glutamine (2mM, Sigma). More than 7 days were needed to allow the cell to form a 
confluent monolayer. 
The cells were ‘split’ and seeded at densities ranging from 18.5x104 cells per well to 
4.5x104 cells per well in triplicates. From an 80mM GYY4137 30mg / 1ml of water (Santa 
Cruz biotechnology, USA) stock solution, serial dilutions of 50, 100, 200 and 400 μM were 
created. The cells were treated over a 24, 48 and 72 hour period.  
 
 
 
 
 
Figure 17 Western blot illustrating normalisation of all available endometrial carcinoma 
cell lines to GAPDH 
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An increase in proliferation can be seen between GYY4137 concentrations of 0 and 50 μM 
within a 24 hour time period as seen in figure 17.  To investigate further the GYY4137 
concentrations were further broken down into 0, 25, 50, 75 and 100 micromolar and 
treated for 24 and 36 hours.  
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Figure 18 Graphical representation of mean and standard error margins (SEM) for viability of 
MFE280s in response to GYY4137 concentrations of 0, 50, 100, 200 and 400 μM at 24, 48 and 72 
hours. 
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Comprehensive numerical analysis of the data has shown a clear increase in proliferation 
of cells at 24 hours between concentrations of 0 and 25 μM. The biphasic appearance of 
the graph and the large SEMs does not make the values at 50 μM concentrations highly 
reliable. All available values for GYY4137 concentration of 50 and 100 μM at 24 hours were 
added to the current data set. This resulted in 15 replicate values being plotted at this 
concentration. 
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Figure 19 Graphical representation of mean and standard error margins (SEM) for proliferation of 
MFE280s in response to GYY4137 concentrations of 0, 25, 50, 75 and 100 μM at 24 and 36 hours. 
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The standard error margins have tightened with the addition of 15 replicate values with no 
change seen in the biphasic nature of this graph. Final concentrations for further 
experiments included 25, 50, and 75 μM at 24 hours.  
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Figure 20 Graphical representation of mean and standard error margins (SEM) for 
proliferation of MFE280s in response to GYY4137 concentrations of 0, 25, 50, 75 and 100 
μM at 24 hours 
89 
 
  The expression of H2S Chapter 5
synthases is altered in endometrial 
carcinomas 
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5.1 Introduction  
 
Endometrial cancer is the 4th most common malignancy seen in women residing in UK and 
EU countries5, 53, 54.  7400 new cases are diagnosed annually with a continual rise in 
incidence54. Endometrial carcinoma was classified into two sub groups. Type 1 
endometrioid carcinomas, whose development was associated with an unopposed hyper-
oestrogenic environment, can be preceded by atypical hyperplasia. Type 2 endometrial 
carcinomas or also known as non-endometrioid carcinomas hold a poor prognosis, are 
oestrogen independent and known to arise from an atrophic endometrium. The general 
presentation of endometrial cancer regardless of type is irregular and continuous bleeding 
secondary to invasion of vessels by malignant cells5, 53-55. Majority of women are post- 
menopausal at presentation with a median age of diagnosis of 63 years. It is an unlikely 
diagnosis in women less than 40 years, although not unknown.  Due to this post-
menopausal endometrium was used as the control group in this study.  
Current evidence implicates the much verified role of unopposed oestrogens both 
endogenous and exogenous in the development of endometrial carcinoma. Dysregulation 
of hormonal balance between oestrogen and progesterone in conditions such as diabetes, 
PCOS65, 71 or obesity56, 68 are known risk factors for the development of endometrial 
carcinomas. Increasing literature was published implicating various molecular pathways in 
carcinogenesis. Pathways such as PTEN, KRAS, and beta-catenin are associated with type 1 
carcinomas and TP53 typically seen in type 2 carcinomas have all been implicated as cancer 
drivers of the genome147. Driver mutations are those that encourage the growth and 
spread of neoplasia whereas other mutations, namely, passenger mutations tend not to 
contribute to cancer development. Discerning between these mutations can further 
current understanding of ominous pathways contributing to development and mortality of 
cancers147.  
Besides the much verified mitotic role of unopposed oestrogen in the development of 
endometrial cancer53-55, this project studies the prospective role of H2S as a biological 
signalling molecule in endometrial cancer. Experimental studies conducted in various 
organic tissues have defined some tissue specific roles of H2S. Furthermore, the presence 
of CBS, CSE and 3-MPST was described in various carcinomas4, 118.  
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No consensus of opinion exists regarding the best method of measuring H2S
132. This 
presents difficulty in direct measurement of H2S and requires the adoption of alternate 
method of detecting H2S. Methods such as IHC and western blot analysis allow the 
detection of H2S synthases in human tissues. Therefore, attempts were made to employ 
IHC staining for the localisation and quantification of the expression of H2S synthases in 
healthy PM endometrium and endometrial carcinoma tissue samples.   
CBS as aforementioned was shown to be up regulated in colorectal and primary serous 
ovarian carcinoma and the subsequent rise in H2S production was implicated in 
tumorigenesis4, 146. To ensure that the changes in proliferation seen are secondary to CBS 
derived H2S they explored the proliferative potential of another by product of CBS 
metabolism i.e. l-Cystathionine. The administration of l-Cystathionine failed to affect the 
proliferation rate of the cells. The release of H2S was directly quantified using the 
methylene blue assay. In addition the pharmacological inhibition of CBS using AOAA and 
shRNA mediated silencing of CBS revealed a reduction in tumour growth in vitro and in vivo 
thereby implicating the rise in H2S levels in carcinogenesis
4.  No change in expression of 
CSE and 3-MPST was observed in colorectal carcinomas.  The neovascularisation potential 
of CSE as a protective agent in cardiovascular disease and in tumour maintenance was 
evidenced by studies reporting the protective function of H2S against progression of 
cardiovascular disease through vasorelaxation, inhibition of cardiovascular remodelling and 
resistance to the formation of foam cells99.  
The release of free radicals and other reactive oxygen species was proposed in endometrial 
carcinogenesis with alteration in the function of the antioxidant superoxide dismustase148. 
This interference between free radical and anti-oxidant activity leading to increased 
oxidative stress has shown a down regulation of 3-MPST/ H2S pathway
119. 3-MPST has not 
been implicated nor its role clearly defined in carcinogenesis. Its cytoprotective role was 
proposed in a variety of tissues149, 150.  
Furthermore, an extensive literature search has shown no previous description of the 
expression of these enzymes or the role of H2S in the endometrium. This following chapter 
describes the examination of differential expression of H2S synthases at a cellular level in 
endometrial tissue acquired from women diagnosed with endometrial cancer and healthy 
PM endometrium with no endometrial pathology, in order to explore the possibility of the 
involvement of H2S or its synthases in endometrial carcinogenesis.  
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5.2 Method: Immunohistochemistry  
 Patient and specimen recruitment 5.2.1
 
The approval for this study was granted by Liverpool Adult Local Research Ethics 
committee (LREC references 11/H1005/4) and written informed consent was gained from 
all patients by GCP trained research personnel. The absolute exclusion criteria for all 
patients included: pregnancy, breastfeeding and women who have had hormone therapy 
within 3 months of surgery. The inclusion criteria required the patients to be competent 
and retain capacity to understand the procedure which was had to take place at the 
Liverpool Women’s Hospital. Further to this the post-menopausal patients did not have 
menstrual bleeding for a minimum of 12 months since their last menstrual period.  Human 
endometrial tissue was obtained from 81 women undergoing gynaecological procedures 
(mean age 67.5 years, mean BMI 29.9kg/m2) at the Liverpool Women’s Hospital. 61 
women had a prior diagnosis of endometrial cancer along with 4 women who were 
diagnosed with complex atypical hyperplasia and underwent surgical treatment in the form 
of hysterectomies. A further 16 women who were post-menopausal with no history of 
abnormal vaginal bleeding or known endometrial pathology undergoing hysterectomies for 
uterine prolapse were recruited into the study. 
Pipelle or full thickness endometrial samples were collected and fixed in NBF. Tissue 
processing, embedding and subsequent IHC staining was completed following the 
protocols listed in the appendix 3. 4µm histological sections were cut and dried onto APES 
coated slides, deparaffinised using xylene and rehydrated through decreasing 
concentrations of alcohol. IHC staining was carried out using a readily available horse-
radish peroxidase (HRP) labelled polymer technique (Vector ImmPRESS, Cat #: MP-7402, 
Vector, Peterborough, UK) with (3,3-diaminobenzidine, DAB) (DAKO Ltd). A hydrogen 
peroxidase (30% in water) block was applied to sections for 10 minutes to inactivate all 
endogenous peroxidase activity. The sections were incubated in a humidifying chamber, 
overnight at 4°C. 70 microliters (µl) of the following antibodies were used for the 
incubation; CBS 5 µg/ml 1:300 (clone 3E1, Abcam, Cambridge, UK), CSE 1:3000 (clone 4E1-
1B7, Abnova, Taiwan) and 3-MPST (SC-376168, clone: H-11, Heidelberg, Germany) 1:400 
dilutions in phosphate-buffered saline (PBS) containing 2% (w/v) bovine serum albumin 
(BSA). For all 3 antibodies the anti-mouse immunoglobulin G (IgG) was applied at a dilution 
1:500 as a negative control.  After an overnight incubation the sections were washed in 
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TBS twice for 5 minutes. 2 drops of the HRP labelled secondary mouse antibody was 
applied to the samples for 30 minutes at room temperature. After a final wash in TBS for 
10 minutes, DAB chromogen was applied to the samples for 10 minutes and the antigen-
antibody complexes visualised as a brown reaction product of tissue. All sections were 
placed into water to immediately stop enzymatic reactions and counterstained for 2 
minutes using Gills-2 hematoxylin. They were washed under running tap water before 
being immersed in 1% acid alcohol to remove excess hematoxylin staining and washed 
again under tap water. The samples were then gradually dehydrated by increasing alcohol 
% gradient and mounted in Consul mount. Owing to the large sample number the slides 
were divided into runs and a positive internal control were used to ensure that the staining 
runs were all consistent. The positive external controls for all 3 antibodies differed and 
were stained at the commencement of staining for each antibody.  
Antibody External positive control 
CBS Liver 
CSE Liver 
3-MPST Human colon 
 
The collected endometrial samples were assigned into 4 groups according to clinic-
pathological features and histological characterisation by qualified clinical pathologists at 
Royal Liverpool University Hospital (RLUH). Two groups of endometrial cancer; type 1 
(n=43) and type2 (n=18) and the healthy control group PM (n=16). The type 1 samples 
were further categorised based on grade (grade1 (n=24), grade 2 (n=11) and grade 3 
(n=8)). The type 2 carcinomas were divided into clear cell (n=4), serous (n=4) and MMMT 
(n=9). Finally the n=4 complex atypical hyperplasias were included.  
 Analysis of IHC staining 5.2.2
 
10 consecutive micrographs (taken with Nikon Eclipse microscope, Nikon, Japan) were 
taken and assessed using the modified quick score method. A variation in staining was 
seen within the sample and these areas were accounted for and scored accordingly.  
 Statistical analysis 5.2.3
 
Non – parametric tests have been used to analyse data which were not normally 
distributed. Mann- Whiney test was used to assess pairs of data and the differential 
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expression between all groups of data was analysed with the Kruskal- Wallis test. These 
tests enabled the calculation of a P value, allowing any statistical significance (p<0.05) if 
present to be highlighted.  
The quick score values for all three antibodies were used to correlate the expression of 
antibodies with steroid receptors e.g. AR, ER-alpha, ER-beta and PR. Spearman Rank 
correlation test was used. The software package IBM SPSS statistics 20 (IBM, 
PORTSMOUTH UK) was used to run the correlation tests. 
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5.3 Results  
 Patient demographics 5.3.1
 
Table 19 Patient Demographics 
Patient cohort 
(sample 
number) 
 Age 
(years) 
Height (m) Weight (kg) BMI (kg/m
2
) Parity  Disease 
stage 
Complex 
atypical 
hyperplasia  
/ CAH (4) 
Mean(± 
SD)  
Median 
Range 
52 ± 5 
54 
44- 55 
1.59 ± 0.03 
1.60 
1.55 – 1.63 
102 ± 41 
98 
50- 154 
38 ± 14 
39 
23- 57 
1  
1 
1 
 
Grade 1 (24) Mean  
Median 
Range 
62 ± 10  
62.5 
36-84 
1.59 ± 
0.076 
1.59 
1.38-1.74 
86 ± 23 
76.5 
52-138 
33.9 ± 8 
30.5 
23.1-53.2 
1± 1 
2 
0-6+ 
2 ± 1 
1 
1-3 
Grade2 (11) Mean  
Median 
Range 
65 ± 13 
64 
37-83 
1.59 ± 0.09 
1.62 
1.47-1.73 
84 ± 32 
81 
48-163 
32 ±  9 
31 
22-54 
2 ± 0 
0 
0-3 
1 ± 1 
1 
1-3 
Grade3 (8) Mean  
Median 
Range 
67 ± 9 
69 
52-80 
Missing 
datum 
Missing 
datum 
29 ± 7 
27 
24- 43 
2 ± 2 
2 
0-6 
2  
2 
1-3 
MMMT/ 
Carcinosarcoma 
 (9) 
 
Mean  
Median 
Range 
73 ± 10 
78 
59-87 
1.57 ± 0.04 
1.57 
1.52-1.65 
 70 ± 17 
66 
48-93 
28 ± 7 
24 
20- 37 
2 ± 
2 
2-4 
1 
1 
1-3 
Serous (5) Mean  
Median 
Range 
68 ± 3 
67 
64-73 
1.59 ± 0.06 
1.58 
1.52- 1.67 
71 ± 11 
71 
57 -84 
28 ± 2 
28 
25- 30 
2 ±  
3 
2-3 
2 
2 
1-3 
Clear cell (4) Mean  
Median 
Range 
68 ± 14 
70 
52-82 
1.59 ± 0.09 
1.63 
1.46-1.65 
75 ± 11 
75 
63-86 
 29 ± 2.0 
30 
26.6-31.5 
6 ± 
6 
1-6 
2 
1 
1-3 
Post-
menopausal 
(16) 
Mean  
Median 
Range 
56 ±15 
56 
51-78 
1.60 ± 0.08 
1.6 
1.45- 1.76 
71 ± 13 
73 
56- 93 
28 ± 4 
27 
20- 38 
3 ± 1 
2 
1-5 
5 
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 Grouped demographics 5.3.2
 
Table 20 Grouped demographics 
Demographics  Mean(± SD)  
Median 
Range 
PM (n=16) Complex 
atypical 
hyperplasia 
(n=14) 
Type 1 (n=43) Type 2 (n=18) 
Age (years) Mean(± SD)  
Median 
Range 
56 ±15 
56 
34-78 
52 ± 5 
54 
44- 55 
64 ± 11 
64 
36- 84 
71 ± 10 
67 
52- 87 
Height (m) Mean(± SD)  
Median 
Range 
1.60 ± 0.08 
1.6 
1.45- 1.76 
1.59 ± 0.03 
1.60 
1.55 – 1.63 
1.59 ± 0.08 
1.59 
1.38- 1.74 
1.58 ± 0.06 
1.58 
1.46- 1.67 
Weight (kg) Mean(± SD)  
Median 
Range 
71 ± 13 
73 
56- 93 
102 ± 41 
98 
50- 154 
83 ± 24 
78 
48- 163 
71 ± 14 
69 
48-93 
BMI (kg/m
2
) Mean(± SD)  
Median 
Range 
28 ± 4 
27 
20- 38 
38 ± 14 
39 
23- 57 
32 ± 8 
30.3 
22- 54 
28 ± 5 
29 
20-37 
Parity Mean(± SD)  
Median 
Range 
3 ± 1 
2 
1-5 
1  
1 
1 
3 ± 2 
2 
0 - 6 
2 
2 
1-3 
 
The individual values for height and weight in some grade 3 endometrioid carcinomas were 
not recorded at time of consenting. These samples were gained prior to the 
commencement of this study and therefore the true values could not be found. However 
due to the presence of BMI values, this missing evidence did not produce bias.  
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 Overview of staining patterns of 3-MPST, CSE and CBS 5.3.3
 
Stained IHC micrographs of the stained sections were taken and the expression of all 3 
enzymes is described below 
 3-MPST staining 5.3.3.1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3-MPST expression was localised to the glandular and stromal compartment of the 
endometrium.  
 
 
 
GE 
S 
Figure 21  (x400) {x40 objective and x10 eyepiece} micrograph illustrating 3-MPST staining in glandular 
epithelium (GE) and stromal (S) compartment in a PM sample  
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 CSE staining 5.3.3.2
 
 
 
 
 
 
 
 
 
 
 
 
 
Two distinct patterns of staining were noted for CSE, e.g. diffuse weakly stained cytoplasm 
(A) and distinct strongly stained cells (B). CSE expression was confined to the endothelial 
and epithelial cells.  As CSE was extensively found to expressed in vascular endothelium, 
micrographs highlighting IHC staining between PM, CAH, type 1 and type 2 endometrial 
carcinomas have been shown in figure 22.  
 
 
 
 
 
Figure 22 (x400) {x40 objective and x10 eyepiece} micrograph illustrating CSE staining in glandular epithelium 
in PM sample 
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Figure 23 (x400) {x40 objective and x10 eyepiece} micrograph illustrating CSE staining in the endothelium 
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 CBS staining  5.3.3.3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBS staining was localised to the cytoplasmic compartment of the glandular epithelium.  
 
 
 
 
 
 
GE 
Figure 24(x400) {x40 objective and x10 eyepiece} micrograph illustrating CBS staining in the cytoplasmic 
compartment of glandular epithelium (GE) in Type 1 EC 
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 3-MPST expression in post-menopausal endometrium, hyperplasias and 5.3.4
endometrial cancer 
 
 
Figure 25 (x400) {x40 objective and x10 eyepiece} micrograph illustrating 3-MPST staining at 1:400 dilution. 
a) PM (n=16), b) CAH (n=4), c) External control (Human colon), d) Type 1 (n=43), e) Type 2 (n=18), f) IgG 
control. 
 
As mentioned in the introduction (refer to page 20, 21 and table 2) due to the difficulties 
faced with the classification of endometrial cancers the results have been analysed by 
categorising EC into type 1/ type 2 and low/ high grade carcinomas.  
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The modified quick score for 3-MPST staining was high in the post-menopausal 
endometrium. A loss of 3-MPST expression can be seen in the complex atypical 
hyperplasias, although not in significant amounts. Both low grade and high grade 
endometrial carcinomas shown an overall loss of 3-MPST staining.  
 
 
 
Figure 26 Graphical representation of overall loss of 3-MPST expression in cancers when compared 
with PM controls. PM (n=16), CAH (n=4), low grade carcinomas (n=35) and high grade carcinomas 
(n=26). 
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No significant loss of 3-MPST staining can be seen in complex atypical hyperplasia due to 
the 2 groups having a similar median. Variances in values between the individual atypical 
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Figure 27 Graph displaying significant loss of 3-MPST staining in endometrial cancers. PM (n=16), CAH 
(n=4), grade 1 (n=24), grade 2 (n=11), grade 3 (n=8), MMMT (n=9), Serous (n=5), Clear cell (n=4) 
Figure 28 Change in 3-MPST expression between PM (n=16) and CAH (n=4) 
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hyperplasia tissues were visible and this discrepancy will need to be investigated further by 
increasing the sample number in the group. If the values remain varied it could be due to 
the fact that the tissues that have a lower expression of 3-MPST could have a higher 
chance of progression to cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant down regulation of 3-MPST expression can be seen in proliferative cancerous 
endometrium when compared with atrophic PM endometrium.  
 
 
 
 
 
 
 
Figure 29 Graphical representation of loss of 3-MPST expression in endometrial cancers when compared 
with PM controls. 
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Independent evaluation of grades of type 1 endometrioid carcinomas shows a significant 
very early loss of 3-MPST in grade 1 endometrioid carcinomas.  
P
os
t-
m
en
op
au
sa
ls
G
ra
de
 1
 E
C
G
ra
de
 2
 E
C
G
ra
de
 3
 E
C
0
2
4
6
8
10
12
14
Q
u
ic
k
s
c
o
re
Kruskal- Wallis p<0.0001
Figure 30 Early loss of 3-MPST is seen in Low grade (n=35), or grade 1 endometrioid carcinomas (n=24) 
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Independent comparison of type 2 endometrial carcinomas shows a similar significant loss 
of 3-MPST expression in these cancers as seen in type 1 endometrioid carcinomas. 
Therefore loss of 3-MPST could be unrelated to the oestrogen dependence and an overall 
feature of endometrial cancer.  
 
 
 
 
 
 
Figure 31 Graphical representation displaying loss of 3-MPST in Type 2 (n=18) endometrial 
cancers when compared with PM controls (n=16) 
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 3-MPST correlation with steroid receptors 5.3.4.1
 
All correlation calculations were done in conjunction with Areege Kamal.  
Prior to correlation of data with steroid receptor expression the endometrial cancer cohort 
was divided into 2 groups. Low grade cancers (n=35) consisted of grade 1+2 endometrioid 
carcinomas. High grade cancers (n=26) encompassed grade 3 and type 2 carcinomas (clear 
cell, serous and MMMT).  Spearman’s rank correlation analysis of low grade carcinomas 
revealed no correlation between the expression of the 3 antibodies and steroid receptors. 
 
3-MPST was found to correlate (r=0.2) weakly with progesterone receptor in high grade 
carcinomas after the conduction of correlational tests.  
 
 
 
 
 
 
 
 
 
 
PR plays a role in cell differentiation and anatagonises the effects of ER suggesting an anti-
proliferative effect on the endometrium. It is proposed to be lost in advanced stage 
endometrioid carcinoma and therefore a subsequent reduction in 3-MPST is to be 
expected. The results below show a reduction in 3-MPST in the endometrium in high grade 
endometrial cancers, thus providing evidence to strengthen the suggestion.  
Figure 32 Graphical representation of the wear positive correlation between PR and 3-MPST in high grade 
endometrial carcinomas. (n=65). 1 point on graph represents more than 1 variable due to same scores 
achieved.  
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Table 21 Correlation between 3-MPST and high grade carcinomas 
109 
 
 Association of 3-MPST expression with clinic-pathological features and outcome 5.3.4.2
data 
 
The IHC modified quick scores for 3-MPST have been analysed against clinical pathological 
features such as myometrial invasion and lympho-vascular invasion. Myometrial invasion 
was categorised according to the 1991 FIGO classification into 2 groups i.e. less than 50% or 
more than 50% myometrial invasion. The lymph-vascular invasion was described as ‘true’ if 
present and ‘false’ if absent.  
Comparison of 3-MPST expression with myometrial invasion has revealed no association 
between the two as illustrated below. Although n=62 EC samples have been stained in this 
project, at the time of correlation studies data for myometrial invasion was only available 
for 50 patients (represented as valid). This is the reasoning for discrepancy between 
numbers. The dots away from the box and whisker plots represent the outliers within the 
data set.  
Case Processing Summary 
 
Myometrial invasion Cases 
Valid Missing Total 
N Percent N Percent N Percent 
3-MPST 
Less than 50% 32 80.0% 8 20.0% 40 100.0% 
more than 50% 18 78.3% 5 21.7% 23 100.0% 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 Graphical evidence showing no association exists between the 3-MPST expression and 
presence of myometrial invasion 
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 Association between lympho-vascular invasion and 3-MPST expression in 5.3.4.3
endometrial cancer  
 
Case Processing Summary 
Lympho-vascular invasion 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
3-MPST 
True 17 73.9% 6 26.1% 23 100.0% 
False 34 82.9% 7 17.1% 41 100.0% 
 
As before data for lympho-vascular invasion was only available for 51 patients in total, 
thereby causing an inconsistency in numbers.  
 
 
Figure 34 Graphical evidence showing no association exists between the 3-MPST expression and presence of 
lympho-vascular invasion 
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 Association between outcome data and 3-MPST expression in endometrial 5.3.4.4
cancer  
 
The outcome data was categorised as ‘1’=event or ‘0’=no event. An event is either 
recurrence of endometrial cancer or death secondary to endometrial cancer. The IHC 
staining results were compared with outcome data to elicit any significant change in 
expression of 3-MPST in people who have had a poor outcome. 
 
Case Processing Summary 
          Outcome 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
3-MPST 
0 5 71.4% 2 28.6% 7 100.0% 
1 9 75.0% 3 25.0% 12 100.0% 
 
 
Figure 35 Graphical representation highlighting the lack of association between 3-MPST expression and 
outcome of patients at 36 month follow-up. 
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 CSE expression in post-menopausal endometrium, hyperplasias and 5.3.5
endometrial cancer 
 
 
 
 
Figure 36 (x400) {x40 objective and x10 eyepiece} micrograph illustrating CSE staining at 1:400 dilution. a) PM 
(n=16), b) CAH (n=4), c) External control (Human colon), d) Type 1 (n=43), e) Type 2 (n=18), f) IgG control. 
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The modified quick score for CSE staining was high in the post-menopausal endometrium 
when compared with complex atypical hyperplasias and cancers.  
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Figure 37 Graphical representation of overall loss of CSE expression in cancers when compared with PM 
controls. PM (n=16), CAH (n=4), low grade carcinomas (n=35) and high grade carcinomas (n=26). 
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No significant reduction in CSE staining was present in CAH when compared with PM 
endometrium. The individual quick scores for CSE staining in CAH are similar and show 
consistency.  
Figure 38 Graph displaying significant loss of CSE staining in endometrial cancers. PM (n=16), 
CAH (n=4), grade 1 (n=24), grade 2 (n=11), grade 3 (n=8), MMMT (n=9), Serous (n=5), Clear cell 
(n=4) 
Figure 39 Change in CSE expression between PM (n=16) and CAH (n=4) 
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An overall significant reduction in CSE staining was seen in all endometrial cancers when 
compared to post-menopausal controls.  
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Figure 40 Graphical representation of loss of CSE expression in endometrial cancers when 
compared with PM controls. 
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Subcategorisation of the endometrial carcinomas into high and low grades has shown a 
greater reduction in CSE expression in high grade endometrial carcinomas when compared 
to low grade carcinomas.  
 
 
 
Figure 41 Graphical representation of a more significant loss of CSE expression in high grade carcinomas 
when compared with low grade carcinomas 
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Categorisation of endometrial cancers into type 1 endometrioid and type 2 non-
endometrioid carcinomas has revealed a greater loss of CSE expression in non-
endometrioid cancers.  
No correlation was found between CSE and steroid receptor expression.  
Figure 42 Graph displaying a more pronounced loss of CSE in type 2 carcinomas when 
compared to type 1 endometrioid carcinomas.  
Kruskal- Wallis test 
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 CSE correlations with steroid  5.3.5.1
Receptors: 
High grade 
Low grade 
PM 
Figure 43 No correlation between CSE and steroid receptors was found. The total numbers of samples are inconsistent due to different numbers of samples stained for 
steroid receptors. 
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 Association with clinic-pathological features and outcome data 5.3.5.2
 
Comparison of CSE expression with myometrial invasion has revealed no association 
between the two as illustrated below.  
 
Case Processing Summary 
Myometrial invasion 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
CSE 
Less than 50% 31 77.5% 9 22.5% 40 100.0% 
more than 50% 17 73.9% 6 26.1% 23 100.0% 
 
 
 
 
Figure 44 Graphical evidence showing no association exists between the CSE expression and presence of 
myometrial invasion 
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 Association between lymph-vascular invasion and CSE expression in 5.3.5.3
endometrial carcinoma  
 
Case Processing Summary 
         Lymph-vascular invasion 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
CSE 
True 16 69.6% 7 30.4% 23 100.0% 
False 33 80.5% 8 19.5% 41 100.0% 
 
 
 
Figure 45 Graphical evidence showing no association exists between the CSE expression and presence of lympho-
vascular invasion 
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 Association between outcome data and CSE expression in endometrial 5.3.5.4
carcinoma  
 
The outcome data was categorised as ‘1’=event or ‘0’=no event. An event is either 
recurrence of endometrial cancer or death secondary to endometrial cancer. The IHC 
staining results were compared with outcome data to elicit any significant change in 
expression of CSE in people who have had a poor outcome. A range of CSE quick score 
values have been included when looking at outcome data , thereby, reducing the possibility 
of skewed results secondary to purely using high or low quick scores. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case Processing Summary 
      Outcome 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
CSE 
0 5 71.4% 2 28.6% 7 100.0% 
1 8 66.7% 4 33.3% 12 100.0% 
Figure 46 Graphical representation highlighting the lack of association between CSE expression and 
outcome of patients at 36 month follow-up 
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 CBS expression in post-menopausal endometrium, hyperplasias and 5.3.6
endometrial cancer 
 
 
Figure 47 (x400) {x40 objective and x10 eyepiece} micrograph illustrating CBS staining at 1:400 dilution. a) PM 
(n=16), b) CAH (n=4), c) External control (Human colon), d) Type 1 (n=43), e) Type 2 (n=18), f) IgG control. 
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No significant change in IHC staining scores for CBS expression can be seen between all 
groups shown above. PM tissue stains revealed a varied expression of CBS in the glandular 
epithelium. The standard error margins for PM and low grade endometrial cancer groups 
are large showing an increased range of quick scores due to varied staining in these groups.  
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Figure 48 No significant change in CBS staining is seen between PM controls and endometrial 
cancers. PM (n=16), CAH (n=4), low grade carcinomas (n=35) and high grade carcinomas (n=26). 
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No significant change in CBS staining can be seen in the complex atypical hyperplasias.  
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Figure 49 No change in CBS expression can be seen in CAH. PM (n=16), CAH (n=4), grade 1 (n=24), 
grade 2 (n=11), grade 3 (n=8), MMMT (n=9), Serous (n=5), Clear cell (n=4) 
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A significant increase in IHC quick scores for CBS staining can be seen in grade 3 
endometrioid carcinomas when compared with the PM group. Nonetheless, this slight 
increase in CBS expression in grade 3 carcinomas could be attributed to a compensatory 
mechanism within the tissue secondary to the down regulation in CSE and 3-MPST 
expression.  
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Figure 50 Significant up regulation of CBS can be seen in Grade 3 endometrioid cancers when compared to 
PM controls. PM (n=16), grade 1 (n=24), grade 2 (n=11), grade 3 (n=8) 
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Comparison of CBS staining between the PM group and Type 2 non–endometrioid 
endometrial carcinomas showed no change.
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Mann- Whitney p=0.4004
Figure 51 No change in CBS expression can be seen in type 2 non- endometrioid 
carcinomas PM (n=16) and Type 2 (n=18) 
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 Correlation of CBS with steroid receptors  5.3.6.1
 
Analysis of high grade (grade 3, MMMT, clear cell and serous carcinomas) cancers displayed 
a strong negative correlation (p<0.007, r = -0.5) between CBS and ER-alpha expression. 
Comparison of the IHC Staining between CBS and ER-alpha reveals weak cytoplasmic 
staining of ER-alpha in high grade cancer when compared to the strong cytoplasmic staining 
seen for CBS in high grade cancers. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52 (x400) {x40 objective and x10 eyepiece} micrographs showing weak cytoplasmic ER-alpha 
staining and strong cytoplasmic CBS expression in high grade cancers 
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ER-alpha regulation in endometrioid carcinomas is proposed to be lost in grade 3 
endometrioid carcinomas. Spearman’s rank analysis of CBS expression when compared to 
ER-alpha has shown a strong negative correlation (r=-0.5). This would suggest an increase 
in CBS expression should be seen with a reduction in ER-alpha expression.  The up 
regulation of CBS in grade 3 endometrioid carcinomas was shown with the IHC staining 
above. Although the staining could be attributed to a compensatory mechanism as 
previously described it could possibly be an independent increase in CBS expression. 
Further investigations using a larger sample number would need to be conducted in order 
to understand the exact mechanism behind the CBS up regulation in grade 3 endometrioid 
carcinomas.  
Figure 53 Graphical representation of the positive correlation between ER-
alpha and CBS expression in high grade carcinomas 
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Table 22 Correlation between CBS and ER-alpha in high grade carcinomas 
AR 
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 Association between myometrial invasion and 3-MPST expression in 5.3.6.2
endometrial cancer  
 
Comparison of CBS expression with myometrial invasion has revealed no association 
between the two as illustrated below.  
 
Case Processing Summary 
          Myometrial invasion 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
CBS 
Less than 50% 30 75.0% 10 25.0% 40 100.0% 
more than 50% 18 78.3% 5 21.7% 23 100.0% 
 
 
 
Figure 54 Graphical evidence showing no association exists between the CBS expression and presence of 
myometrial invasion 
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 Association between lympho-vascular invasion and CBS expression in 5.3.6.3
endometrial carcinoma  
 
Case Processing Summary 
Lympho-vascular invasion 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
CBS 
True 17 73.9% 6 26.1% 23 100.0% 
False 32 78.0% 9 22.0% 41 100.0% 
 
 
 
 
Figure 55 Graphical evidence showing no association exists between the CBS expression and presence of 
lympho-vascular invasion 
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 Association between outcome data and 3-MPST expression in endometrial 5.3.6.4
cancer  
 
The outcome data was categorised as ‘1’=event or ‘0’=no event. An event is either 
recurrence of endometrial cancer or death secondary to endometrial cancer. The IHC 
staining results were compared with outcome data to elicit any significant change in 
expression of CBS in people who have had a poor outcome. A range of CBS quick score 
values have been included when looking at outcome data, thereby reducing the possibility 
of skewed results secondary to purely using high or low quick scores. 
 
 
 
 
 
Case Processing Summary 
Outcome 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
CBS 
0 5 71.4% 2 28.6% 7 100.0% 
1 9 75.0% 3 25.0% 12 100.0% 
Figure 56 Graphical representation highlighting the lack of association between CBS expression and 
outcome of patients at 36 month follow-up 
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5.4 Discussion 
 
This study reports the expression of the three H2S synthesising enzymes; CBS, CSE and 3-
MPST in atrophic post-menopausal endometrium, hyperplastic and endometrial cancer 
tissue. 3-MPST staining was identified in the cytoplasmic portion of endometrial glands and 
stromal compartments of PM, hyperplastic and endometrial cancer samples. CSE was 
distributed between the cytoplasmic portion of glandular epithelium and endothelial cells 
and CBS expression was limited to the cytoplasm of glandular epithelium.  Immunostaining 
scores for CSE (p=0.0047) and 3-MPST (p<0.001) were significantly lower in cancerous 
tissues when compared with post-menopausal controls. No overall differentiation in CBS 
(p=0.1363) expression was present between all groups.  
 
The primary aim of the study was to explore the change in expression of the 3 H2S 
synthesising enzymes in endometrial cancer and hyperplastic tissue compared with healthy 
post-menopausal endometrium. 3-MPST expression was considerably higher in the PM 
endometrium when compared with endometrial cancer tissue. Although no significant loss 
of 3-MPST was noticed in CAH group an early drastic loss of 3-MPST in low grade 
endometrioid cancers suggests as possible cytoprotective role for 3-MPST in the 
endometrium. The cytoprotective function of 3-MPST derived H2S was reported in a 
mammalian retinal degeneration by modulation of calcium ion influx151, rodent neurology 
amongst others152. In light of this evidence it could be suggested that 3-MPST may have a 
similar cytoprotective role and its loss coupled with activation of other cancer pathways 
may result in the development of cancer. Furthermore, a reduction in expression of 3-MPST 
was proposed in conditions under increased oxidative stress119. The production of free 
radical and reactive oxygen species (ROS) as a by-product of normal cellular metabolism is 
implicated in a range of diseases. The endometrium has a high cell turnover rate and is 
known to use circulating lipids for the synthesis of structural lipids120. Additional resources 
are required by cancerous and hyperplastic endometrial tissue for the generation of 
endogenous fatty acids.  This use of lipids in this pathway promotes local oxidative stress in 
these tissues. The antioxidant disease system within the body including superoxide 
dismustase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione 
transferase (GST) and catalase (CAT) are involved in counteracting the effects of these free 
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radicals120.  Alterations in the antioxidant system and increased oxidative stress have been 
implicated in the pathophysiology of many disease states of the endometrium including 
hyperplasia and adenocarcinomas120. Lipid peroxidation levels and antioxidant enzymes 
activities in women with cancer have been explored to show an enhanced lipid 
peroxidation and altered uterine antioxidant activity when compared with benign diseases 
of the endometrium.  The increased lipid hydroperoxides results in a rise in liberation of 
free radicals120. SOD was shown to regulate free radical levels by targeting tyrosine or 
histidine residues. SOD activity was evidenced to be suppressed in both hyperplastic and 
cancerous endometrium with a more pronounced reduction in adenocarcinomas148. 
Although the results concluded do not define whether changes in antioxidant activities are 
secondary to or a causal factor of increased oxidative stress in these disease states, a 
primary comparison between the lipid peroxidation and antioxidant activity was described.  
In addition studies looking at the effect of increased oxidative stress on cellular 
bioenergetics secondary to H2S synthesised by the 3-MPST pathway have shown the 
inhibition of 3-MPST activity, thereby altering the positive bioenergetics role of the 3-
MPST/ H2S pathway
119.  
 
This study reports a reduction in expression of 3-MPST in endometrial cancer; a state of 
increased oxidative stress. Considering previous evidence suggesting the down regulation o 
of 3-MPST mediated production of hydrogen sulphide is therefore justified. However, the 
post-menopausal samples used in this study are atrophic therefore cellular proliferation 
and hence strong expression of 3-MPST is not expected secondary to its role in stimulating 
cellular bioenergetics. Though the levels of 3-MPST are higher in post-menopausal 
endometrium further investigations looking at the cycling endometrium need to be 
considered. Once the expression of 3-MPST is defined in the proliferating endometrium it 
can them be compared against PM, hyperplastic and cancerous endometrium. Although the 
IHC staining of tissue has expressed the presence of 3-MPST the functionality of this protein 
has not been described. Therefore further tests would need to be conducted to understand 
whether the proteins have a functional role. The early and increased loss of 3-MPST seen in 
low grade endometrioid cancers suggest a role for the ‘loss of 3-MPST’ as a marker of 
disease. A larger sample size would need to be recruited to increase the statistical strength 
of these suggestions. The correlation of 3-MPST with steroid receptors revealed a weak 
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positive correlation between PR and 3-MPST (r=0.2). PR plays a role in cell differentiation 
and anatagonises the effects of ER and therefore has an anti-proliferative effect on the 
endometrium. It is proposed to be lost in advanced stage endometrioid carcinoma and 
therefore a subsequent reduction in 3-MPST is to be expected.  
 
Angiogenesis is a pre-requisite for development and maintenance of tumour cells4.  This 
facilitates the delivery of nutrients, oxygen and removal of by-products of cellular 
metabolism. Several previous studies have reported the role of CSE/ H2S pathway in the 
regulation of vasculature within mammalian tissue including ischaemic cardiovascular 
disease or regulation of blood pressure136. In contrast, the role of CSE mediated production 
of H2S and its regulation of tumour angiogenesis has not been explored. Multiple 
angiogenic factors are secreted by tumours, thereby promoting angiogenesis138, 153-155. In 
addition CSE mediated production of H2S has also been shown to contribute towards the 
secretion of angiogenic factors such as VEGF resulting in endothelial cell migration155. No 
change in CSE expression was reported in the study conducted looking at CSE expression in 
colon cancer cells and they did not explore the role of CSE mediated production of H2S in 
endothelial cells4. The suppression of CSE in colon tumour tissue using PAG on a colon 
cancer cell line (HCT-116) showed no changed in tumour proliferation, suggesting that CSE 
did not play a primary role in the supporting tumour growth and proliferation4.  
 
In this study the expression of CSE was only described in the glandular sections of the 
tumour tissue and PM samples. Micrographs (x400) {x40 objective and x10 eyepiece} 
revealed increased CSE expression in the endothelial cells of endometrial cancer tissue and 
no CSE staining in the PM tissue. The PM endometrium samples used in this study were all 
atrophic and therefore minimal activity is expected with respect to angiogenesis. The lack 
of CSE staining in the endothelial compartment of PM samples and the presence of CSE 
staining in endometrial cancer cells supports this theory. IHC staining and modified quick 
score values showed an overall reduction in expression of CSE in the glands through all 
histological grades in type 1 and type 2 cancers. Though the glandular expression of CSE is 
down regulated its function may be attributed to vascular changes and therefore further 
studies and scoring of the endothelial staining of CSE need to be done. Correlation of CSE 
136 
  
 
expression in endometrial cancer tissues with previously stained data for all steroid 
receptor expression has found no correlation between the CSE and the various receptors.  
 
Studies looking at the role of CBS in health have proposed its importance in metabolic 
processes within the body156-158. In the absence of CBS serious clinical manifestations may 
develop including lens dislocation, mental retardation, atherothrombotic vascular disease 
and osteoporosis. The presence of CBS has also been proposed for the synthesis of a major 
anti-oxidant known as glutathione (GSH), thereby suggesting an important role for CBS in 
facilitating anti-oxidant pathways. In contrast, CBS up regulation has also been proposed in 
the development of Down’s syndrome156 and carcinogenesis4, 146. Several previous studies 
have demonstrated the role of H2S donors in ATP generation and in different cell lines in 
vitro159. An increase in the catalytic function of the glycolytic enzyme GAPDH was proposed 
secondary to the presence of H2S. A study conducted in patient matched normal mucosa 
and colon cancer biopsies and colorectal cancer cell lines revealed a selective up regulation 
of CBS in these cancers with no change seen in CSE and 3-MPST4. The tumorigenic potential 
of H2S has also been investigated in primary serous ovarian carcinomas
146. Patient tissue 
microarray was utilised to conduct in vitro and in vivo studies investigating the expression 
of CBS. In vitro effects of CBS silencing were seen to reversible with the exogenous 
application of H2S donors. In cisplatin resistant orthoptic models, siRNA silencing of CBS was 
seen to inhibit tumour growth and sensitise ovarian response to chemotherapeutic agents 
e.g. Cisplatin146.  
 
The IHC staining of CBS showed no significant change in expression between all groups. The 
presence of CBS in post-menopausal endometrium may be related to the synthesis of anti-
oxidant GSH. However, PM endometrium is atrophic and therefore a low glycolytic activity 
would suggest low rates of mitochondrial respiration and release of free radicals, thereby 
requiring low levels of anti-oxidants secondary to reduced oxidative stress in the PM 
endometrium. Although CBS was proposed to be expressed in the PM endometrium the 
functionality of this protein is still unknown. Further investigations would need to be 
conducted to highlight the function of this protein in the PM endometrium. Sub-
categorisation of the cancer cohort into histological grades revealed a significant (p=0.04) 
rise in CBS expression between the post-menopausal cohort and grade 3 endometrioid 
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endometrial cancer group (n=8). It could be possible that this up regulation of CBS could be 
a compensatory mechanism due to the significant suppression of CSE and 3-MPST in 
endometrial cancers. Spearman’s rank correlation of CBS protein expression and previous 
data for steroid receptor IHC staining revealed a strong negative correlation between ER-
alpha and CBS (r=-0.5). Although type 1 endometrioid endometrial cancers are oestrogen 
regulated this regulation was proposed to be lost in grade 3 endometrioid carcinomas. 
Therefore, the loss of ER-alpha is expected and a subsequent rise in CBS should be seen, 
which is shown by IHC staining and correlation studies. Therefore, if the rise in CBS is still 
present once an increased sample number was stained and correlated the presence of CBS 
in endometrial cancers could possibly be a potential be a marker for poor disease 
prognosis.  
 
The clinical pathological features of the endometrial cancers such as extent of 
myometrial invasion and lympho-vascular invasion have been compared against the 
expression of the three H2S synthesising proteins to reveal a possible association 
between the two groups. Myometrial invasion was categorised according to the 
1991 FIGO classification into <50% or >50% invasion into the myometrial wall. 
Lympho-vascular invasion was included if present and rejected if it does not exist. 
No association was found between the 3 proteins and the clinical pathological 
features. Further to this outcome data was used where ‘1’ represents an event such 
as recurrence of endometrial carcinoma or death due to endometrial cancer at 36 
month follow-up. Comparison of all 3 proteins with outcome data has shown no 
association between the expression of the 3 proteins in the endometrium and a 
poor outcome.   
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5.5 Limitations  
 
The use of IHC staining has shown the presence of all 3 proteins in the endometrium. 
However, this study has not been able to show whether the proteins have a functional role 
in the endometrium. In addition the expression of the 3 proteins has not been described in 
the normal healthy cycling endometrium and would need to be investigated further to see 
the overall change in expression between cycling, PM and cancerous endometrium.  
The large standard error margins between experimental groups can be attributed to the 
unequal numbers in the individual groups. Although this study was conducted using a large 
sample size to increase the strength of the findings it is necessary to increase the sample 
number of grade 2+3 endometrioid carcinomas and type 2 endometrial carcinomas.  
 
5.6 Summary  
 
In summary this study has identified the expression of CBS, CSE and 3-MPST using IHC in 
PM, CAH and endometrial carcinomas. Detailed information regarding the changes in 
expression of the 3 enzymes across all groups and any correlation with steroid receptors 
was highlighted. PM endometrium has abundantly expressed all 3 enzymes more than the 
CAH or endometrial cancers. The early loss of both CSE and 3-MPST in endometrial cancer 
suggests a role for them as possible marker of disease. No significant difference in 
expression of CBS was noted across all groups, although CBS was significantly up regulated 
in grade 3 endometrioid carcinomas. A strong negative correlation seen between CBS and 
ER-alpha has confirmed the possibility that H2S may play a role in carcinogenesis in 
advanced endometrioid carcinomas and the increase in CBS could be a possible indicator of 
poor prognosis. A higher sample size will be needed to increase the strength of this 
suggestion. Although endometrial cancer is regulated through a vast variety of pathways, 
this study focused on H2S mediated carcinogenesis as no current evidence exists with 
respects to this pathway in the endometrium.   
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  In vitro examination of Chapter 6
effects of H2S in endometrial 
cancer cell proliferation 
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6.1 Introduction 
 
Hydrogen sulphide is ‘third’ upcoming gaseous transmitter in mammalian physiology152. Its 
potential as a regulator of vascular tone and angiogenesis was increasingly investigated in 
cardiovascular system136. In vivo it is naturally synthesised by colonic bacteria and by 3 
enzymes including CSE, CBS and 3-MPST from the substrate L-cysteine. Though the precise 
mechanisms are not defined the role of H2S was found to be varied in different tissues 
displaying pro- or anti-apoptotic effects on cells in culture125, 160, 161.  
To date limited research is present investigating H2S effects on carcinogenesis both in vivo 
and in vitro. Previous research has reported the protective role of H2S on colon cancer cells 
preventing apoptosis secondary to effects of β-phenylethyl isothiocyanate162. Recently 
evidence has shown H2S increases colon cancer cell and primary serous ovarian carcinoma 
proliferation and reduced cellular apoptosis in human colon cancer cell lines i.e. HCT-1164, 
146. Increased level of H2S has also resulted in a reduction of survival in other cell lines such 
as WIDR163.  
In vitro experiments examining the effects of H2S sulphide on cell lines with the use of H2S 
donors may show discrepancies in results due to the type of H2S donor used. Inorganic 
sulphide salts such as sodium hydrogen sulphide (Na HS) and sodium sulphide (Na2S) have 
been extensively used in the investigations exploring the biological effects of H2S. The salts 
have a very short half-life of 5 minutes when combined with water2. Their instant reactivity 
results in a large surge of H2S production. Cell culture treatment extends over a period of 
days making this an unlikely source of controlled H2S release. High levels of H2S are also 
toxic to cells and so would invariably result in erroneous results and reduce the strength of 
the conclusions drawn looking at the effect of H2S on cancer cell survival
2.  
Studies using the synthetic H2S donor GYY4137 (derived from Lawesson’s reagent) have 
shown the concentration dependent death of seven different human cancer cell lines 
(HeLa, HCT-116, Hep G2, HL-60, MCF-7, MV4-11 and U2OS) with no effect on survival on 
normal human lung fibroblasts (IMR90, WI-38)125. This study compared the effect of NaHS 
and GYY4137 on survival of the above cancer cell lines. GYY4137 is known to release H2S in 
a slow and controlled manner when in aqueous solution over a period of days. 
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H2S measurement was under much scrutiny
130, 164. Many methods of using 
spectrophotometry or fluorescence in the measurement of H2S have been described. No 
one method was universally agreed as the most accurate measurement of H2S. The choice 
of method used is dependent on resources and the medium in which H2S is being detected. 
In this study due to the inability to directly measure H2S, an alternate method was decided 
upon. The MTT assay is a proliferation assay and was used to detect the change in number 
of viable cells by reading the absorbance.  
In this study GYY4137 was used as the H2S donor to investigate the effect on endometrial 
cancer cell lines. In addition the substrate L-cysteine has also been used to treat cells to 
identify any changes in cell proliferation through H2S synthesis.  Normal endometrial cell 
lines are unable to thrive and therefore no normal endometrial cell lines are in existence. 
This posed a problem as we are still unaware of the effect of GYY4137 on normal 
endometrial cells. This study is the first to describe an effect if present of H2S donors on 
endometrial cancer cell lines.  
L-cysteine is a substrate for the production of H2S via the trans-sulphuration pathway and 
metabolised by all 3 enzymes165. The addition of L-cysteine to the MFE280s and observation 
of its effects on proliferation of these cells will elucidate whether the enzymes CBS, CSE and 
3-MPST are functional and producing H2S. Furthermore,  a range of concentrations of l-
cysteine have been used to look at the change in proliferation of the MFE280s if present.  
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6.2 Methods 
 
 Demographics  6.2.1
 
The human endometrial MFE280 cell line (#98050131) was from Public Health England, 
Salisbury, UK. The cells were derived from a recurrent, poorly differentiated endometrial 
carcinoma from an elderly patient. 
 Cell culture 6.2.2
 
MFE280 cell culture   
Stocks of MFE280 in 90% FBS and 10% Dimethyl sulphoxide (DMSO) were stored at -70ºC.  
For recovery, cells were rapidly thawed in a 37ºC waterbath and plated in pre-warmed media 
DMEM (Sigma, UK) containing 10% FBS (BioSera, UK), PrimocinTM  (50 mg/ml, 1:500 in media, 
InvivoGen) and L-glutamine (2mM, Sigma). Once established the cells were maintained in 
monolayer culture in an atmosphere containing 5% CO2/air at 37
ºC with media changes every 
three days.  Their confluence was monitored every 24 hours until an appropriate confluence 
(80-90%) had been reached.  Due to the poor differentiation status of MFE280s more than 
7 days were needed to allow the cell to form a confluent monolayer.  
Treatment of cells 
As mentioned in chapter 3 an 80mM GYY4137 stock solution in water was prepared (30mg 
/ 1ml; Santa Cruz Biotechnology, USA) Serial dilutions in media were then produced from 
the stock solution at concentrations of 25 µM, 50 µM, 75 µM and 100 µM. A 200 mM L-
cysteine stock solution in water was prepared (25 mg/ml; Sigma, UK) for experiments, L-
cysteine was used at 1 mM and 3 mM diluted in media.  
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 Cell proliferation-MTT assay 6.2.3
 
MFE-280 cells were seeded into the wells of a 96-well microtiter plate at different densities 
ranging from 18.5x104 cells per well to 4.5x104 cells per well in triplicate.  The cells were 
allowed to attach for 24 hours after which the media was changed and cells treated with 
GYY4137 and l-cysteine. The treatment period was 24 and 36 hours for GYY4137 and 24 and 
48 hours for L-cysteine. At the end of this period the media was changed and another 100 
µl of media added to which 20 µl of 3(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma, USA) reagent (5 mg/ml in PBS) was added to each well. After 3.5 
hours incubation at 37 ºC the media was carefully aspirated and the insoluble formazan 
crystals that had formed were solubilised  in acidified isopropanol (4mM HCl 0.1% Triton X-
100 in isopropanol) covered with foil and gently shaken for 15 minutes on a Varishaker 
(DYNATECH) . The absorbance was measured at 570nm wavelength using the MultiSkan 
Ascent (funded by Liverpool University, Thermo Electron Corporation, UK). The software used 
to read absorbance was Ascent software version 2.6 (Thermo lab systems).  
Absorbance readings were averaged and corrected for blank (media alone with MTT reagent) 
and the ratio relative to control calculated with control being 1. 
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6.3 Results  
 GYY4137 treatment of MFE280s in normal media 6.3.1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The endometrial cancer cell line (MFE280) was treated with increasing concentrations of 
GYY4137 over a 24 and 36 hour period and its effect on cell proliferation assessed by the 
MTT assay. A positive effect on cell number was seen after 24 hour treatment which was 
not sustained at 36 hours. In fact treatment at the highest dose for 36 hours had a negative 
effect on cell number. There appears to be a biphasic response of MFE280 cells to GYY4137. 
The discrepancies in replicate values are addressed later in the discussion.  
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Figure 57 Graphs showing the MFE280 cell viability after treatment with GYY4137: a) 3 replicates plotted for all 
concentrations of GYY4137, B) 15 replicate values plotted for GYY4137 concentrations of 50 and 100 µM with 3 
replicates for 25 and 75 µM. 
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  L-cysteine treatment of MFE280s 6.3.2
 
 
 
 
 
 
 
 
 
 
The MFE280s cell line was treated with increasing concentration of the H2S substrate L-
cysteine over a 24 and 48 hours period. The cells were maintained in reduced serum media 
prior to the conduction of this experiment to ensure that any change increase in 
proliferation would be secondary to the addition of L-cysteine and subsequent H2S 
production.  As shown above after 24 hours of treatment at 1mM concentration of l-
cysteine inhibited cell proliferation. The 48 hour treatment period shows no effect at 1 mM 
on endometrial cancer cells with an inhibition of proliferation at higher concentrations.  
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6.4 Discussion 
 
This study has shown the concentration dependent reduction in proliferation of the 
MFE280s cell line using increasing concentrations (25, 29, 75, 100 μM) of GYY4137 and L-
cysteine (1 and 3 mM). However, at lower concentrations of 25 μM the GYY4137 has 
positive effect increasing cell viability over 24 hours. This stimulatory effect on the cancer 
cells could suggest a possible role for H2S in stimulating cellular proliferation. The 
implications of this are discussed later in this chapter. Early investigations looking at H2S 
and its alternating roles on human cells have produced evidence claiming its protective role 
on colon cancer cells from apoptosis due to β-phenylethyl isothiocyanate162. Since then 
recent evidence has emerged reporting the role of CBS induced production of H2S 
increasing colon cancer cell proliferation and reduction of cellular apoptosis in many cell 
lines with no detriment to normal cell lines. In contrast, studies have shown the reduction 
in survival of other colonic cell lines163. The presence of conflicting evidence can be 
attributed to the different mechanisms in which the investigations have been conducted 
including the type of H2S donor used, or the experimental timings and concentrations of 
H2S donors or enzyme inhibitors used.  
This study employs the reduction of tetrazolium to measure cell viability and proliferation. 
The mitochondrial dehydrogenase enzymes in viable cells cleave the tetrazolium rings to 
produce insoluble purple formazan crystals. These are subsequently solubilised in acidified 
isopropanol. The cell number is therefore directly proportional to amount of formazan, as 
reflected in the absorbance reading. Though NaHS was used widely in investigating H2S its 
high reactivity in aqueous solutions results in a rapid release of H2S. The experiments have 
been conducted over a period of days and require a sustained release of H2S. Therefore 
GYY4137 was administered to cell cultures. The cells were treated over 24 and 36 hours.  
A rise in proliferation of MFE280s was noticed using GYY4137 concentration of 25 μM at 24 
hours. At subsequent fall in proliferation was noticed at 50 μM with a rise in proliferation 
seen again at 75 μM. Higher concentrations such 100 and 200 μM were shown to cause a 
cell death seen in preliminary experiments conducted during optimisation of GYY4137. The 
biphasic appearance of the graph is unconvincing for a host of reasons. Firstly, 
experimental errors such as pipetting errors or uneven evaporation of culture media from 
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the wells could possibly lead to erroneous results. Secondly, the standard error margins at 
25 and 75 μM concentrations of GYY4137 are larger. This would indicate greater degree of 
error at these values. A total of 15 replicate values were available for 50 and 100 μM 
concentrations in comparison to the 25 and 75 μM concentrations, thereby tightening the 
standard error margins at 50 and 100 μM. Finally considering the values at 36 hours, 
GYY4137 is not seen to have a proliferative effect on the MFE280s. At 36 hours it can be 
seen that the cell viability is constant at 25 μM and reduces thereafter.  Therefore more 
replicate values will need to be completed and added to the existing data set to ensure the 
increase in proliferation seen at 25 and 75 μM at 24 hours is an accurate representation of 
cell proliferation. 
The role of H2S donors in activation of mitochondrial ATP generation and promotion of 
catalytic activity enzyme GAPDH via sulphhydration was reported166.  GAPDH is mainly 
involved in glycolysis but has also been implicated in non- metabolic processes, such as; 
transcription activation, apoptosis initiation amongst others. Proliferation, migration and 
invasion are all ATP dependent processes and therefore inhibition of cellular production of 
ATP results in an inhibition of the above functions. Studies where intracellular H2S levels 
have been reduced by the inhibition of CBS in colorectal carcinomas have revealed an 
inhibition of tumour growth4. Human colon cancer biopsies and patient-matched normal 
margin mucosa showed an up regulation of CBS and subsequent increase in H2S on colon 
cancer. Comparison of human colon cancer derived epithelial cell lines and normal colon 
cancer cell lines revealed a selective up regulation of CBS in colon cancer cell lines (HCT116, 
HT-29, and LoVo) with no change in CBS expression seen in normal colon cell lines 
(NCM356).  Inhibition of CBS using AOAA or short hairpin RNA- mediated silencing of CBS 
resulted in a reduced proliferation, migration and invasion of the HCT116 cell co-cultures 
and reduced mitochondrial function4.  In vivo studies treating nude mice with an enzyme 
inhibitor (AOAA) reduced the tumour blood flow, thereby reducing growth of the cancer. 
No change was observed in CSE or 3-MPST expression.  The by-products of cysteine 
metabolism by CBS are H2S and L-Cystathionine. Administration of 1 mM L-cystathionine to 
both NCM356 and HCT-116 showed no effect on their proliferation. It was therefore 
concluded that H2S was the driving force behind the enhanced proliferation seen in these 
cell lines4.  
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In contrast, novel evidence was published verifying the use of H2S donors as anti- cancer 
drug targets. Seven different human cancer cell lines e.g. cervical carcinoma (HeLa), 
colorectal carcinoma (HCT-116), hepatocellular carcinoma (Hep G2), myelomonocytic 
leukemia (HL-60), breast adenocarcinoma (MCF-7), acute promyelocytic leukemia (MV4-11) 
and osteosarcoma (U2OS) have been used, excluding endometrial carcinomas125. All cell 
lines have been treated with GYY4137 or NaHS in culture medium resulting in the liberation 
of quantifiable levels of H2S. Their survival was compared against cell lines treated with 
NaHS. The H2S levels were measured using the methylene blue assay. The expected rapid 
release of H2S from culture medium containing NaHS was confirmed peaking at 20 minutes 
before reaching undetectable levels at 90 minutes. The release of H2S in the presence of 
GYY4137 was more controlled and sustained over 7 days and was <10% of the H2S release 
seen with NaHS125. In addition a non- sulphur containing control of GYY4137 known as 
ZYJ1122 was found to be inactive in all cell lines. Further investigations involving GYY4137, 
NaHS and ZYJ1122 at two different concentrations (400 and 800 μM) cultured for a 5 day 
period showed a small increase in cell death with higher concentration of NaHS and no 
effect with ZYJ1122. In contrast, GYY4137 showed a significant (75-80%) increase in cellular 
apoptosis at a concentration of 800 μM. The concentration of GYY4137 producing an 
inhibitory effect is much higher than the measurement seen in the culture medium <20 μM. 
The intracellular accumulation of GYY4137 and concentrated release of H2S leading to cell 
death was proposed.125  
Similarly in this project concentrations above 100 μM were found to have an inhibitory 
effect on cell viability. Concentrations of 25 μM were found to cause a stimulatory effect 
over a short duration as aforementioned. Further culture studies using either monoculture 
or co-culture with endometrial stromal cells will allow the deduction of whether the 
positive effect seen in these preliminary studies is accurate. If the effect seen is found to be 
true then it could be possible that in vivo H2S has a stimulatory role. Concentrations of 100 
μM and above are high and may not be normally present in cells in the endometrium. 
However, as no studies exist looking at the levels of H2S in the endometrium it is not 
possible to attribute any role to H2S until this is looked at. If H2S is found to stimulate 
mitochondrial respiration and increase proliferation, H2S inhibitors may have a role in 
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treatment against carcinogenesis. Further investigations are needed prior to forming 
conclusions.  
Furthermore, a xenograft model in immunocompromised mice was used to elicit the effect 
of GYY4137 on tumour growth125.  Results of this study confirmed the concentration- 
dependent death of cancer cell lines in response to GYY4137 (400 μM -800 μM) but not 
NaHS. It was found that NaHS was less potent and inactive in cell lines. Furthermore, 
GYY4137 (400 µM, 5-8 days) was found to promote apoptosis of cancer cell line (MCF-7) by 
causing cell cycle arrest in the G2/M phase and activation of apoptosis  but exerted no 
apoptotic effects on cancer cell lines (IMR90) suggesting a cancer cell specific role of 
GYY4137. Though this mechanism of H2S causing cell death has never been proposed it was 
shown to promote cellular proliferation through the activation of MAPK125. Furthermore, 
H2S is a strong reducing agent and could exert its effects through altering redox reactions 
within cells.  
The results of in vitro experiments conducted in this study looking at the effect of H2S 
donors such as GYY4137 and H2S substrates i.e. L-cysteine on endometrial cancer cells are 
novel. In most studies measuring H2S in vitro was completed by using the methylene blue 
assay to directly measure levels of H2S. Due to the lack of resources in the laboratories 
resulted in the adoption of a proliferation assay known as MTT to indirectly measure effects 
of H2S.   
  
In addition the treatment of cells with the H2S substrate L-cysteine exhibited an overall 
inhibition of cellular proliferation. The cells were maintained in 5% charcoal stripped media 
and therefore any increase in proliferation should be secondary to the proliferative effects 
of H2S. Other by-products are produced through the metabolism of L-cysteine via the trans-
sulphuration pathway. In order to maximally ensure the alteration in proliferation is 
secondary to the H2S produced, methods of measuring the release of by-products such as 
ammonia should be employed. A sharp decline in cell viability is noticed with 1 mM 
concentrations at 24 hours after which increasing the concentration of L-cysteine showed 
no change in cell proliferation.  At 48 hours although no cell proliferation is evident, the cell 
death was not as rapid with a more controlled decline in cell viability. In addition it is 
necessary to consider that L-cysteine treatments were carried out with the cells growing in 
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5% charcoal stripped media. MFE280s were found to sensitive to changes in their nutrition. 
Therefore it could be possible that the inhibition of cellular proliferation could be secondary 
to poor cellular nutrition rather than an inhibitory effect secondary to H2S produced from l-
cysteine or released from GYY4137.   
 
The evidence acquired so far in this study from in vitro experiments shows an overall 
reduction in endometrial cancer cell proliferation with increasing concentrations of H2S 
correlating with the evidence seen in the study conducted by Zeng Wei Lee et al125. 
Furthermore, higher concentrations of GYY4137 (100 μM) were seen to cause endometrial 
cancer cell death. The lack of normal endometrial cell lines secondary to their inability to 
thrive in culture poses difficulties in eliciting the effect of H2S on normal endometrial cells. 
This is a major limitation as without this knowledge it is not possible to propose the use of 
H2S donors as a potential treatment for endometrial cancer cells.  
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6.5 Limitations  
 
Due to the lack of normal endometrial cells it is difficult to investigate the effect of H2S on 
normal endometrial cells. As the cell culture results are displaying an overall inhibitory 
effect in proliferation of endometrial cancer cell lines at high doses of GYY4137 it is 
important to know whether these concentrations are detrimental to the survival of normal 
endometrial cells  
The MFE280s are a poorly differentiating cell line and were very sensitive to changes in 
media. When cultured in 5% charcoal stripped media they struggled to thrive. As the 
physiological state of the cells was difficult to delineate the possibility the inhibition seen 
could be secondary to a natural cellular apoptosis due to the cells being unable to thrive in 
the media.  
Mitochondrial dehydrogenase enzyme activity can vary in different cells and therefore the 
amount of tetrazolium rings cleaved during the assay will differ. This could possibly result in 
divergent results. However as the replicates are compared directly to the controls this 
should not produce bias within the results. Furthermore, the cells have been exposed to a 
variety of chemical substances which may interfere with the cells ability to react with the 
tetrazolium compounds, producing inaccuracy in the results.  
Though the addition of a slow release H2S donor has caused a reduction in cellular 
proliferation, to ensure that the inhibition is secondary to H2S a non-sulphur containing 
compound should also be used at similar concentration under similar experimental 
conditions as a control.  
A dramatic reduction in cell viability is seen upon treating the cells with L-cysteine for 24 
hours at 1mM concentration. It is important to measure other by products released as part 
of the trans-sulphuration pathway such as L-Cystathionine, Homocysteine and ammonia to 
ensure that the change in proliferation is due to liberated H2S. 
Other assays that could be employed to verify the results seen with the MTT assay include 
measuring the release of energy i.e. ATP with the use of an ATP assay kit. ATP is found 
exclusively in the mitochondria and a rise in ATP production would be expected in cancers.  
152 
  
 
Although the MTT assay is effective at measuring cell proliferation a direct measurement of 
H2S is necessary. As aforementioned hydrogen sulphide is present in 2 forms in vivo and 
therefore it is also necessary to delineate which form of H2S is responsible for the effects 
seen. The methylene blue assay was used widely and would need to be employed to 
increase the strength of measurement and results.  
 
6.6 Summary  
 
The effect of H2S has never before been described in endometrial cancer cells. Preliminary 
experiments conducted in this study describe an overall reduction in cellular viability with 
increasing concentrations of GYY4137. Although conflicting evidence exist with respect to 
H2S and its effect on proliferation, its alternative role as a tissue specific, anti- or pro-
apoptotic  agent was theorised. Further experiments need to be conducted in order to 
deduce the specific role that H2S plays in endometrial cancer and the normal endometrium. 
The lack of normal endometrial cell lines in existence due to difficulties in culturing these 
cells means that alternate methods of exploring the presence of H2S in this tissue is 
necessary, and these have been discussed later in the general discussion.  The normal 
cellular concentration of H2S within the human endometrium has not been measured.  
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  General Discussion Chapter 7
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This study report describes the expression of the three H2S synthesising enzymes; CBS, CSE 
and 3-MPST in atrophic post-menopausal endometrium, hyperplastic and endometrial 
cancer tissue. Immunostaining scores for CSE (p=0.0047) and 3-MPST (p<0.001) were 
significantly lower in cancerous tissues when compared with post-menopausal controls. No 
overall differentiation in CBS (p=0.1363) expression was present between all groups. In vitro 
cell cultures using an H2S donor GYY4137 were found to cause an overall reduction in 
cancer cell survival. The addition of a H2S substrate L-cysteine reduced cell proliferation at 1 
mM and 3 mM concentrations over 24 and 48 hours.  The primary findings of this study 
have elucidated the differential staining patterns of the 3 H2S synthases. Correlation of 
these enzymes with steroid receptors in similar sample groups found associations between 
them, discussed below.  
 
The protective role of H2S under conditions of acute oxidative stress by scavenging 
superoxide anions and suppression of vascular superoxide production was suggested. In 
vitro treatment of mitochondria isolated from murine hepatoma cells with H2O2 has shown 
a decrease in H2S production via the 3-MPST pathway
119.  An unopposed hyper oestrogenic 
state is a major risk factor for the development of endometrial carcinoma. Oestrogen 
metabolism was hypothesised as an important factor in endometrial carcinogenesis56, 68. In 
endometrial cancer and endometrial hyperplasia a 50% decrease in the antioxidant 
superoxide dismustase when compared with benign endometrial disease including uterine 
polyps and myomas was described in the presence of increased oxidative stress. Hence a 
reduction in clearance of free radicals occurs suggesting an accumulation of free radicals in 
endometrial cancer tissues120. The down regulation of SOD was shown to be accompanied 
by a 100% increase in glutathione reductase activity in endometrial carcinoma and a 60-
100% increase of both glutathione and glutathione reductase in endometrial hyperplasias.   
A down regulation of H2S production via the 3-MPST pathway under conditions of increased 
oxidative stress was proposed, suggesting a reduction in expression of 3-MPST in 
endometrial carcinogenesis120.  
3-MPST was expressed strongly in the PM endometrium. The findings of this study show an 
early loss of 3-MPST in the glandular epithelial cells of low grade endometrial carcinomas 
(p<0.0001). Although no significant loss of 3-MPST expression was noted in CAH, the score 
for the intensity of staining varied greatly. The variability of CAH could mean that those 
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with lower expression of 3-MPST could progress to EC. Only 4 CAH samples have been 
stained and therefore the strength of this suggestion is not strong. Further to this 
comparison of type 1 and 2 endometrial carcinomas against PM endometrium reveals a 
significant down regulation across all groups. Correlation of 3-MPST with steroid receptors 
revealed a weak association (r=0.2) with PR in high grade cancers and no association in low 
grade cancers. In health PR has an anti- proliferative effect on the endometrium with a loss 
of PR suggested in advanced cancers. The positive correlation between PR and 3-MPST 
would suggest a combined loss of both in advanced endometrial carcinomas. Evidence from 
this study is in agreement with this relationship, showing a loss of 3-MPST in advanced 
cancer.   
CSE staining in the glandular epithelial cells was evidenced to be down regulated 
significantly (p=0.004) in endometrial cancer when compared to healthy post-menopausal 
endometrium. Comparison of low and high grade endometrial carcinomas with PM controls 
revealed a grade dependent loss of CSE expression (p=0.004), with a more significant 
reduction in high grade cancers (p=0.001). Comparison of type 1 and 2 cancers with PM 
tissue samples revealed a greater loss in type 2 non-endometrioid carcinomas (p-0.001) 
compared with type 1 endometrioid carcinomas. No significant difference in expression 
exists between the CAH and PM groups. The standard error margins for the CAH group are 
close together showing little variation in CSE expression within this group. This lack in 
variation could also be attributed to the small sample size (n=4) and a larger sample size 
would need to show similar lack of variance to strengthen this idea. As no significant 
reduction in CSE expression is seen CAH, the loss of CSE in glandular epithelium as a 
possible disease indicator is not possible as yet.  
Evidence has claimed a role for H2S produced by CSE in angiogenesis
133, 137, 139. A 
comprehensive literature search has revealed evidence claiming the increased vascular 
endothelial expression of CSE in circulatory and neoplastic disease167. CSE mediated 
production of hydrogen sulphide was shown to play an important protective role in 
cardiovascular disease by producing vasodilation114 and angiogenesis.  Previous study in 
colorectal carcinoma showing an up regulation of CBS showed no change in expression of 
CSE but claimed that CBS mediated production of H2S was responsible for angiogenesis. H2S 
mediates angiogenesis through a variety of pathways: the mitogen activated protein kinase 
156 
  
 
pathway, PI-3K/Akt pathway and ATP- sensitive potassium channels114. H2S is also known to 
inhibit phosphodiesterase, thereby promoting angiogenesis104. As most evidence at present 
implicates CSE in vascular endothelium, staining within the vascular endothelium in 
endometrial carcinomas and PM endometrium should be investigated. As aforementioned 
the focus of this study was placed on the CSE expression within the glandular epithelium. 
However, analysis of tissue micrographs stained with CSE in the vascular endothelium (refer 
to figure 22) has revealed minimal to no endothelial staining of CSE in PM endometrium. 
This is expected, as all the PM samples are atrophic. Hyperplastic samples have shown 
areas of endothelial staining and type 1 and 2 endometrial cancer samples have also shown 
positive endothelial staining for CSE. Therefore at a glance it can be deduced that CSE is 
being expressed by the vascular endothelium of proliferating endometrium when 
compared with no staining seen in PM endometrial tissue. However, quantification of 
intensity of staining using the modified quick score method needs to be done along with 
staining of normal cycling endometrium to reveal any changes in CSE expression in the 
vascular endothelium between the 3 phases of the menstrual cycle. Without this 
knowledge it is difficult to understand and deduce the role of CSE in the endometrium. 
No significant differential expression of CBS was seen to exist between any of the groups 
involved in this study. CBS up regulation and subsequent increase in H2S production have 
been shown to play a role in tumourigenesis and maintenance in colorectal 
adenocarcinomas and epithelial ovarian carcinomas. The physiological roles of H2S include 
vasorelaxation, angiogenesis and promotion of cellular bioenergetics7, 87. It is these 
properties of H2S that have implicated it in carcinogenesis. Loss of CBS was shown to reduce 
cellular viability and alter antioxidant levels, trigger apoptosis and enhance drug 
sensitivity146. Extensive research was done verifying glutathione (GSH) as an antioxidant, 
but selective targeting of GSH in cancer cells was a major clinical challenge168. CBS has 
therefore been suggested as a good alternate target in ovarian epithelial cells due to its 
minimal expression in normal cells.  
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This current study has shown relatively high expression of CBS in the post-menopausal 
endometrium. The current role and expression of CBS in the normal cycling endometrium 
has not been defined and would need to be clearly assessed. Although no overall difference 
in CBS expression was seen in this study, investigating oestrogen and non-oestrogen 
dependent cancers separately revealed an increase in CBS expression in grade 3 
endometrioid carcinomas (p=0.04). Although endometrioid cancers are associated with 
oestrogen regulation in advanced disease a loss of oestrogen regulation was postulated via 
the loss of ER-alpha. Correlation studies conducted as part of this study have shown a 
strong negative correlation between the expression of ER-alpha and CBS (r=-0.5). This up 
regulation of CBS could be associated with advanced disease in endometrial carcinomas 
and may potentially occupy a role as a prognostic marker. In addition synthesis of reactive 
oxygen species (ROS) is evidenced to be increased in CBS silenced cells169. This was 
attributed to the reduction in GSH activity and possible reduction in superoxide dismustase 
activity. Many active intermediates are also released as by-products of these chemical 
pathways which are subsequently converted to free radicals. This enhanced production of 
ROS results in DNA damage resulting in mutations that may contribute to carcinogenesis170. 
H2S was evidenced to exert tissue specific actions and its regulation via the 3 enzymes is not 
identical between various organs in the body. This alternating role of H2S may explain why 
the results are not in agreement with published evidence in other cancers. In contrast, the 
up regulation of CBS in grade 3 endometrioid carcinomas could possibly be a compensatory 
mechanism in response to the loss of 3-MPST and CSE.  
The clinical pathological features of the endometrial cancers such as extent of 
myometrial invasion and lympho-vascular invasion have been compared against the 
expression of the three H2S synthesising proteins to reveal a possible association 
between the two groups. Myometrial invasion was categorised according to the 
1991 FIGO classification into <50% or >50% invasion into the myometrial wall and 
lympho-vascular invasion was included if present and rejected if it does not exist. No 
association was found between the 3 proteins and the clinical pathological features. 
Further to this outcome data was used where 1 represents an event such as 
recurrence or death due to endometrial carcinoma at 36 month follow-up and 0 
represents no events. Comparison of all 3 enzymes with outcome data showed no 
association between the expression of enzymes and outcomes of disease.  
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Previously literature was published investigating the use of slow release H2S donors 
as anti-cancer drug targets170. The alternating role of H2S in exerting pro-apoptotic 
or anti-apoptotic effects was reportedly previously in cultured cells, though the 
exact mechanisms still remain undefined161. H2S donors are known activators of 
mitochondrial ATP generation and promoters of GAPDH catalytic activity via 
sulphhydration. The stimulatory effect of H2S on cellular bioenergetics has 
implicated it in proliferation, migration and invasion as they are all ATP dependent 
mechanisms.  In vitro and in vivo treatments of neoplastic and normal cell lines with 
the slow release GYY4137 revealed an overall anti-proliferative effect on neoplastic 
cells with no effect on normal cell line proliferation. The use of a rapid releasing H2S 
donor showed no effect on either the neoplastic or normal cell lines. A study was 
conducted investigating the role of various slow release H2S donors (GYY4137 
analogues) to elicit their anticancer potential. A dose- dependent cellular apoptosis 
of neoplastic cells of seven differing human cancer cell lines was seen, with no effect 
on normal human cells170. As discussed conflicting evidence exists implicating the 
H2S donors or enzyme inhibitors as possible therapeutic drugs targets. This 
conflicting evidence could be a result of the complex and ambiguous role of H2S and 
its synthases in tumorigenesis.   
 
In vitro experiments conducted in this study describe the effects of H2S donors such 
as GYY4137 and H2S substrates i.e. L-cysteine on the MFE280 endometrial cancer 
cell line. Results of the in vitro experiments have shown an overall inhibitory effect 
of GYY4137 and l-cysteine on endometrial cancer cells at higher concentrations. The 
cells were treated over 24 and 36 hours. Higher concentrations such 100 and 200 
μM were shown to cause a cell death seen in preliminary experiments conducted 
during optimisation of GYY4137. An overall biphasic appearance of results was 
visible describing a rise in proliferation of MFE280s at GYY4137 concentration of 25 
μM at 24 hours, after which a fall in proliferation is seen at 50 μM with a rise in 
proliferation seen again at 75 μM. Any concentrations higher than 75 μM were 
shown to inhibit cell viability. The large SEMs seen at GYY4137 concentrations of 25 
and 75 can be attributed to the smaller number of replicate values plotted when 
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compared to the other two concentrations of 50 and 100 μM. The error in results 
could be due to experimental error such as pipetting errors or uneven evaporation 
of culture media from wells.  In addition considering the values at 36 hours, 
GYY4137 is not seen to have a proliferative effect on the MFE280s reiterating the 
need for further experiments to confirm whether the rise in proliferation seen in 
significant or not.  
 
Treatment of cells with the H2S substrate l-cysteine exhibited an overall inhibition of 
cellular proliferation. Treatment of cells with 1mM concentration of l-cysteine at 24 
hours revealed a sharp decline in cell viability with 3mM concentrations being toxic 
to the cells. At 48 hours no cell proliferation is evident with a gradual decline in cell 
viability seen. As 5% charcoal stripped serum was used to grow and maintain the 
MFE280s prior to treatment with l-cysteine it is possible that the decline in cell 
viability seen could be secondary to the cells being unable to thrive in sub-optimal 
conditions.  
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7.1 Limitations 
 
Further studies will need to be conducted in order to quantify enzyme functionality in the 
endometrium. An additional technique such as quantitative real-transcriptase polymerase 
chain reactions (QRT-PCR) or Western blot method should be used. The use of QRT-PCR to 
confirm findings would have been completed, but the lack of published isotype specific- 
primers resulted in difficulties to adopt this method. Also published primers for CBS and 3-
MPST were very expensive and could not be purchased due to lack of funding.  In addition 
statistical analysis of IHC data involved the use of non –parametric tests. These tests are 
known to reduce the strength of the results and thereby produced statistically insignificant 
p values.  
Although a large sample cohort of 81 endometrial samples have been collected and 
stained, variation in sample numbers within the groups reduces significance of results. 
Lower numbers of samples were present for CAH, grade 3 endometrioid and type 2 
endometrial carcinomas. Patients who are suffering from advanced stage cancers are 
treated with chemotherapy or radiotherapy prior to surgery. These adjuvant therapies are 
known to affect the cellular architecture of the tumours and therefore would not be 
suitable for use in the study thus resulting in obstacles for recruitment of patients with high 
grade cancers. Increasing number of samples within the groups stated above should 
improve the significance of data.  
In vitro studies using endometrial cancer cell lines required optimisation, as covered in 
chapter 4. The lower expression of CBS, CSE and 3-MPST in the primary cell line used; 
Ishikawas when compared to the MFE280s resulted in the need to use this cell line instead. 
MFE280s are a slow growing cell line maintained as a monolayer. They require a longer 
time to reach an appropriate confluence before use. Moreover, to maintain this cell line in 
reduced serum media (5% FBS, Charcoal stripped) resulted in increased difficulties in 
handling these cells. The use of a sulphur containing H2S should be compared against 
another non-sulphur containing compound as a control to ensure that the change in cell 
viability seen is secondary to the presence of H2S.  
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In addition mitochondrial dehydrogenase enzyme activity is proposed to vary in different 
cells and the exposure of cells to different treatments would possibly affect their ability to 
react with tetrazolium compounds.  
During the conduction of in vitro studies, direct measurement of H2S could not be done due 
to the lack of appropriate equipment. Therefore, for accuracy the methylene blue assay or 
other suggested methods of H2S detection would need to be employed.  
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7.2 Future work  
 
While this thesis has demonstrated the variable expression of CBS, CSE and 3-MPST 
between PM and endometrial cancer, their expression in normal cycling endometrium has 
not been defined. Future IHC staining needs to be conducted to allow the analysis of 
change in expression, if present, between cycling, atrophic and cancerous endometrium.  In 
addition the normal endometrial samples will need to be subcategorised into the 3 
different phases of the menstrual cycle to analyse any correlation between changes in 
enzyme expression within the 3 phases. Normal expression of the 3 H2S synthesising 
enzymes can then be correlated with steroid receptors to reveal any associations. Further 
to this a new group consisting of hyperplasias without atypia should be included. The 
comparison between atypical hyperplasias and grade 1 EC should also be focused on as it is 
important for the prediction of progression of disease.  
Expression of CBS, CSE and 3-MPST was confirmed and located with the use of IHC 
methodologies. To confirm the IHC results methods such as Western blotting or 
quantitative real-transcriptase polymerase chain reactions (QRT-PCR) should be done to 
quantify mRNA levels of proteins to be verified. However, as the functionality of the 
enzyme is unknown with the stated methods, direct measurement of enzyme function 
needs to be assessed. Continuous assays with the use of UV-visible spectroscopy / 
fluorescence + phosphorescence spectroscopies or discontinuous assays can be used 
depending on the experimental outcomes.  
As aforementioned sample numbers between the endometrial cancer groups were not 
equal, thus limiting the significance of the study. Increasing the sample numbers to achieve 
consistency within the groups can increase statistical significance of the data. Therefore 
more patients with high grade cancer that have not undergone hormone therapy will need 
to be recruited to take part in the study. 
Methods of H2S detection can be direct or indirect. Indirect methods have already been 
employed in this thesis e.g. the use of in vitro experiments investigating the proliferative 
potential of endometrial cancer cells using the MTT assay. Additional assays confirming the 
results found with the MTT assay and others looking at effects of H2S on invasion and 
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migration of cells can also be conducted. As described earlier, H2S has autocrine and 
paracrine effects. Its autocrine effects include an increase in cellular bioenergetics which 
can be measured to identify its effect on intact cells and isolated mitochondria. 
Angiogenesis is a result of the paracrine effects of H2S and could be analysed by 
quantification of blood vessel density. The lack of resources at the laboratories posed 
difficulties in direct measurement of H2S levels in cell lines. Therefore further functional 
studies aimed at directly measuring H2S production should be carried out. Since its 
introduction by Fischer in 1883, the methylene blue assay is a widely used, sensitive and 
specific method for the measurement of H2S. Fluorescence read- out of sulphide with the 
use of a hydrogen sulphide probe is another method of directly measuring H2S. The low ppb 
range (detection limit) of the probe allows identification of small amounts of H2S to be 
identified. The probe though highly sensitive is functional in solutions and therefore the 
methylene blue assay would be more suited for measurement of H2S in cell lines. 
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7.3 Conclusion 
 
In conclusion this study has identified the expression of CBS, CSE and 3-MPST using IHC in 
PM, CAH and endometrial carcinomas. In vitro studies have shown an overall inhibition of 
cellular proliferation with the use of a H2S donor GYY4137 and H2S substrate l-cysteine.  
3-MPST was shown to be expressed in the cytosol of glandular epithelium and within the 
stromal compartment of the cells. It cytoprotective role was described in many tissues and 
its presence in the PM endometrium could possibly be protective from carcinogenesis.  Its 
expression was shown to be significantly lost early in low grade endometrioid carcinomas 
and in high grade endometrial carcinomas. This early loss of 3-MPST suggests a possible 
role for its use as a disease marker. Further investigations as described above would need 
to be completed prior to claiming any definite functions. A weak positive correlation was 
found between PR and 3-MPST (r=0.2) between high grade cancers. A reduction in PR was 
suggested in advanced cancers and the loss of 3-MPST seen in high grade cancers in this 
study could correlate the relationship between PR and 3-MPST.  
Two types of staining have been confirmed with CSE expression including diffuse 
cytoplasmic staining in the cytoplasmic compartment of epithelial and endothelial cells and 
discrete strongly stained cells. The nature of the cells that are strongly stained is still 
unclear.  The overall expression of CSE in the epithelial cells was demonstrated to be lost in 
cancers when compared to post-menopausal cells. The loss of CSE in cancers could possibly 
suggest a role for it as a possible carcinogenesis marker. Increasing sample numbers and 
employing more techniques will elucidate the role of CSE in the glandular epithelium of 
endometrial cells. Brief analysis of endothelial staining has shown a lack of CSE expression 
in the PM endometrium and an increase in endometrial cancer. As CSE was described 
extensively in angiogenesis future experiments will need to focus on endothelial staining of 
CSE.  
CBS was localised to the cytoplasm of glandular epithelium. No significant overall change in 
CBS expression was noted between PM and cancerous endometrium.  Grade 3 
endometrioid carcinomas have shown a significant increase in CBS expression when 
compared with PM endometrium. This could be secondary to a compensatory mechanism 
due to the suppression of 3-MPST and CSE. In contrast, the strong negative correlation 
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between ER-alpha and CBS suggest a possible role of CBS up regulation to be a marker of 
poor prognosis.  
Comparison of expression of the three enzymes with outcome data and clinic-pathologic 
features have shown no association of 3-MPST, CSE and CBS with poor outcomes of disease 
or myometrial/ lympho-vascular invasion, respectively.  
In vitro treatment of the MFE280 endometrial cancer cell line with l-cysteine has shown an 
overall inhibition of cancer cell proliferation. L-cysteine concentrations of 1mM and 3 mM 
have at 24 and 48 hours have shown a reduction in cell viability. However, as the MFE280 
cell line was maintained in 5% charcoal stripped media the lack of cellular viability could be 
secondary to the inability of the cells to thrive under suboptimal conditions. The results 
seen with the administration of GYY4137 produced a graph with a biphasic appearance. 
GYY4137 concentrations of 50 and 100 μM were seen to suppress endometrial cell viability 
whereas concentrations of 25 and 75 μM were seen to stimulate cellular proliferation. The 
SEMs for 50 and 100 μM concentrations are narrower due to a total of 15 replicates being 
plotted at these concentrations but 25 and 75 μM concentrations only 3 replicates have 
been produced. Therefore it is more likely the values at these concentrations would consist 
of error when compared to GYY4137 concentrations of 50 and 100 μM. More investigations 
will need to be done at these concentrations to ensure that they are valid.   
Further investigations using established cell lines such as primary endometrial cancer cell 
lines in monoculture might aid in exhibition of direct effects of H2S on their proliferative 
function. Using a co-culture system where the endometrial cancer cells are grown in 
conjunction with stromal cells and their proliferation assessed in response to H2S (H2S 
donors) is more physiologically relevant method of assessment.  As H2S was suggested to 
alter cellular bioenergetics the use of flow cytometry to analyse cell cycles may possibly be 
a more sensitive methods to assess subtle changes in response to H2S. Other major 
alterations in cancer cells include their increased migratory potential and invasiveness. By 
using 3D cultures in vitro or in animal models would be suitable in assessing migration and 
invasion potential of cancer cells in response to H2S.  
As the expression of H2S synthases are altered further work on examining the direct effect 
of known endometrial mitotic agents such as oestrogen could be examined by the 
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conduction of explant cultures on benign post-menopausal endometrium, to determine 
whether any alteration in the expression of H2S synthases is present in response to 
oestrogen.  
If H2S induced alteration in cell function can be proven with the experiments mentioned 
above, subsequent set of experiment s may provide a novel perspective allowing the 
utilisation of existing H2S synthase inducers or inhibitors to counter act the undesired 
effects if identified. Ultimately there is a possibility of translating further work in this area 
into clinically relevant novel treatment strategies.  
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Appendix 3 Standard operating procedures (SOPs) 
3A. Tissue Processing  
Background  
Formalin fixed tissue is dehydrated, cleared then impregnated with paraffin wax using the 
automated Shandon Citadel 1000 processing machine. The processing setting for most 
sample types is programme A that operates using the schedule provided below. The total 
processing time is 18 ¾ hours, therefore the processor is generally run overnight. Starting 
the processor at 2pm will result in completion of the cycle at 8:45 the following morning.  
 
Programme A Processing Schedule:  
4% formalin in neutral buffer 45 minutes  
60% Ethanol 1 hour  
70% Ethanol 1 hour  
90% Ethanol 1 hour  
100% Ethanol 1 hour  
100% Ethanol 1 ½ hours  
100% Ethanol 2 hours  
Xylene 1 1 hour  
Xylene 2 1 ½ hours  
Xylene 3 2 hours  
Wax 1 2 ½ hours  
Wax 2 3 ½ hours  
 
Equipment information:  
Citadel processor (serial number CA 1390 EO 608) manufacturer: Thermo electron 
Corporation. Manufacturer’s address: 93 – 96 Chadwick Road, Astmoor, Runcorn, Cheshire, 
WA7 1PR England.  
 
Maintenance and contract:  
185 
  
 
Maintained/serviced by Thermo Fisher Scientific 93 – 96 Chadwick Road, Astmoor, Runcorn, 
Cheshire, WA7 1PR England. Tel: 01928 562 541, Fax: 01928 562 512. 
Solvent Information:  
Ethanol and xylene are purchased from Chemistry solvent stores (University of Liverpool). 
The wax (Histoplast PE REF8330) is purchased from Thermo Scientific 93 – 96 Chadwick 
Road, Astmoor, Runcorn, Cheshire, WA7 1PR England. The 10% neutral buffered formalin is 
purchased from Sigma Life science, Fancy Road, Poole, Dorset, BH12 4QH.  
 
Health and Safety Precautions  
Wear a laboratory coat, safety spectacles and nitrile gloves. Xylene and formalin are 
harmful by contact to skin and eyes or if ingested or inhaled. Refer to the risk assessments 
and COSHH forms before starting procedure.  
Overnight processing procedures requires the completion of permits provided in safety 
circular SCR14/3 (link to document provided below). A ‘Yellow permit’ (for long term 
operation) should be prepared by the DSC or laboratory manager and the copy secured in a 
clear plastic folder on the door outside laboratory 4. The ‘Pink’ permit (valid for the 
duration of the experiment only) should be prepared by the processor user and the 
document should be placed on or adjacent to the apparatus. Information that needs to be 
recorded on the pink copy includes:  
a) experimental details  
b) times and dates of experiment  
c) emergency procedures  
d) name, address and telephone number of the processor user  
e) signature of researcher concerned and a countersignature from the laboratory 
manager/DSC.  
 
PROTOCOL  
 
A Preparation of Solvent Containers on Processing Machine:  
Between processing runs, ethanol solutions are stored in labelled bottles to prevent 
evaporation. These are found in the metal solvent cabinet under the bench in Laboratory 4. 
Therefore the solvent containers must be re-filled before tissue processing commences. To 
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access the processor solvent container, press the raise button on the hand held controller. 
Remove the evaporation covers from the top of the processor then press rotate or 
check/fill button. The rotate function will cause the operating head assembly to advance 
one position 
and the check/fill option rotates the head three positions. Remove the container using the 
metal handles and add 1.5L of the required ethanol solution (the top of the bevelled edge 
on the solvent container is approximately 1.5L). Repeat process until all ethanol containers 
are filled. It is also advisable to check the level of the xylene, formalin and the wax 
containers on a regular basis. If fresh 100% ethanol is used to top up or prepare solutions 
for the processor ensure the ethanol log is updated with the volume used. The ethanol log 
is situated in DSC office (room 1128).  
 
B Sample Processing Procedure  
 
1. Label plastic cassettes with the sample ID number using pencil.  
2. Carefully remove the tissue from the formalin pot using forceps and place into the small 
wire inserts. Secure the inserts into the plastic cassettes and re-check the sample ID. 
Dispose of the used formalin in the red labelled waste container which is stored below the 
fume hood.  
2. Arrange the cassettes so they are loosely spaced in the processing baskets  
3. Press Go To 1 on the hand held controller, slot the processing baskets onto the holder 
over the formalin and place weight on top of the basket.  
4. Press Lower button on the hand held controller (to lower the basket into the formalin).  
5. Check the time is correct by pressing clock (alter time by pressing the + button or whilst 
holding in the clock button if necessary).  
6. Select the appropriate processing time function:  
 
Date of Processing  Processing Time  Hand Held Controller Action  
Monday-Thursday  Before 2pm  Press delay on button  
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Monday-Thursday  After 2pm  Press autostart button  
Friday  Before 2pm  Press days delay, hold this 
in, scroll to 2 days using the 
+ button then press delay 
on.  
Friday  After 2pm  press days delay, hold this 
in, scroll to 1 day using the + 
button, then press delay on  
 
7. Complete the citadel 1000 user log (the folder is situated by the embedding station in 
laboratory 4) with sample, solvent and programme information. 
8. When the processing cycles are completed, switch on the Shandon Histocentre 3 
embedding machine. 
9. Press raise button on the hand held controller and remove baskets from holder.  
10. Place blocks into heated reservoir in the embedding machine.  
11. Wipe processing baskets with absorbent towels to remove surplus wax then place 
equipment into the oven (heated to ~100°C) for several minutes to remove any residue.  
12. Soak biopsy inserts in xylene for several hours/overnight to remove wax residues. Leave 
the inserts in the fume hood to air dry  
13. Remove the alcohols from the processing machine using the method described in 
section A and pour solutions in the labelled storage bottles using a funnel. The storage 
bottles are then placed in the flammable solvent metal storage cabinets.  
14. Update the citadel 1000 processing user log.  
 
C Disposal of Waste Solvents  
The solvents must be changed on a regular basis (depending on time of year and processor 
usage) to ensure efficient processing of the tissue samples. Waste solvents must be placed 
in the red solvent waste containers and identified clearly with the appropriate labels 
provided by Lisa Heathcote or Jo Drury. Pouring the molten solution into a container and 
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cooling until the wax is set can discard contaminated waste wax. The wax container can 
then be disposed of in the LWH clinical waste. Refer to the waste disposal protocol (SOP 25) 
for further information.  
3B: CUTTING PARAFFIN SECTIONS  
Background  
Preparation of 3-5 micron thick sections from wax – embedded tissue is a commonly used 
histological technique. This SOP will describe how to prepare these using the Microm 
HM335 rotary microtome and attaching sections onto aminopropyl triethoxy silane (APES) 
coated slides.  
 
HEALTH AND SAFETY REQUIREMENTS  
Wear a laboratory coat and nitrile gloves. Care needs to be taken when performing this 
procedure because there is a risk of sharps injury from the microtome blades. Refer to the 
physical hazards safety circular, risk assessments and COSHH forms before starting 
procedure. Also ensure waste wax sections are cleaned from the floor and the general 
working area at the end of the procedure to prevent risk of slip/trip injuries. Place all waste 
tissue sections in the clinical waste bags and the used microtome blades and slides into the 
yellow clinical waste sharps bins. DO NOT COMMENCE WORK WITH THE MICROTOME 
UNTIL SUFFICIENT TRAINING WAS PROVIDED AND AUTHORISATION WAS RECEIVED FROM 
LISA HEATHCOTE OR JO DRURY.  
 
EQUIPMENT INFORMATION:  
Microm HM335 rotary microtome is supplied by MICROM Company. Manufacturer’s 
address: Microm UK Ltd., 8 Thame Park Business Centre, Leinman Road, Thame, OX9 3XA. 
Further information can also be obtained on http://www.microm-online.com.  
Microscope slides (twin frost size 26 x 76mm-Printed “IVD CE” 90º ground edges, catalogue 
number MAE-1000-03P Pack of 1000) are purchased from Liverpool Women’s Hospital 
(NHS) purchasing department.  
Coverslips 22 x 22mm, 22 x 40mm and 22 x 50 are purchased from Liverpool Women’s 
Hospital (NHS) purchasing department.  
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 Microtome blades (MB Dynasharp Catalogue Reference 3050836) are purchased from 
Thermo Scientific 93 – 96 Chadwick Road, Astmoor, Runcorn, Cheshire, WA7 1PR England.  
 
Forceps, paint brush, section dryer and water bath are supplied by Raymond A Lamb Ltd. 
Manufacturer’s address: Units 4 & 5, Parkview industrial estate, Eastbourne, East Sussex, 
BN23 6QE England.  
 
METHOD:  
1. Carefully fill the water bath with distilled water ensuring the electrical connection points 
remain dry.  
2. Turn on water bath from the plug and set the power switch from O to I  
3. The water will need to be heated to 40°C. The best way do to this is to first turn the 
temperature dial to 10 (maximum setting) for 7-8 minutes and then turn the dial down to 
2.5. If the temperature of the bath is above 40°C, pour in distilled water to lower the 
temperature.  
4. Scrape away any surplus wax from the edges of the cassette to ensure a good fit in the 
holder then place the tissue block in the refrigerator. Cool the block for at least 30 minutes 
prior to cutting.  
5. Ensure that the handwheel is locked in the upper range of the vertical movement by 
turning the lever downwards.  
6. Press the reverse course feed button to move the knife carrier away from the specimen.  
7. Turn the clamping lever on the blade holder to the front and swing the protective bracket 
forwards. Insert the feather S35 blade into the slot behind the clamping plate ensuring the 
blade is level on the rail (use forceps to manipulate the blade if necessary). Use half of the 
blade for cutting at a time. Preferably use left side first and then the right side.  
8. Return the clamping lever to the original position (in line with the black frame of the 
blade) to lock the blade in place. The protective bracket should also be returned to the 
original position when the microtome is not in use to minimise the risk of sharps injury.  
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9. The blade angle is pre-set to 10- C and should not require adjustment. These settings 
should remain the same to ensure minimal amounts of tissue are wasted when different 
laboratory workers prepare sections from the same block.  
10. Insert the specimen against the ‘fixed jaw’ of the universal cassette clamp and secure by 
pulling the lever to the front. Ensure that each specimen cassette is always inserted in the 
same orientation (horizontal placement in the universal cassette clamp with the specimen 
number on the left) and inserted to the far left of the clamp.  
11. Unlock the handwheel by turning the lever upwards. Rotate handwheel in a clockwise 
direction until the centre of the tissue block is level with the blade holder. Then lock the 
handwheel by turning the lever downwards. 
12. Press the forward course feed button to move the blade carrier near to the specimen. 
To establish whether the blade is close to the specimen view the distance between the two 
at a side angle. Also, gently move the handwheel up and down to see if the specimen is not 
touching the blade. When you are satisfied that both blade and specimen are close to each 
other move the handwheel so the specimen is away from the blade, this prevents scoring 
the specimen block in the middle. 
13. The required section and trimming thickness are set by means of a circular knob on the 
left of the instrument. Press the circular control knob to switch between section (FEED) and 
trimming (TRIM) thickness. The corresponding LED will be displayed on the operating 
control panel: 
Green LED lights up when the FEED function is used 
Yellow LED lights up when the TRIM function is selected. 
14. When a new tissue block is used, select TRIM and turn the control knob until the 
corresponding LED is set at 20μm. 
15. Unlock the handwheel and start trimming by rotating the handwheel in a clockwise 
direction. Once you begin to see specks on tissue in the sections change the TRIM settings 
from 20μm to 10μm. 
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16. Continue to trim on the new setting until a representative amount of tissue is exposed 
in the tissue block. 
17. Select FEED and turn the control knob until the corresponding LED is set at the required 
section thickness (usually 3-5μm). Rotate the handwheel until the first section generated. 
Gently hold the end of the section with forceps and continue to cut until a ribbon 
(consisting of approximately 6 sections) is produced. Discard the first few sections when 
first cutting on the feed section as usually the first few are too thick. 
18. Carefully float the sections onto the pre-warmed water bath. Leave or a minute or so 
until the wrinkles in the section disappear. Separate the sections by applying gentle 
pressure using forceps. Select the best sections and float onto APES-coated slides. It is 
considered to be good laboratory practice to attach each section in the same orientation on 
the surface of the slide where you can read the IVD sign. 
19. Label the frosted part of the slide with the specimen ID and thickness (using a pencil). 
Place slides in a rack to dry at room temperature for several hours (preferably over-night). 
20. When not cutting for a few minutes the specimen block moves slightly out of place 
which potentially can create thicker sectioning when you go back to cutting. To avoid 
creating thicker sections press the reverse course feed button very slightly to move the 
knife carrier away from the specimen by a small amount.  
21. During the cutting procedure a build-up of wax on either side of the blade carrier. This 
can potentially cause scoring of the section. Using a soft brush, brush in an upward 
direction against the blade carrier to remove the wax, this is to prevent blunting of the 
blade and cutting down of the brush if a downward direction was used.  
22. If the sections start to wrinkle during the cutting procedure, then the tissue block has 
become too warm and needs to be refrigerated for at least 10 minutes. To remove the 
tissue block, press the reverse course feed button until the specimen is safely away from 
the blade holder. Return the safety bracket to the upright position. Remove the tissue block 
by pressing the lever on the universal cassette clamp.  
23. Remove any unused tissue sections from the water bath surface using kitchen roll.  
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24. When the microtome blade needs to be replaced, return the tissue block to the furthest 
position using the course feed button and lock the handwheel. Unlock the lever on the 
blade carrier and place the microtome blade into the yellow clinical waste sharp bin. NEVER 
try to remove the microtome blade when the tissue block is close to the blade edge 
because there is a risk of sharps injury and also the risk of damaging the tissue block.  
25. When the sections have dried, place the slides into a staining rack and bake for 60 
minutes in a slide drier (pre-warmed to 60°C), or 37°C overnight. Place slides in a suitable 
‘dust free’ container until required for the immunohistochemical staining procedure.  
 
3C APES coating procedure 
Background  
 
The Aminopropyl triethoxy silane (APES) coating procedure is used to improve tissue 
adhesion by producing a positive charge on the surface of the slide. The protocol described 
below was modified from the original method described by Maddox and Jenkins in 1991 
(full reference provided in the appendices).  
 
HEALTH AND SAFETY REQUIREMENTS  
The APES concentrate is a toxic chemical that is moisture sensitive and requires storage at 
0-5°C; it is an irritant and can cause burns. Normal laboratory precautions, including the 
wearing of gloves and the use of a fume cupboard, should be taken when handling the 
concentrate solution. Refer to the risk assessments and COSHH forms before starting 
procedure. Place all waste solutions into a labelled red solvent waste can and attach a 
solvent label (available from Lisa Heathcote or Jo Drury by request).  
 
EQUIPMENT INFORMATION:  
Microscope slides (twin frost size 26 x 76mm-Printed “IVD CE” 90º ground edges, catalogue 
number MAE-1000-03P Pack of 1000) are purchased from Liverpool Women’s Hospital 
(NHS) purchasing department.  
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APES solution (catalogue number A3648) is purchased from Sigma-Aldrich Company Ltd. UK 
distributor address: The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT.  
Staining racks and glass jars are supplied by Raymond A Lamb Ltd. Manufacturer’s address: 
Units 4 & 5, Parkview industrial estate, Eastbourne, East Sussex, BN23 6QE England.  
 
METHOD:  
26. Place slides into plastic racks. Each rack holds 24 slides  
27. Prepare a 2% APES working solution by mixing 5ml APES with 245ml 100% ethanol, or 
for the bulk method 40ml APES with 1960ml 100% ethanol. The APES solution is stable for 
several hours; therefore coat as many racks as possible to save reagents and time.  
28. Prepare a glass staining trough containing 100% ethanol  
 
Position 1: APES working solution  
Positions 2 – 4: distilled water  
 
29. Place slides racks in 100% ethanol. Dip several times to dislodge dust etc., and then 
drain the staining racks on absorbent paper towels.  
30. Incubate the slides for 5 minutes in APES working solution.  
31. Rinse slides in three changes of distilled water (2 minutes incubation for each rinse).  
32. Drain slides on absorbent towels and air dry overnight, or dry in a section dryer for 1 
hour at 37°C.  
 
33. Discard the first change of distilled water. Place the staining jar containing fresh distilled 
water at the last rinse location (position 5). Therefore the 2nd change of water has becomes 
the first etc.  
34. Repeat steps 5 through to 9 for each rack of slides.  
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35. Transfer the coated slides to a dust free container labelled ‘APES’ and the date of 
coating (APES slides are stable for approximately 3 months).  
 
3D. Preparation of paraffin sections for staining 
Background  
Factors that prevent adhesion of sections to blank slides are usually attributed to moisture 
under the section, and almost always become apparent after heat antigen retrieval. The 
method of heating slides prior to immunohistochemical staining ensures tissue sections 
adhere to the glass slide. It is important the sections are not over-baked, as this could 
increase background staining and decrease target staining. 
In order to prepare slides for staining, tissue must be deparaffinised using xylene and 
gradually rehydrated with descending grades of alcohol. 
Health and Safety Precautions: 
Wear a laboratory coat, safety spectacles and nitrile gloves. Xylene is harmful by contact to 
skin and eyes or if ingested or inhaled. Work in the fume hood for dewaxing procedure. 
Refer to the risk assessments and COSHH forms before starting procedure. 
Materials 
- Staining racks and glass jars are supplied by Raymond A Lamb Ltd. Manufacturer’s 
address: Units 4 & 5, Parkview industrial estate, Eastbourne, East Sussex, BN23 6QE 
England. 
- Ethanol and xylene are purchased from Chemistry solvent stores (University of Liverpool). 
- Section Dryer. Model E28.5. Supplier information: Raymond A. Lamb, Eastbourne, BN23 
6QE, England. 
Method 
1. Switch on Section Dryer Model E28.5. Adjust temperature using the temperature dial 
(see below for temperature required). 
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2. Label slides with the stain/antibody and concentration to be used, and date in pencil. 
3. Place slides for staining in metal slide racks. 
4. Heat to 60°C for 60 minutes or overnight at 37°C. 
5. Dewaxing solutions are in staining dishes in the fume hood in room 1125. Place the slide 
rack in xylene-1 for 10 minutes. Long forceps can be used to facilitate the transfer of the 
slide rack between dishes. 
6. Drain off excess xylene, and transfer to the dish labelled “xylene-2” for 10 minutes. 
7. Drain off excess xylene, and briefly blot on paper towel. 
8. Place the slide rack in the dish labelled “100% ethanol-1” for 5 minutes. 
9. Drain off excess ethanol, and transfer to the dish labelled “100% ethanol-2”. 
10. Drain off excess ethanol, briefly blot on paper towel and transfer to 90% ethanol for 1 
minute. 
11. Drain off excess ethanol, briefly blot and transfer to 70% ethanol for 1 minute. 
3E Immunohistochemistry 
Background 
Immunohistochemical staining is a valuable tool for detecting specific antigens in tissues. In 
order to perform the standard staining procedure, first the tissue section has to be 
prepared (SOP 04, 05 and 06), deparaffinised and then rehydrated (SOP 08). Antigen 
retrieval (SOP 09) is then performed to break any protein cross-links, therefore unmasking 
the antigens and epitopes in the tissue sections. The Vector ImmPRESS TM reagent kit, HRP 
is a two-step Immunohistochemical staining technique. This system is based on an HRP 
labelled polymer which is conjugated with secondary antibodies. The labelled polymer does 
not contain avidin or biotin. Consequentially non-specific staining resulting from 
endogenous avidin-biotin activity in liver, kidney, lymphoid tissues and cryostat sections is 
eliminated or significantly reduced. The interpretation of any positive staining or its 
absence should be complemented by morphological and histological studies with proper 
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counts. Any endogenous peroxidase activity is quenched by incubating the specimen with 
Peroxidase block. The specimen is incubated with an appropriately characterised and 
diluted mouse primary antibody, followed by incubation with the labelled polymer. Staining 
is completed by incubation with 3’3-Diaminobenzindine (DAB) + substrate - chromogen 
which results in a brown–coloured precipitate.  
Definition  
This SOP will explain how to stain tissue using an unlabelled antibody. Please read entire 
procedure before staining sections. Perform all antibody and staining incubations in a 
humid chamber and do not allow sections to dry out. Isotype and system controls should 
also be run. Carefully time all tests. Do not touch test specimens on slides during the 
staining procedure.  
Health and Safety Precautions  
The main health and safety risks to this procedure arise from chemicals/reagents that are 
potentially hazardous, such as hydrogen peroxide (H2O2), xylene, ethanol, and DAB (3’3-
diaminobenzindine). Gloves must always be worn when working with any of these 
chemicals.  
EQUIPMENT INFORMATION  
Staining dishes  
Humidified chamber  
Cover slips  
General points:  
Ensure that solutions cover the whole specimen – if necessary use a piece of Parafilm to 
spread.  
Antibody information:  
All current antibody datasheets are held in a labelled lever arch file in room 1128. 
Additional information on appropriate antibody concentration, antigen retrieval conditions 
and incubation time/temperature is held in an Excel spreadsheet (C:\Documents and 
Settings\jadrury.livad\My Documents\Dharani\Dharani abs.xlsx).  
Reagent information: 
TBS: 6 g/l Trizma base (T1503, Sigma-Aldrich) + 8.7 g/l NaCl (S7653, Sigma-Aldrich). Adjust 
pH to 7.6 with HCl.  
BSA: A3803 (Sigma Aldrich)  
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H2O2: H1009 (Sigma-Aldrich)  
ImmPRESS anti-mouse IgG kit (50 ml) (MP-7402, Vector Laboratories)  
ImmPRESS anti-rabbit IgG kit (50 ml) (MP-7401, Vector Laboratories)  
ImmPRESS anti-goat IgG kit (50 ml) (MP-7405, Vector Laboratories)  
ImmPACT DAB (120 ml) (SK-4105, Vector Laboratories)  
Shandon Gill 2 Haematoxylin (Thermo Scientific)  
1% acid alcohol: 1 ml HCl/100 ml 70% ethanol  
Shandon Consul-Mount (Thermo Scientific)  
Supplier information:  
Sigma-Aldrich Company Ltd, The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT. Tel: 
0800 717181. Fax: 0800 378785. Web: www.sigma-aldrich.com.  
Thermo Scientific, Bishop Meadow Road, Loughborough, LE11 5RG. Tel: 01509 231166 Fax: 
01509 231893.  
Vector Laboratories Ltd. 3, Accent Park, Bakewell Road, Orton Southgate, Peterborough, 
PE2 6XS. Tel: 01733 237999. Fax: 01733 237119. Web: www.vectorlabs.com.  
METHOD (Paraffin sections):  
1. Place slides in a staining dish containing TBS and incubate 5 minutes at room 
temperature.  
2. Prepare 0.3% H2O2/TBS (2.5 ml 30% H2O2 + 247.5 ml TBS)  
3. Incubate slides in 0.3% H2O2/TBS bath 10 minutes at room temperature.  
4. Prepare humidified chamber by placing folded paper towels in the centre gulley’s and 
soaking with distilled water.  
5. Decant H2O2/TBS and tap off any remaining solution. Carefully wipe around the specimen 
and the back of the slides with a tissue to remove excess liquid.  
 
6. Place slides in a staining dish filled with TBS and incubate 5 minutes at room 
temperature.  
7. Tap off any remaining solution, carefully wipe around the specimen and the back of the 
slides with a tissue to remove excess liquid.  
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8. Mark area to be stained with DAKO hydrophobic marker pen ensuring that the tissue is 
surrounded with sufficient space to allow spreading of antibodies.  
9. Place slides in a staining dish filled with TBS and incubate 5 minutes at room 
temperature.  
10. Prepare antibody diluent (TBS/0.5 % BSA eg. 250 μl 10% BSA + 4750 μl TBS)  
11. Prepare appropriate dilutions of each antibody, allowing 50 μl per section.  
12. Tap off any remaining solution, carefully wipe around the specimen and the back of the 
slides with a tissue to remove excess liquid.  
13. Place slides in humidified chamber.  
14. If necessary, add one drop horse serum block to each section, spread with parafilm to 
ensure that the whole section is covered, and incubate 20 minutes at room temperature.  
15. Tap off the serum block and proceed to step 17.  
16. Steps 14 and 15 can be omitted if staining is clean without blocking.  
17. Apply 50μl of the appropriate antibody to each section, spread with parafilm to ensure 
that the entire section is covered and incubate 30-120 minutes at room temperature or 
 
18. Tap off the antibody solution onto paper towels prior to placing the slides in a staining 
dish filled with TBS.  
19. Incubate 5 minutes at room temperature.  
20. Decant TBS and refill.  
21. Incubate 5 minutes at room temperature.  
22. Tap off any remaining TBS, carefully wipe around the specimen and the back of the 
slides with a tissue to remove excess liquid.  
23. Return slides to the humidified chamber and apply 1 drop labelled polymer-HRP. Ensure 
that the polymer matches the primary antibody.  
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24. Spread with parafilm to ensure that the entire section is covered and incubate 30 
minutes room temperature.  
25. Tap off the polymer solution onto paper towels prior to placing the slides in a staining 
dish filled with TBS.  
26. Incubate 5 minutes at room temperature.  
 
27. Decant TBS and refill.  
28. Incubate 5 minutes at room temperature.  
29. Prepare substrate/chromogen solution: 30μl/ 1ml substrate (require 50 μl per section).  
30. Tap off any remaining TBS, carefully wipe around the specimen and the back of the 
slides with a tissue to remove excess liquid.  
31. Return slides to the humidified chamber and apply 50 μl substrate/chromagen solution.  
32. Spread with parafilm to ensure that the entire section is covered and incubate 10 
minutes room temperature.  
33. Place slides in staining rack and immerse immediately in tap water to stop the reaction.  
34. Turn on fume hood in lab 4.  
35. Counterstain using filtered Gill 2 haematoxylin in lab 4. Immerse for 1 minute 30s.  
36. Immerse in tap water and rinse until water is clear.  
37. Dip briefly in acid alcohol, and immediately back into tap water (5 minutes).  
38. Incubate 1 minute in 70% ethanol.  
39. Blot off excess and incubate 1 minute in 90% ethanol.  
40. Blot off excess and incubate 3 minutes in 100% ethanol.  
41. Repeat step 40.  
42. Blot off excess and incubate 5 minutes in xylene.  
43. Blot off excess and incubate 10 minutes in xylene.  
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44. Remove a few slides at a time and apply sufficient mountant to cover the section.  
45. Choose an appropriately sized coverslip and apply to the slide.  
46. Remove air bubbles by using a cocktail stick or yellow pipette tip to gently press on the 
coverslip and “chase” bubbles to the edge.  
47. Leave to dry in fume hood.  
 
 
 
 
 
 
 
 
 
 
 
